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ABSTRACT 
 
Jessie P. Buckley: Prenatal phthalate exposures and childhood adiposity: examining the 
obesogen hypothesis  
(Under the direction of Stephanie M. Engel) 
 
Background: Phthalate exposures, particularly during fetal development, are 
hypothesized to be obesogenic with effects of anti-androgenic phthalates potentially differing by 
child’s sex. Previous studies are primarily cross-sectional and did not evaluate gestational 
exposures. To address these gaps, we assessed associations of prenatal phthalate exposures 
with childhood body size in three prospective birth cohorts. 
Methods: In Aim 1, we utilized data from the Mount Sinai Children’s Environmental 
Health Study (MSSM) to assess associations of third trimester maternal urinary phthalate 
metabolite concentrations with percent fat mass among children aged 4 to 9 years (N = 180 
children with 364 visits). In Aim 2, we pooled data from three Children’s Environmental Health 
Studies to examine prenatal maternal urinary phthalate concentrations in relation to 
overweight/obese status and age- and sex-standardized body mass index (BMI), weight, and 
height z-scores among children aged 4 to 7 years (N = 707 children with 1416 visits). For both 
studies, we estimated associations between standard deviation increases in natural log 
phthalate metabolite concentrations and longitudinal body size measures using Bayesian 
multilevel logistic and linear regression. We estimated associations in multiple metabolite 
models adjusted for confounders such as maternal pre-pregnancy BMI, gestational weight gain, 
smoking during pregnancy, and breastfeeding. We evaluated heterogeneity of associations by 
child’s sex and, in the pooled study, by race/ethnicity and cohort.  
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Results: In Specific Aim 1, children in the highest tertile of creatinine-corrected maternal 
third trimester urinary concentrations of summed di-(2-ethylhexyl) phthalate metabolites 
(∑DEHP) had lower percent fat mass than children in the lowest tertile (β = -3.06, 95% CI: -
5.99, -0.09). In Specific Aim 2, prenatal urinary mono-3-carboxypropyl phthalate (MCPP) 
concentrations were associated increased odds of overweight/obese status (OR per SD = 2.12, 
95% CI = 1.16, 3.96). We also observed inverse associations of maternal urinary mono-ethyl 
(MEP) and mono-benzyl (MBzP) concentrations with z-scores among girls and non-Hispanic 
black children, respectively. 
Conclusions: Our findings suggest that prenatal exposure to MCPP, but not other 
phthalates, may be obesogenic. Associations of ∑DEHP, MEP, and MBzP with decreased body 
size in some subgroups indicate that prenatal exposures to these phthalates may also interfere 
with physical development.  
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CHAPTER I. INTRODUCTION AND SPECIFIC AIMS 
 Introduction A.
Childhood obesity rates increased substantially in the past several decades (Ogden and 
Carroll 2010). According to the most recent National Health and Nutrition Examination Survey 
(NHANES) population-based survey, 1 in 10 US children aged 2 to 5 years and nearly 1 in 5 
children aged 6 to 19 years meets the definition of obese (Ogden et al. 2010). While energy 
balance is a key determinant of weight change, evidence suggests that well-known causes of 
obesity, including poor diet, physical inactivity, and genetic predisposition, may not fully account 
for the rapid increase in obesity rates (Heindel and vom Saal 2009; Keith et al. 2006). 
Laboratory research supports the hypothesis that common environmental chemicals may 
negatively impact lipid regulation in favor of weight gain (Fromme et al. 2007; Heindel and vom 
Saal 2009; Janesick and Blumberg 2011). However, epidemiological studies of environmental 
causes of obesity are limited.  
Human exposure to phthalates is ubiquitous and a number of lines of evidence point to 
phthalates as possible obesogens. Although there is currently no epidemiologic literature 
regarding prenatal exposure to phthalates and childhood growth, studies suggest that other 
endocrine disrupting chemicals may affect risk of overweight and obesity (Blanck et al. 2002; 
Gladen et al. 2000; Hertz-Picciotto et al. 2005; Karmaus et al. 2009; Lamb et al. 2006; Mendez 
et al. 2011; Smink et al. 2008; Verhulst et al. 2009). In addition, toxicologic research supports 
the hypothesis that early life phthalate exposures may affect fat accumulation (Feige et al. 2010; 
Hao et al. 2012; Schmidt et al. 2012) or pathways associated with offspring obesity (Bility et al. 
2004; Desvergne et al. 2009; Feige et al. 2010; Hurst and Waxman 2003; Lampen et al. 2003; 
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Maloney and Waxman 1999; Sargis et al. 2009). Epidemiologic studies, primarily cross-
sectional, have reported associations between phthalate metabolite concentrations and body 
mass index (BMI), obesity, weight, or waist circumference in children (Boas et al. 2010; de Cock 
et al. 2014; Hatch et al. 2008; Teitelbaum et al. 2012; Trasande et al. 2013; Wang et al. 2013). 
Furthermore, effects of phthalates on body size may differ by child’s sex for metabolites of 
phthalates with anti-androgenic activity, as has been reported in studies of other developmental 
endpoints (Engel et al. 2009; Swan et al. 2010; Wolff et al. 2008). Identifying a link between 
prenatal phthalate exposures and childhood adiposity could have a substantial public health 
impact given that nearly 40% of US children are overweight or obese (Ogden et al. 2010). 
The goal of this dissertation is to examine associations between phthalate 
concentrations measured in maternal urine collected during pregnancy and longitudinal 
measures of body size assessed during early childhood (ages 4 to 9 years) in three US birth 
cohorts: the Mount Sinai School of Medicine Children’s Environmental Health Center (MSSM) 
Study, the Columbia Center for Children’s Environmental Health (CCEH) Study, and Health 
Outcomes and Measures of the Environment (HOME) Study.  
In Specific Aim 1, we examine the relationship between third trimester maternal urinary 
phthalate concentrations and percent fat mass among children aged 4 to 9 years in the MSSM 
cohort and evaluate effect measure modification by child’s sex. Bio-electrical impedance 
analysis was used to measure body composition (including percent fat mass) at follow-up visits 
scheduled at approximately ages 4-5.5, 6, and 7-9 years. MSSM is the only cohort that collected 
body composition data, which provides quantitative estimates of fat mass and is a more 
sensitive indicator of increased adiposity than anthropometry alone. Associations between 
phthalate metabolite concentrations and BMI z-scores are also estimated with the goals of 1) 
assessing the degree to which associations between body composition and BMI z-scores agree 
(i.e., is BMI z-score sufficiently sensitive to detect associations between phthalate metabolite 
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concentrations and fat mass?) and 2) facilitating comparisons with other studies that do not 
have body composition data with which to evaluate potential obesogenic effects.  
In Specific Aim 2, we estimate associations between phthalate concentrations measured 
in maternal urine collected during pregnancy and anthropometry outcomes (overweight or 
obesity, and weight, height, and BMI z-scores) collected at ages 4 to 7 years in the MSSM, 
CCEH, and HOME birth cohorts. All three cohorts collected longitudinal measures of 
anthropometry using similar standardized protocols. This aim builds upon the findings of Aim 1 
by replicating analyses of associations between prenatal phthalate concentrations and 
anthropometry in two additional cohorts. Furthermore, pooling these data provides increased 
sample size to detect small effect sizes and explore effect measure modification by factors such 
as child’s sex and race/ethnicity. 
For both aims, associations between biomarkers of prenatal phthalate exposure and 
longitudinal outcome measures are estimated using mixed effects models to account for 
repeated measures for each child. We fit these models using a flexible Bayesian framework to 
simultaneously account for the issues of missing exposure (metabolite concentrations below the 
limits of detection), covariate, and outcome data. We adjust for important confounders including 
maternal pre-pregnancy BMI, gestational weight gain, smoking during pregnancy, and 
breastfeeding and estimate associations in multiple metabolite models to account for potential 
confounding among correlated metabolites.   
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 Specific Aims B.
Specific Aim 1 
Estimate associations of third trimester urinary phthalate metabolite concentrations with 
longitudinal assessments of percent fat mass collected from children aged 4 to 9 years in the 
MSSM cohort.  
Sub Aim 1.1: Examine effect measure modification by child’s sex.  
 Sub Aim 1.2: Estimate associations with BMI z-scores. 
 
Specific Aim 2 
Estimate associations of prenatal urinary phthalate metabolite concentrations with longitudinal 
assessments of overweight/obese status and BMI, weight, and height z-scores among children 
aged 4 to 7 years in the MSSM, CCEH, and HOME cohorts. 
Sub Aim 2.1: Examine effect measure modification by cohort, child’s sex, and 
race/ethnicity. 
 
Hypotheses 
We hypothesize that higher prenatal phthalate concentrations will be positively associated with 
body size outcomes related to body fatness (i.e., percent fat mass, BMI, weight, and 
overweight/obese status) measured among children. Metabolites of di-(2-ethylhexyl) phthalate 
(DEHP), dibutyl phthalates (DBP), and butylbenzyl phthalate (BzBP) will be most strongly 
associated with fat and body size outcomes. Associations will be stronger in boys, particularly 
for metabolites of phthalates with anti-androgenic activity (e.g., DEHP, DBP, and BzBP). 
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CHAPTER II. REVIEW OF THE LITERATURE 
 
  Childhood Obesity A.
 
Prevalence and Impact of Childhood Obesity 
Childhood overweight and obesity, defined as greater than the 85th and 95th percentile of 
BMI for age and sex among children under age 20, is an emerging epidemic in the United 
States (US) and around the world. Globally, over 43 million children under the age of 5 are 
overweight, of whom 35 million live in developing countries (World Health Organization 2011). In 
the US, 11.9% of children aged 2-19 are obese and 31.7% are overweight (Ogden et al. 2010). 
Children of African American and Hispanic ethnicity have a particularly high prevalence of 
overweight and obesity. The prevalences of overweight and obesity are higher among both non-
Hispanic black (35.9%, 20.0%) and Hispanic (38.2%, 20.9%) children aged 2-19 compared to 
non-Hispanic white children (29.3%, 15.3%) (Ogden et al. 2010). 
Obese children are at risk of becoming obese adults (Serdula et al. 1993), with the 
concomitant risks of diabetes, heart disease, cancer, and many other conditions. In addition, 
overweight and obese children exhibit early physiologic changes associated with these chronic 
health conditions. For example, a recent systematic review and meta-analysis reported that 
obese children aged 5 to 15 have signs of early cardiovascular disease including higher systolic 
and diastolic blood pressure, cholesterol, triglycerides, fasting insulin, insulin resistance, and left 
ventricular mass compared to their normal-weight peers (Friedemann et al. 2012). The 
economic cost of childhood obesity is also substantial. The estimated annual cost of treating 
obesity-related diseases in children aged 6-17 increased from $35 million in 1979-1981 to $127 
million in 1997-1999 (Wang and Dietz 2002). 
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Measuring Body Size in Children  
This dissertation utilizes two methods of assessing child body size: 1) bio-electrical 
impedance analysis (BIA) of body composition, and 2) anthropometric measurements of body 
size.  
BIA is a body composition measurement method that provides estimates of fat-free 
mass and fat mass. BIA requires that a person stand barefoot on a device resembling a scale to 
make contact with electrodes that send current through the body. BIA measures impedance, or 
opposition to a weak electrical current flowing through body tissues. Lean body mass has a low 
impedance because it is mostly aqueous and conducts electricity well, whereas fat mass has 
high impedance. Impedance is proportional to total body water and is used to estimate fat-free 
mass.  
As BIA is an indirect method for assessing body composition, estimates of fat-free mass 
are obtained by using the measured impedance values in prediction equations developed 
against a reference standard. Based on a two-compartment model of the body (fat mass and 
fat-free mass), fat-free mass can be subtracted from the individual’s weight to obtain an 
estimate of fat mass (Ellis 2001; Houtkooper et al. 1996). Percent body fat is then estimated as 
100 x (weight – fat free mass)/weight (Ellis 2001). Fat mass index and fat-free mass index are 
height-adjusted measures of fat and lean mass (fat mass index = fat mass / height2, fat-free 
mass index = fat-free mass / height2) (Freedman et al. 2005b; Lohman and Going 2006).  
BIA may provide more precise estimates of adiposity than anthropometry since it 
distinguishes between fat and lean mass. There is known variation in fat mass within a given 
BMI and vice versa, particularly in children (Ellis 2001; Wright et al. 2008). For example, a high 
BMI can be achieved through greater muscle or bone mass rather than fat mass (Lohman and 
Going 2006). BIA provides a means for identifying children with excess fat versus children who 
are heavy due to greater lean mass, which is important in terms of future disease risk. 
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BIA relies on the assumption that fat-free mass has a relatively constant water content, 
which may not be the case among young children (Ellis 2001). Using pediatric-specific 
prediction equations helps to reduce misclassification of fat-free mass. Tanita leg-to-leg BIA 
does not perform as well as gold standard estimators of body density such as underwater 
weighting or total body water by isotope dilution. However, validation studies have reported 
good performance of BIA measurements in comparison to gold standard measures (Jebb et al. 
2000; Nunez et al. 1997; Xie et al. 1999) and BIA is considered a valid estimator of adiposity for 
epidemiology studies (Ellis 2001; Houtkooper et al. 1996). Benefits of BIA in comparison to 
other body composition techniques are that BIA is low cost, portable, and non-invasive 
(Houtkooper et al. 1996).  
In contrast to BIA, anthropometry is an inexpensive and non-invasive method for 
measuring body characteristics that is commonly used in epidemiology studies. It includes 
measures of height, weight, and circumferences or lengths of various body regions. 
Anthropometric measurements that are used to assess body fatness include metrics such as 
weight, BMI, or waist circumference. Because weight is a measure of total mass that 
incorporates muscle, bone, organs, and fat, greater weight does not necessarily indicate greater 
adiposity. BMI is a measure of excess weight for height [BMI (kg/m2) = weight (kg)/height (m)2] 
that is widely used in field studies as an indicator of adiposity. Waist circumference is a measure 
of central adiposity.  
 Raw anthropometric measurements can be used on their own for outcomes studies but 
they do not account for natural changes in growth patterns over childhood (Kuczmarski et al. 
2002). Instead, raw measures are often converted to percentiles or z-scores in order to compare 
a child’s weight, height, waist circumference, or BMI to a reference population. Percentiles and 
z-scores are usually age- and sex- specific and can be further customized (e.g., race or ethnic 
groups). Percentiles are used to determine the percent of a reference population that would 
have a value less than an individual’s value. For example, a BMI percentile of 85 indicates that 
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85% of the reference population has a BMI percentile of less than 85.  Overweight and obesity 
are clinical definitions of excess body fat that are defined using BMI percentiles, where 
overweight is greater than the 85th percentile and obesity is greater than the 95th percentile. Z-
scores represent the difference between the individual’s value and the mean value in the 
reference population divided by the standard deviation in the reference population. Z-scores are 
useful for longitudinal modeling of growth as the expected value at any time point is 0 if the 
population is a random sample of the population used to create the reference. Further, z-scores 
are standardized to the population standard deviation, reducing likelihood of heteroscedasticity. 
The 2000 CDC growth charts are often used in epidemiology studies to calculate age- and sex-
specific percentiles or z-scores in reference to the US population (Kuczmarski et al. 2002). 
Using age- and sex-standardized measures facilitates valid comparisons in pediatric studies 
since children are in a period of rapid change with patterns that differ between girls and boys.   
In children, BMI is a moderately sensitive and highly specific indicator of adiposity, and 
adolescents with a high BMI are at greater risk for adverse health outcomes in adulthood 
(Freedman and Sherry 2009). Evidence suggests that body composition methods may not 
outperform anthropometry when assessing associations between adiposity and metabolic risk 
factors (Stevens et al. 2008). For example, studies of blood pressure, blood glucose, high-
density lipoprotein cholesterol, insulin, and triglycerides in adults have reported that 
anthropometric measures such as BMI are as or more predictive of these physiologic markers of 
adiposity than BIA or dual-energy X-ray absorptiometry (Hemmingsson et al. 2009; Lee et al. 
2008; Willett et al. 2006). A further benefit of using anthropometric measures is that they are 
more easily understood by the public and facilitate risk communication (Stevens et al. 2008). 
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 Environmental Causes of Obesity  B.
 
Emerging evidence suggests that factors other than energy balance may contribute to 
the rapid rise in obesity rates (Heindel and vom Saal 2009; Keith et al. 2006) and several 
discoveries have led to a search for environmental causes of obesity. First, the concomitant 
increase in production of synthetic chemicals with rising obesity rates has implicated 
environmental exposures as potential risk factors for obesity (Baillie-Hamilton 2002), although 
this putative link suffers from the ecological fallacy. Second, prenatal factors such as fetal 
growth restriction and gestational tobacco smoke exposure have been demonstrated to affect 
obesity risk, indicating that in utero environmental exposures may program an obesogenic 
phenotype (Braun et al. 2010a; Heindel and vom Saal 2009; Oken et al. 2008). Third, adipose 
tissue is now recognized to be an active endocrine organ with chemical and hormonal signaling, 
which makes it a potential target for endocrine disrupting chemicals (Cooke and Naaz 2004; 
Newbold et al. 2009). Taken together, these findings provide a basis for exploring the role of 
endocrine disrupting chemicals in promoting obesity. 
The “environmental obesogen hypothesis” theorizes that prenatal exposure to endocrine 
disruptors increases susceptibility to obesity through a fetal programming mechanism that may 
1) alter control of adipose tissue development pathways, 2) increase the number of fat cells, 3) 
modify food intake and metabolism, and 4) affect insulin sensitivity and lipid metabolism 
(Diamanti-Kandarakis et al. 2009; Grun and Blumberg 2009; Heindel and vom Saal 2009). 
There is emerging human evidence of an association between prenatal or early life 
exposure to environmental endocrine disruptors and body size in childhood, particularly 
persistent organic pollutants (for example: (Blanck et al. 2002; Gladen et al. 2000; Gladen et al. 
2004; Halldorsson et al. 2012; Hertz-Picciotto et al. 2005; Jacobson et al. 1990; Karmaus et al. 
2002; Lamb et al. 2006; Mendez et al. 2011; Patandin et al. 1998; Smink et al. 2008; Valvi et al. 
2012; Verhulst et al. 2009)). These studies have reported positive associations between early 
life dichloro-diphenyldichloroethylene (DDE) and hexachlorobenzene (HCB) exposure and 
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childhood growth, and associations with polychlorinated biphenyls (PCBs) that depend on 
gender, timing, and dose (Tang-Peronard et al. 2011).  Overall, these studies provide evidence 
that endocrine disrupting chemicals may alter childhood growth and lend support to the 
obesogen hypothesis.   
 
 Phthalate Exposures and Health Effects C.
Phthalates are synthetic diesters of phthalic acid used in a variety of industrial and 
consumer products. Phthalates are often grouped by molecular weight, with low molecular 
weight phthalates having fewer than 8 carbons in the alkyl chain and high molecular weight 
having 8 or more carbons.  High molecular weight phthalates are added to plastics to make 
them flexible and durable. Low molecular weight phthalates are used as adhesives, detergents, 
and solvents. Sources of phthalate exposure in consumer products are varied and include 
polyvinyl chloride plastics, building materials, medical devices, pharmaceuticals, automotive 
components, toys, food packaging, cosmetics, fragrances, and pesticides (Schettler 2006). Over 
three million metric tons are produced annually (Bizzari et al. 2000). 
 
Human Exposure to Phthalates 
Human exposure to phthalates is ubiquitous, arising from contact with a wide range of 
consumer products. Phthalates may enter the body through ingestion, inhalation, dermal 
absorption, or intravenous injection. Biomonitoring of the phthalate metabolites has identified 
virtually universal exposure internationally and across all age ranges. At least 10 metabolites 
are commonly detected and three metabolites, mono-ethyl (MEP), mono-n-butyl (MBP), and 
mono-benzyl (MBzP), were present in more than 97% of urinary samples analyzed in the 1999-
2000 NHANES survey (Silva et al. 2004).  
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Widespread phthalate exposure has prompted concern about potential adverse health 
effects, particularly with respect to fetal exposures since phthalate metabolites can cross the 
placenta (Mose et al. 2007). Due to these concerns, some phthalates have been regulated in 
consumer products in the US and abroad ([Anonymous] 2005a, b, 2008). The US federal 
regulations focus on reducing childhood exposures DEHP, DBP, and BzBP by regulating their 
presence in bath toys or other small plastic toys that can be mouthed by children. However, fetal 
exposure to phthalates may occur through maternal contact with phthalate-containing products, 
and, in some circumstances, banned phthalate diesters have merely been replaced by others 
that are both unstudied and unregulated. 
 
Biomarkers of Phthalate Exposure 
 
Biomarkers of phthalate exposure are a useful dosimeter because they incorporate 
exposure from multiple routes and sources. Phthalates can be measured in urine, serum, saliva, 
seminal fluid, breast milk, amniotic fluid, meconium, and placenta. However, urinary biomarkers 
of phthalate metabolites are the preferred method of measuring human exposure (Calafat and 
McKee 2006; Hogberg et al. 2008). Metabolite levels in urine are higher than in other media, 
can be more precisely measured, and are less intrusive to study subjects than collection of 
other biologic specimens. Measurement of phthalate metabolites rather than diesters also 
reduces the risk of contamination from phthalate-containing laboratory equipment, whereas the 
use of phthalate metabolite concentrations in blood or blood products as exposure biomarkers is 
questionable (Calafat et al. 2013). 
Phthalates are quickly metabolized and excreted in urine, with elimination half-lives of 
less than 24 hours (<3 hours for phthalates and <12 hours for metabolites) (Koch et al. 2005). 
Diesters are metabolized to primary and secondary metabolites that are more bioavailable in the 
body. Phthalates and their metabolites, as well as concentrations measured in a US population-
based sample, are described by molecular weight class in Table 1. 
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Studies examining repeated urine samples over periods of up to 3 months have reported 
intraclass correlations between 0.2 and 0.8, indicating that a single sample may be useful to 
project long term exposure to some phthalates but not others (Adibi et al. 2008; Fromme et al. 
2007; Hauser et al. 2004; Marcus et al. 2010). Within person reproducibility of urinary phthalate 
metabolite levels measured on consecutive days ranges from 0.5 to 0.8, depending on the 
phthalate (Hoppin et al. 2002). Thus, there is substantial variability in individual exposures over 
time and repeat samples are optimal for classifying an individual’s phthalate exposures. 
However, many sources of phthalate exposure are frequent and may result in steady-state 
levels (Calafat and McKee 2006; Hauser et al. 2004). The probability of correctly classifying 
“high exposure” over a 6-12 week period by using a single sample was reported in two studies 
to range between 0.50 and 0.74, depending on the metabolite (Adibi et al. 2008; Hauser et al. 
2004). Urinary concentrations of phthalate metabolites in a single urine sample may be 
moderately predictive of DBP, DiBP, DEP, and BzBP exposures during pregnancy, with greater 
variability for DEHP (Adibi et al. 2008; Braun et al. 2012; Ferguson et al. 2014a). 
 1
3
 
 
Table 1. Phthalate metabolite classification and concentrations measured in the 2001-2002 National Health and Nutrition 
Examination Survey (NHANES)  
Class Phthalate  Abbreviation Metabolite  Abbreviation 
NHANES* median (µg/g) 
Total Population Pregnant Women 
Low Molecular Weight      
 Dibutyl  DBP Mono-isobutyl MiBP  2.5 3.3 
 Mono-n-butyl  MnBP  17.4 22.7 
 Diethyl  DEP Mono-ethyl  MEP 97.4 306.4 
 Dimethyl  DMP Mono-methyl  MMP 1.3 2.1 
High Molecular Weight      
 Benzylbutyl  BzBP  Mono-benzyl  MBzP  9.7 15.7 
 Di-2-ethylhexyl  DEHP Mono-2-ethylhexyl  MEHP 3.9 10.4 
 Mono- (2-ethyl-5-hydroxyhexyl) MEHHP 16.6 22.8 
 Mono- (2-ethyl-5-oxohexyl) MEOHP 11.2 17.8 
 Mono- (2-ethyl-5-carboxypentyl) MECPP 27.0† n/a 
 Di-n-octyl  DnOP Mono- (3-carboxypropyl) MCPP 2.5 3.5 
 Di-isodecyl DIDP Mono-(carboxynonyl) MCNP 4.5‡ n/a 
 Di-isononyl DINP Mono-(carboxyoctyl) MCOP 2.5‡ n/a 
* Median creatinine-corrected concentration among the total population (Centers for Disease Control and Prevention) and pregnant 
women (Ye et al. 2009)   
† MECPP concentration in the 2003-2004 NHANES (not measured in 2001-2002) 
‡ MCNP and MCOP concentration in the 2005-2006 NHANES (not measured in 2001-2002) 
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Phthalate Health Effects  
Phthalate metabolite biomarker concentrations are among the highest of all endocrine 
disrupting chemicals (EDCs), and phthalates interfere with hormone homeostasis in animal, 
human, and in vitro studies (Committee on the Health Risks of Phthalates 2008; Shen et al. 
2009). Experimental animal studies have reported adverse reproductive and developmental 
outcomes due to phthalate exposure and suggest that phthalates may have endocrine-
disrupting properties (Lyche et al. 2009). A collection of reproductive endpoints observed in 
male animals following phthalate exposures, termed the phthalate syndrome, includes reduced 
sperm counts, histological changes in the testes, cryptorchidism, hypospadias, and reduced 
fertility (National Science Foundation 2008). Developmental outcomes observed in animals 
exposed to phthalates include reduced weight gain and survival of pups, male reproductive tract 
malformations, neural tube defects, and developmental delays (National Toxicology Program 
(NTP) 2003a, b, c, d, e, f, 2006).  
There is a small but growing epidemiologic literature on potential adverse human health 
effects of phthalates. Human in utero exposure has been linked to altered gestational duration, 
reduced anogenital distance in boys, and impaired behavior and executive functioning skills 
(Adibi et al. 2009; Engel et al. 2010; Latini et al. 2003; Swan et al. 2005; Swan 2008; Whyatt et 
al. 2009; Wolff et al. 2008). Reproductive, respiratory, metabolic, and thyroid effects in children 
and adults have also been reported (Bornehag and Nanberg 2010; Duty et al. 2003; Hatch et al. 
2008; Hauser et al. 2006; Huang et al. 2007; Stahlhut et al. 2007). A recent review of the state 
of the literature on phthalate exposures and children’s health concluded that consistent 
evidence from well-designed studies support the existence of an association between early life 
DEHP and BzBP exposures and allergic diseases, with more limited evidence for associations 
of phthalate exposures with infant birth size, gestational length, physical development, 
neurodevelopment, and, in male infants, shorter anogenital distance (Braun et al. 2013). 
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 Phthalates and Childhood Obesity D.
Proposed Biologic Mechanisms 
Evidence suggests that phthalates may promote an obesogenic phenotype by altering 
peroxisome proliferator-activated receptors (PPARs), affecting hormone levels, or acting as anti-
androgens (Figure 1). Phthalate metabolites have been shown to modify PPARs alpha and 
gamma in animal models, which may influence developmental programming of the metabolic 
system by increasing adipogenesis and altering insulin and leptin levels. Animal evidence 
indicates that phthalate exposures affect hormone signaling and cross-sectional studies in 
humans have reported associations between concentrations of some phthalate metabolites and 
thyroid hormone levels. Additionally, several phthalates exhibit anti-androgenic activity, which 
may cause sex-specific changes in muscle and fat development.  
 
 
Figure 1. Association between prenatal phthalate exposure and childhood adiposity 
 
PPARs are nuclear receptor proteins that activate gene expression and have important 
roles in regulating energy metabolism, cell proliferation, and inflammation. PPAR alpha is 
expressed in several body compartments including liver and adipose tissue and is an important 
regulator of glucose metabolism. Studies of PPAR alpha null mice have shown altered lipid 
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homeostasis and fatty acid metabolism. PPAR gamma is expressed in adipose tissue and plays 
a key role in adipogenesis, insulin sensitivity, and lipid storage.  
Phthalate metabolites have been shown to modify PPARs alpha and gamma in animal 
models, which may influence developmental programming of the metabolic system by 
increasing adipogenesis and altering insulin and leptin levels (Bility et al. 2004; Boberg et al. 
2008; Casals-Casas et al. 2008; Desvergne et al. 2009; Feige et al. 2010; Hurst and Waxman 
2003; Lampen et al. 2003; Maloney and Waxman 1999; Sargis et al. 2009). The experimental 
animal literature has focused primarily on DEHP or its metabolites as they are known to be 
hepatotoxic and PPAR alpha is expressed in liver. These studies indicate that DEHP and its 
metabolites affect both PPAR alpha and gamma expression. Studies have also reported 
changes in PPAR alpha and gamma expression associated with DBP and BzBP but not DMP or 
DEP metabolites.  
If phthalates affect obesity through a PPAR mechanism, associations might also be 
observed between phthalate exposures and diabetes because PPARs regulate glucose 
homeostasis. Cross-sectional studies have reported associations between phthalates and 
diabetes or insulin resistance in adults, though results were inconsistent regarding which 
phthalates were associated with outcomes and whether metabolites were associated with 
increased, decreased, or no difference in prevalence of diabetes  (James-Todd et al. 2012; Lind 
et al. 2012b; Stahlhut et al. 2007; Svensson et al. 2011).  
Thyroid and thyroid stimulating hormones are integral for regulating growth and 
metabolism. Experimental evidence indicates that phthalates affect thyroid hormone signaling 
(Breous et al. 2005; Ishihara et al. 2003; Shimada and Yamauchi 2004; Sugiyama et al. 2005; 
Wenzel et al. 2005). In rats, DEHP lowers free thyroxine (T4) levels and alters iodide uptake in 
thyroid follicular cells (Hinton et al. 1986; Howarth et al. 2001; Poon et al. 1997; Price et al. 
1988; Wenzel et al. 2005) and DBP exposure causes reduced triiodothyronine (T3) and T4 
levels (O'Connor et al. 2002). The growth hormone insulin-like growth factor 1 (IGF-1) may also 
17 
 
be influenced by phthalates. In utero DBP and DEHP exposure in rats has been reported to 
increase mRNA expression for IGF pathway genes (Bowman et al. 2005; Lin et al. 2008). 
Though cross-sectional studies do not provide causal evidence, reports of associations between 
urinary phthalate metabolites and thyroid hormones, including T3, T4, thyroglobulin, and thyroid-
stimulating hormone, have generally found inverse associations (Boas et al. 2010; Huang et al. 
2007; Meeker et al. 2007; Meeker and Ferguson 2011). 
Androgens are sex steroid hormones with key roles in male reproductive development.  
Studies have consistently reported effects of in utero DEHP, BzBP, and DBP exposures on 
male androgen-related reproductive endpoints in rats and mice, including hypospadias, 
cryptorchidism, reduced testosterone production, and decreased sperm counts (Fisher 2004; 
Gray et al. 2006; Lottrup et al. 2006; Pan et al. 2006). Two prospective studies have examined 
early life phthalate exposures in relationship to androgen-mediated effects. Swan et al. reported 
associations between prenatal levels of MEP, MBP, and DEHP metabolites and shortened 
anogenital distance, reduced penile width, and incomplete testicular descent (Swan 2008). Main 
et al. reported correlations between MEP, MBP, MMP, MEHP, and MINP in breast milk and 
reproductive hormone levels in the serum of 3 month old boys (Main et al. 2006).  
Androgens may also be linked to changes in adiposity since these hormones affect body 
composition by promoting skeletal muscle development and inhibiting lipid storage in fat cells.  
Since men have higher levels of androgens such as testosterone, they typically have more 
muscle and less fat than women. Androgen levels are associated with obesity and metabolic 
syndrome in adults, with notable differences in relationships by sex (Barber et al. 2006; Moulana 
et al. 2011).  Low testosterone levels are associated with poorer cardiovascular health and 
larger waist circumference in men.  In women, high testosterone levels are associated with 
increased BMI, metabolic syndrome, and polycystic ovary disease. Because phthalates inhibit 
androgen activity, it is hypothesized that effects of phthalates through this pathway would result 
in increased adiposity in men but decreased or no change in women. 
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Toxicological Evidence 
 Toxicological studies have directly assessed the role of early life exposure to DEHP or 
its hydrolytic metabolite, MEHP, in the development of obesogenic phenotypes, with results 
indicating species- and dose-specific effects. Two studies of perinatal MEHP or DEHP exposure 
in mice reported increased body weight and fat deposition in offspring, though one study 
observed effects only at the lowest dose (0.05 but not 0.25 or 0.5 mg MEHP/kg/day) (Hao et al. 
2012) and the other reported effects only at the highest dose (5 but not 0.05 mg DEHP/kg/day) 
(Schmidt et al. 2012). Two studies of pregnant rats exposed to doses ranging from 1 to 400 mg 
DEHP/kg/day reported no difference in offspring total body weight (Campioli et al. 2014; 
Kobayashi et al. 2006). In contrast, relatively high dose DEHP exposure (2% by body weight) 
induced PPAR alpha-mediated reductions in body weight and fat mass in both rats (Itsuki-
Yoneda et al. 2007) and mice (Xie et al. 2002). Interestingly, Feige et al. reported that although 
high dose DEHP exposure (500 mg/kg body mass/day) protected against diet-induced obesity 
via PPAR alpha activation in wild-type mice, mice with humanized PPAR alpha gained more 
weight and adipose tissue than untreated controls (Feige et al. 2010). While the causes of 
species differences remain unclear, effects of DEHP on other, less understood pathways (e.g., 
liver metabolism, thyroid function, or androgen activity) may play a role. 
 
Epidemiological Evidence 
Several studies, primarily cross-sectional, have reported associations between phthalate 
metabolite concentrations and BMI, obesity, weight, or waist circumference in children (Boas et 
al. 2010; de Cock et al. 2014; Hatch et al. 2008; Teitelbaum et al. 2012; Trasande et al. 2013; 
Wang et al. 2013) and adults (Hatch et al. 2008; Lind et al. 2012a; Song et al. 2014; Stahlhut et 
al. 2007). However, none assessed exposure to phthalates during gestation, which is thought to 
be a relevant critical time period for effects related to development of obesity (Dietz 1994). A 
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recent review of the literature on phthalates and body size concluded that findings are 
inconsistent regarding which phthalates are associated with outcomes or whether associations 
are positive or inverse (Goodman et al. 2014). Furthermore, a causal link between phthalate 
exposures and subsequent body size cannot be established in cross-sectional studies that 
measure concurrent exposures and outcomes (Engel and Wolff 2013).  
In the only previous study of early life phthalate exposure and BMI in humans, de Cock 
et al. examined quartiles of DEHP metabolite concentrations measured in cord blood (likely 
reflecting primarily intrapartum exposures) in relation to repeated BMI measurements in the first 
year of life among 89 Dutch infants (de Cock et al. 2014). Children in the lowest MECPP quartile 
and boys in the lowest MEOHP quartile had higher BMI in the first year, though there was no 
evidence of dose-response and the same pattern was not observed for MEHHP, another 
secondary oxidative metabolite of DEHP. This study has several important limitations. Analyses 
were stratified by phthalate quartile and sex yielding very small sample sizes at each time point 
(<10). Further, the use of phthalate metabolite concentrations in blood or blood products as 
exposure biomarkers is questionable (Calafat et al. 2013). While the authors only measured 
secondary or oxidative metabolites, that may reflect true biological exposures, it is possible that 
cord plasma DEHP metabolites arise from hospital-based exposures to DEHP at the time of 
delivery (Vandentorren et al. 2011; Yan et al. 2009). 
 
 Knowledge Gaps E.
While there is evidence that prenatal exposure to other environmental EDCs affect 
childhood growth and may have sex-specific effects (Blanck et al. 2002; Gladen et al. 2000; 
Gladen et al. 2004; Hertz-Picciotto et al. 2005; Karmaus et al. 2009; Lamb et al. 2006; Mendez 
et al. 2011; Smink et al. 2008; Verhulst et al. 2009), no studies have yet prospectively examined 
prenatal phthalate exposure and body size in humans.  
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Cross-sectional analyses cannot disentangle the temporal ordering of exposure and 
outcome; it is unclear whether phthalate exposures are causally related to obesity or phthalate 
body burden differs in obese individuals due to differences in exposure to phthalate sources. 
For example, it is plausible that phthalate exposures differ among obese individuals due to 
differences in exposure through 1) dietary sources, both amount and types of foods (Serrano et 
al. 2014), 2) personal care product use, due to larger surface area, (Buckley et al. 2012; Duty et 
al. 2005; Just et al. 2010; Watkins et al. 2014) or 3) medications to treat comorbid conditions, 
since DBP and DEP are used to coat some medications (Hernandez-Diaz et al. 2013).   
Previous studies have been unable to examine prenatal exposure, which is thought to be 
the relevant critical window for an effect of phthalates on adiposity. No prior studies of children 
have measured adiposity using bio-electrical impedance analysis, which is a strength of the 
current study. Finally, prior investigations of phthalates and of other EDCs have been limited in 
their ability to examine effect heterogeneity by sex due to small sample sizes or populations 
comprised of only males or females. This prospective study of prenatal phthalate exposures 
addresses the above gaps in the scientific evidence regarding the role of phthalates in affecting 
body size or promoting obesity in children.
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CHAPTER III. METHODS 
 
 Study Design Overview A.
 
This dissertation assesses associations between maternal urinary phthalate metabolite 
concentrations during pregnancy and longitudinal measures of childhood body size among 
members of the MSSM, CCEH, and HOME birth cohorts. Specific Aim 1 assesses the 
association of third trimester maternal urinary phthalate concentrations and percent fat mass 
during childhood in the MSSM cohort, the only study that assessed body composition. Specific 
Aim 2 examines prenatal phthalate exposures in relation to anthropometry outcomes in all three 
cohorts and assesses effect measure modification and dose-response in this larger pooled 
sample. For both aims, we used a Bayesian multilevel modeling framework to incorporate 
multiple observations per child, stabilize estimates of correlated phthalate metabolites, and 
account for missing data in exposures, covariates, and outcomes.  
 
 Study Populations B.
 
The NIEHS/EPA funded Mount Sinai Children’s Environmental Health and Disease 
Prevention Research Center enrolled 479 primiparous women from the Mount Sinai prenatal 
clinic and two adjacent private practices between 1998 and 2002. Women had to have had a 
prenatal care visit by 26 weeks gestation, no serious medical complications (hypertension, 
diabetes, thyroid disease), consumed less than 3 alcoholic beverages per day, and had no 
illegal drug use. Seventy-five women were subsequently excluded because of medical 
complications, very premature births (<32 weeks gestation or <1500 grams), delivery of an 
infant with birth defects, inability to obtain biological specimens before delivery, change of 
residence, or refusal to continue participation. The final cohort consists of 404 mother-infant 
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pairs for whom birth data are available. Children attended follow-up clinic visits scheduled at 
approximately ages 1, 2, 4, 6, and 7 years. Data regarding maternal characteristics were 
collected by an in person, two hour structured interview administered to mothers by trained 
research assistants during third trimester prenatal care visits. This questionnaire was 
administered to all mothers (n = 404) and ascertained information on environmental exposures, 
sociodemographic characteristics, maternal health, and lifestyle habits. Pregnancy and delivery 
characteristics, birth outcomes, gestational age, and infant sex were ascertained from the 
computerized perinatal database at Mount Sinai Hospital. Duration of breastfeeding was 
ascertained by maternal questionnaire at the earliest follow-up visit. A number of studies within 
this sample have been published (Berkowitz et al. 2003; Berkowitz et al. 2004; Engel et al. 
2007; Engel et al. 2009; Engel et al. 2010; Wolff et al. 2007; Wolff et al. 2008). 
The Columbia Center for Children’s Environmental Health enrolled 727 pregnant women 
between 1998 and 2006. The cohort was restricted to non-smoking women 18-35 years old who 
self-identified as either African American or Dominican and who had resided in Northern 
Manhattan or the South Bronx in New York City for >1 year prior to pregnancy. Women were 
excluded if they used illicit drugs; had diabetes, hypertension, or known human 
immunodeficiency virus; or had their first prenatal visit after gestational week 20. Women were 
enrolled if a 48-hour personal air sample was collected during their third trimester and a blood 
sample was collected from the mother and/or newborn at delivery. The cohort was 
predominantly full term (no infant was born <32 weeks gestation or <1500g). Follow-up visits 
were conducted at 6 months and 1, 2, 3, 5, and 7 years. Investigations of this sample have been 
previously published (Adibi et al. 2008; Adibi et al. 2009; Just et al. 2010; Perera et al. 2006; 
Perera et al. 2003; Whyatt et al. 2009). 
The Health Outcomes and Measures of the Environment (HOME) Study is an ongoing 
NIEHS/EPA funded prospective birth cohort. Among 1,263 eligible women, 468 enrolled in the 
HOME Study between March 2003 and January 2006. Because the HOME Study contains a 
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nested, randomized trial of in-home lead and injury hazard controls women had to be living in 
housing built before 1978. Additional eligibility criteria included: <19 weeks gestation upon 
enrollment; living in Brown, Butler, Clermont, Hamilton or Warren counties in Ohio; intention to 
continue prenatal care and deliver at collaborating obstetric practices; human immunodeficiency 
virus negative; and not receiving seizure, thyroid, or chemotherapy/ radiation medications. A 
total of 389 women delivered live-born, singleton infants without birth defects. Children returned 
for annual follow-up visits between 1 and 5 years of age. Characteristics of this sample have 
been previously described (Braun et al. 2009; Braun et al. 2010a; Braun et al. 2010b; Braun et 
al. 2011). 
 
Human Subjects 
Women provided informed consent prior to participation and children aged ≥ 7 years 
provided assent. The MSSM, CCEH, and HOME studies received approval from the Institutional 
Review Boards of the Mount Sinai School of Medicine, Columbia University, and the University 
of Cincinnati College of Medicine, respectively. The involvement of the Centers for Disease 
Control and Prevention (CDC) laboratory was determined not to constitute engagement in 
human subjects research. 
This dissertation utilizes previously collected, de-identified data and no study participants 
were contacted for additional information. The project was approved by the Institutional Review 
Board of the University of North Carolina at Chapel Hill on February 13, 2012. 
 
Study Sample for Specific Aim 1 
 Children in the MSSM study (N = 404) were invited to return for three follow-up visits 
scheduled at approximately ages 4-5.5 (mean=4.9), 6 (mean=6.2), and 7-9 (mean=7.8) years. 
Of the 188 children who returned for at least one follow up visit between ages 4 and 9 years, 
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maternal prenatal phthalate metabolite concentrations were available for 182 children. Following 
previous work (Wolff et al. 2008), we excluded two observations obtained from a very dilute 
urine sample (<10 mg/dL creatinine) due to the potential for inaccurate biomarker 
measurements. Thus, the final sample for Specific Aim 1 is 180 children with body composition 
and anthropometry measurements collected at a total of 364 follow up visits. 
 
Study Sample for Specific Aim 2 
Specific Aim 2 utilizes data from all three cohorts. These studies were designed with 
many common features and the feasibility of pooling data is supported by the following 
circumstances: (1) urine samples were collected during the same period of pregnancy and 
levels are comparable across cohorts; (2) urine samples were analyzed for phthalate 
metabolites at the same laboratory; (3) body size assessment protocols were performed in the 
same manner at each study site; (4) there are overlapping ages at which outcomes were 
assessed between the studies; and (5) there is information on key confounding factors available 
from all cohorts. 
The study population for Specific Aim 2 includes children in the MSSM, CCEH, and 
HOME studies with measured maternal urinary phthalate concentrations during pregnancy. We 
excluded infants born at <32 weeks gestation or <1500 grams (n = 1 CCEH and 5 HOME cohort 
members) and samples with a very dilute urine concentration (<10 mg/dL creatinine, n = 
9)(Wolff et al. 2008). Of the 1143 children meeting our baseline inclusion criteria, the final study 
sample included 707 children with weight and height data collected at one or more follow-up 
visits occurring between 4 and 7 years of age (n = 1416 follow-up visits). 
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 Exposure Assessment C.
 
Data Collection 
 Women provided a spot urine sample at mean ± standard deviation (SD) gestational 
ages of 31.6 ± 5.1 (MSSM), 34.4 ± 3.0 (CCEH), and 27.1 ± 2.2 (HOME) weeks. All three cohorts 
shipped third trimester spot urine specimens to the laboratory of Dr. Antonia Calafat at the 
Centers for Disease Control and Prevention (CDC) where samples were analyzed for phthalate 
metabolites. Sample collection and storage as well as analytic methods and quality control 
procedures have been previously described (Kato et al. 2005; Silva et al. 2008; Valentin-Blasini 
et al. 2007). The CDC lab is Clinical Laboratory Improvement Amendments certified and follows 
strict quality control protocols that are enforced by post-analysis independent statistical review 
before release of results. Internal batches include blanks and urine pools whose results must 
conform to a stipulated quality control range, or else the batch is rerun (Norrgran et al. 2006; 
Westgard et al. 1981). In addition, a blind pool is incorporated every tenth sample. When results 
for a batch’s external quality control deviate from the overall values, CDC reruns that batch 
(specimens are retained until the study is complete). Correction factors were applied to MBzP 
(0.72) and MEP (0.66) concentrations and limits of detection (LOD) to adjust for inaccuracies in 
analytical standards (Centers for Disease Control and Prevention 2012).  
 
Measures 
Phthalate metabolites measured in all three cohorts include MBP, MIBP, MEP, MBZP, 
MCPP, MEHP, MEHHP, MEOHP, and MECPP. Following previous work (Wolff et al. 2008), we 
examined DEHP metabolites (MECPP, MEHHP, MEHP, MEOHP) as a micromolar sum 
(ΣDEHP, micromoles per liter) as they are highly correlated, represent exposure from the same 
sources, and cannot be independently intervened upon.   
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To facilitate comparison of phthalate effect sizes in each Aim, we standardized the 
natural log concentration of each phthalate metabolite to its mean and SD. For Specific Aim 2, 
we standardized metabolites to their distributions in the pooled sample. To examine non-
monotonic associations (e.g., threshold effects), we also explored the form of exposure-
response relationships using quantile groups (tertiles for Aim 1 and quartiles for Aim 2). For 
these analyses, we categorized exposure using creatinine-corrected concentrations 
(micrograms per gram creatinine for metabolites or micromoles per gram creatinine for 
∑DEHP).  
 
 Outcome Assessment D.
 
Body Composition 
MSSM assessed body composition of children using leg-to-leg BIA at study visits 
scheduled at approximately 4-5.5, 6, and 7-9 years of age (1-3 study visits per child). The Tanita 
scales were donated by the company and are not commercially available (Tanita TBF-300). 
These scales were specifically designed for use in pediatric research with features such as 
small foot pads. Study staff were trained to use the BIA equipment using standard protocols.  
There is no agreed upon set of prediction equations for BIA analysis in children. The 
Tanita scales feature a built-in, proprietary pediatric prediction equation for calculating body 
composition estimates. The product specifications note that the built-in pediatric equations are 
valid for children aged 7 years and older. The prediction equations cannot be directly validated 
since body composition measures using gold or alloyed gold standard methods are unavailable 
in this cohort (e.g., dual-energy X-ray absorptiometry, underwater weighing). 
As an exploratory analysis, we compared the body composition values calculated by the 
Tanita scale to values estimated using two validated equations in the published literature 
(Clasey et al. 2011a; Horlick et al. 2002). Clasey et al. created and cross-validated BIA body 
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composition equations in a population of 436 white, non-Hispanic children aged 5-11 (Clasey et 
al. 2011a).  The study population included overweight and obese children in order to generate 
equations that are valid in these children, which have been underrepresented in samples used 
to validate other pediatric body composition equations. Unpublished work by these authors 
reported that the equation performs equally well among a sample of non-Hispanic black and bi-
racial children (Clasey et al. 2011b). The Clasey et al. equation predicts fat-free mass on the 
basis of height, weight, and impedance values.   
Horlick et al. generated equations based on a multi-ethnic population of 1170 New York 
City children aged 4-18 (Horlick et al. 2002). They published two sets of equations. The first 
equation predicts fat-free mass based on height, impedance, weight, age, and sex. The second 
equation additionally includes race/ethnicity and Tanner stage. Because Tanner staging is not 
available in the MSSM cohort, only the first equation was evaluated.  
 The Horlick et al. equation performed very poorly in our sample, with 103 of 364 fat-free 
mass estimates exceeding the child’s total mass. Therefore, we did not evaluate this equation 
further.  The Clasey et al. equation performed better, with estimated fat-free mass values 
exceeding total mass for only two children. The Pearson correlation coefficient between percent 
fat mass estimated using the Clasey et al. equation versus the built-in Tanita equation was very 
high (0.97).  
This similarity is not unexpected, as previous studies have shown that various prediction 
equations perform similarly well in terms of 1) the correlation between predicted and observed 
total body water and fat-free mass (Horlick et al. 2002) and 2) the rank order of children by body 
fat mass (Williams et al. 2007). Based on this exploratory analysis, we used the Tanita 
proprietary equations as they did not have implausible estimates and produced fat mass values 
that are highly correlated with those estimated by an equation validated for the age range in the 
current study. 
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Anthropometry 
Weight and height were measured at follow-up visits scheduled for approximately ages 
4-5.5, 6, and 7-9 years (MSSM), 5 and 7 years (CCEH), and 4, 5, and 7-9 years (HOME). In all 
three cohorts, study staff obtained anthropometric measurements using standard, uniform 
protocols for standing height and weight. We obtained body size measures from children in bare 
or stocking feet wearing light clothing (i.e., pediatric gown, underwear, or shorts and a t-shirt). 
We measured weight using a digital scale (HOME and CCEH 5 year visit) or a pediatric Tanita 
scale (MSSM and CCEH 7 year visit) (models TBF-300 and BC-418, Tanita Corporation of 
America, Arlington Heights, Illinois) and determined height using wall-mounted stadiometers.  
We calculated BMI as weight (kg) / height (m)2 and computed age- and sex-standardized 
BMI, weight, and height z-scores and percentiles using a CDC SAS macro (Centers for Disease 
Control and Prevention 2004). For Specific Aim 2, we also classified children at each follow-up 
visit as overweight or obese if their age- and sex-standardized BMI percentile exceeded 85. 
 
 Covariates E.
Variables Included in Outcome Models 
Each birth cohort administered questionnaires during pregnancy and early childhood and 
gathered additional information on the health status of mothers and children from medical and 
birth records. We identified variables on confounding pathways using directed acyclic graphs. 
These covariates included the following variables, which are described in greater detail below. 
• Maternal race/ethnicity 
• Maternal age 
• Maternal education 
• Maternal work status during pregnancy  
• Parity (Specific Aim 2) 
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• Maternal smoking during pregnancy 
• Maternal pre-pregnancy BMI 
• Maternal height 
• Adequacy of gestational weight gain (Specific Aim 1) 
• Gestational weight gain (Specific Aim 2) 
• Calendar date of urine collection 
• Urine dilution 
• Child’s sex 
• Breastfeeding 
• Months of age at follow-up 
• Physical activity (Specific Aim 1) 
• Cohort (Specific Aim 2) 
 
There are differences in both phthalate exposure patterns (Silva et al. 2004) and 
childhood obesity risk (Ogden et al. 2010) by race and ethnic group. We thus included 
race/ethnicity as a covariate and examined whether associations of phthalate metabolites with 
childhood body size were heterogeneous by race/ethnicity. Mother’s self-reported race/ethnicity 
was categorized as non-Hispanic white, non-Hispanic black, Hispanic, or other.  In Specific Aim 
1, we grouped children of Hispanic and other race/ethnicity based on the similarity of their 
outcome and covariate distributions. In Specific Aim 2, all four categories were included.  
Phthalate exposures vary by age (Silva et al. 2004) and maternal age is a known risk 
factor for various pregnancy outcomes including fetal growth. Maternal age at delivery was 
ascertained using the mother’s birth date and the date of delivery in all three cohorts.   
 Measures of socioeconomic status (SES) are associated with phthalate levels in women 
of reproductive age. For example, lower socioeconomic status is associated with higher levels 
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of MBZP and lower levels of DEHP metabolites (Kobrosly et al. 2012). Prevalence of childhood 
obesity also varies by SES. Therefore, we included two measures of maternal SES in our 
analyses: maternal education and maternal work status during pregnancy. Maternal education 
was ascertained using the baseline questionnaire in all cohorts. We categorized education as 
<high school, high school or General Educational Development (GED), some college, or 
≥college degree.  For Specific Aim 1, we further dichotomized maternal education as <college 
degree or ≥college degree based on distributions with exposures and outcomes. For Specific 
Aim 2, we included all four categories. Maternal work status was ascertained by questionnaire. 
For both Aims, we classified women as either employed or as a homemaker or student.  
 Parity is associated with birth weight, which is in turn related to childhood adiposity, and 
increasing number of siblings has been associated with lower BMI. Parity may also be related to 
differences in phthalate exposure sources such as personal care product use. Specific Aim 1 
did not include this variable as MSSM restricted to primiparous women. For Specific Aim 2, we 
assessed parity by questionnaire at baseline and classified women as primaras or multiparas. 
We also examined modification by parity as a sensitivity analysis exploring the influence of 
cohort restriction criteria. 
Gestational smoke exposure is a risk factor for childhood obesity (Oken et al. 2008). We 
classified pregnancy smoking status as either active or passive using different criteria for each 
cohort. For MSSM, we determined maternal smoking during pregnancy based on self-report. 
For HOME, we classified women as active smokers during pregnancy if the average of three 
cotinine concentrations (measured at 16 weeks, 26 week, and birth) exceeded 3 ng/mL 
(Benowitz et al. 2009). CCEH excluded women with evidence of active smoking based on either 
self-report or cotinine concentrations. As we did for parity, we also examined modification by 
maternal smoking during pregnancy as a sensitivity analysis for cohort restriction criteria in 
Specific Aim 2. 
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Maternal BMI is a strong predictor of offspring BMI (Salsberry and Reagan 2005; Weng 
et al. 2012) and may be associated with differences in phthalate exposure sources (e.g., diet, 
personal care products, medication use). We calculated pre-pregnancy BMI based on maternal 
self-reported weight and height (kg/m2) at enrollment. We adjusted for maternal height due to its 
genetic influence on child body size. 
Gestational weight gain may be associated with offspring adiposity (Weng et al. 2012) 
and with phthalate exposures through diet, personal care products, or medication use. We 
calculated gestational weight gain as the last pregnancy weight (measured or reported by the 
mother) minus self-reported pre-pregnancy weight. For Specific Aim 1, we calculated adequacy 
of gestational weight gain as the ratio of observed gestational weight gain to the expected 
gestational weight gain based on the 2009 Institute of Medicine recommendations: (observed 
weight gain / expected weight gain ) x 100 (Bodnar et al. 2010). Expected weight gain was 
calculated as follows: recommended weight gain in the first trimester + (gestational age at 
delivery – 13 weeks) x recommended second and third trimester weekly rate of gain. 
Recommended weight gains are based on the mother’s pre-pregnancy BMI. We used the 
continuous adequacy of weight gain variable in all models. For tabular display of distributions, 
adequacy of weight gain was categorized as less than recommended (<86%), recommended 
(86-120%), or more than recommended (>120%) (Bodnar et al. 2011). We did not calculate 
adequacy of gestational weight gain for Specific Aim 2 as pre-pregnancy BMI was missing for 
some CCEH and HOME participants and therefore we were not able to determine 
recommended weight gains for each trimester of pregnancy.  Instead, we adjusted for 
gestational weight gain (lbs) as a continuous variable.  
We adjusted for calendar date of urine collection to account for temporal trends in 
phthalate exposures and prevalence of childhood obesity. 
Creatinine and specific gravity are used in studies of urinary exposure biomarkers to 
correct for urine dilution. MSSM and HOME measured creatinine in maternal urine samples. 
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CCEH measured specific gravity in all urine samples (n = 339), with creatinine additionally 
measured in a subset (n = 137). Methods for adjusting for urine dilution in Specific Aim 2 are 
described below. 
Child’s sex was ascertained from birth records and included as a covariate in both 
Specific Aims. There are sex differences in the distribution, amount, and timing of fat 
accumulation in boys and girls. Because there may be anti-androgen mediated effects of 
phthalate exposures on body size, child’s sex was evaluated as an effect measure modifier.  
Although breastfeeding occurs after phthalate exposure, it has been associated with 
childhood BMI (Weng et al. 2012) and may lie on an unblocked backdoor path between 
phthalate exposures and body size outcomes. Breastfeeding was assessed by questionnaire at 
follow-up and categorized as ever/never. 
We adjusted for age at follow-up (in months) to account for variation in child body size 
measures by age. In models of continuous outcomes, we also included an interaction between 
age at follow-up and child’s sex due to differences in distributions by age and sex. 
 In an effort to increase precision of our estimates for Specific Aim 1, we adjusted for 
physical activity at each follow-up visit. For MSSM, we classified children as active if the 
parent/caretaker reported the child was “active most of the time” or inactive if the child was 
“active some of the time” or “hardly at all”. Physical activity information was not available for 
CCEH or HOME and was therefore not considered for inclusion in Specific Aim 2.  
 Finally, for Specific Aim 2, we adjusted for cohort in all pooled analyses to account for 
unmeasured differences in study populations and protocols that may influence phthalate 
exposures, childhood adiposity, and covariate values. 
 
Variables Included in Covariate Imputation Models  
 We ascertained two additional variables in order to predict missing covariate values.  For 
Specific Aim 1, gestational age at delivery was ascertained via medical records and used to 
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predict maternal last pregnancy weight. For Specific Aim 2, we included gestational age at urine 
collection as a predictor of urinary creatinine concentration. We calculated gestational age at 
urine collection by subtracting the number of weeks between urine collection and delivery from 
the gestational age at delivery (weeks) reported on the medical record.  
 
Variables Included as Predictors of Missing Outcomes 
 For Specific Aim 2, we included four additional variables reported in a previous study to 
predict subject retention in the CCEH cohort (Rundle et al. 2012). Receipt of public assistance 
during pregnancy (yes/no) and maternal satisfaction with living conditions (5 point Likert scale) 
were ascertained by questionnaire at enrollment. Two neighborhood-level characteristics, 
poverty rate and Spanish language linguistic isolation, were determined using census data 
within a 1 kilometer radius of the participant’s residence at enrollment.  
 
 Statistical Methods F.
Overview 
The general statistical approach used in Specific Aims 1 and 2 was similar, and will be 
described below with additional details where the two studies differed.  Our general modeling 
approach utilized a Bayesian hierarchical framework for fitting linear and logistic mixed effects 
models with random intercepts to account for multiple observations per child. We selected a 
Bayesian framework in order to estimate associations while simultaneously accounting for 
several potential biases, including imputing metabolite concentrations below the LOD (Aim 1), 
stabilizing estimates from multiple metabolite models (Aims 1 and 2), imputing missing at 
random covariate data (Aims 1 and 2), and conducting sensitivity analyses exploring potentially 
informative loss to follow-up (Aims 1 and 2).  
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Metabolite Concentrations Below the LOD 
It has become standard practice to set biomarker values below the LOD to a fixed value. 
This approach results in appreciable bias when greater than 5-10% of the concentrations are 
non-detects (Lubin et al. 2004). In the MSSM, CCEH, and HOME studies, all phthalate 
metabolites except for MEHP were measured above the detection limits in ≥95% of urine 
samples. MEHP is a hydrolytic metabolite of DEHP and was used to calculate the ∑DEHP 
variable but was not examined on its own. Thus, using a single replacement technique is 
unlikely to bias effect estimates. In Specific Aim 2, where the values of the LODs differed 
between cohorts due to changes in CDC laboratory methodologies over time, we set phthalate 
metabolite concentrations below the LOD to the value of the LOD divided by the square root of 
two (Hornung and Reed 1990). 
In Specific Aim 1, we utilized an alternative approach to account for phthalate metabolite 
concentrations below the LOD by imputing values from a truncated normal distribution. This 
approach has been applied in previous studies (Carmichael et al. 2010; Uh et al. 2008). For 
each metabolite, the parameters of the truncated normal distribution were defined by the mean 
and SD of the observed distribution, a lower bound of 0, and an upper bound set equal to the 
LOD. The natural logs of these parameters were used to impute natural log metabolite 
concentration values at each iteration of the Markov chain Monte Carlo (MCMC) algorithm using 
the WinBUGS package djl.trunc.norm. The ΣDEHP variable was computed using the 
component metabolite values (MEHP, MEHHP, MECPP, MEOHP) at each MCMC iteration.  
 
 
Missing at Random Covariate Data 
 For both Aims, we imputed missing covariate data by including parametric models for 
variables with missing data within the MCMC procedure under the assumption that data were 
missing at random. Predictors of missing covariate values were selected on the basis of 
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observed or expected relationships between each missing covariate and variables measured in 
the study population.  
In Specific Aim 1, we imputed missing values for adequacy of gestational weight gain (n 
= 22), breastfeeding (n =1), and physical activity at follow-up (n = 3 children with 8 visits). 
Missingness in the adequacy of gestational weight gain variable was due to missing last 
pregnancy weights. Therefore, we included a linear regression model to predict last pregnancy 
weight on the basis of maternal education, race/ethnicity, sex, smoking during pregnancy, work 
status during pregnancy, maternal age at delivery, birth weight, maternal height, gestational 
age, maternal first pregnancy weight, and maternal pre-pregnancy BMI. The predicted last 
pregnancy weight was then used to calculate adequacy of gestational weight gain at each 
iteration of the MCMC algorithm, as described in Section E above.  
The missing breastfeeding value was multiply imputed using a logistic regression model 
on the basis of maternal education, race/ethnicity, child’s sex, maternal smoking and work 
status during pregnancy, maternal age at delivery, adequacy of gestational weight gain, 
maternal pre-pregnancy BMI, and birth weight.  
In contrast to the previous two variables that were measured once per child, physical 
activity was assessed at each follow-up visit.  Therefore, we included a logistic mixed effects 
regression model with random intercepts to predict missing physical activity values at each 
follow-up visit on the basis of race/ethnicity, maternal pre-pregnancy BMI, maternal smoking 
during pregnancy, age (in months), birth weight, and child’s sex.  
For each variable with missing data, we included quadratic or cubic terms for continuous 
predictors if they exhibited non-linear relationships among those without missing data 
(evaluated visually using generalized additive models in the SAS procedure PROC GAM). 
A similar approach was used to impute missing values in Specific Aim 2. To calculate 
missing values for pre-pregnancy maternal BMI (n = 58) and gestational weight gain (n = 107), 
we included linear regression models for maternal first pregnancy weight, maternal height, and 
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maternal last pregnancy weight. We used the same set of predictors for these three 
anthropometric variables: cohort, race/ethnicity, maternal education, parity, maternal smoking 
and work status during pregnancy, child’s sex, maternal age at delivery, and the other maternal 
anthropometric variables (e.g., for maternal first pregnancy weight, we included maternal height 
and maternal last pregnancy weight). Linear, quadratic, and cubic terms were included for 
maternal age and maternal anthropometric variables to allow for non-linear relationships. 
Maternal pre-pregnancy BMI and gestational weight gain were then calculated using the 
imputed values at each iteration of the MCMC algorithm.  We also included a logistic regression 
model for missing breastfeeding values (n = 6) based on cohort, maternal education, 
race/ethnicity, parity, and maternal smoking during pregnancy. 
 
Missing Creatinine Concentrations 
 In Specific Aim 2, we used a similar approach to multiply impute missing creatinine 
concentrations. As mentioned previously, CCEH measured specific gravity in all urine samples 
(n = 339), with creatinine additionally measured in a subset (n = 137). To obtain a common 
measure of urine dilution, we multiply imputed missing natural log creatinine concentrations in 
CCEH using a linear regression model at each iteration of the MCMC algorithm in our Bayesian 
models. Independent variables included specific gravity; gestational age and calendar date at 
urine collection; maternal education, race/ethnicity, parity, BMI, and height; child’s sex; and 
gestational weight gain. Higher order polynomials were included for specific gravity, gestational 
age and calendar date at urine collection, and maternal height as they exhibited non-linear 
associations with creatinine among those with measured values. 
As described above (Section C. Exposure Assessment) we constructed creatinine-
corrected metabolite concentrations to assess non-linear dose-response relationships. In order 
to obtain creatinine-corrected metabolite concentrations in the CCEH cohort, we assigned the 
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posterior mean creatinine concentration predicted by our model to each participant without a 
creatinine measurement.  
We explored the performance of the imputation model by setting a random 25% sample 
of measured creatinine concentrations to missing and assessing the Spearman correlation 
coefficient between the true values and posterior mean values predicted by our model (R2 = 
0.61). Additionally, we compared assignment of CCEH participants into exposure quartiles using 
metabolite concentrations corrected for either specific gravity or creatinine. Cohen’s weighted 
Kappa coefficients were similar among those with measured or imputed creatinine 
concentrations (Table 2). Although this analysis does not directly evaluate the validity of the 
creatinine prediction model, it indicates that the imputed values agree with specific gravity as 
well as the measured creatinine concentrations in terms of classifying phthalate metabolite 
concentrations into quartiles based on urine dilution.  
 
Table 2. Cohen’s weighted Kappa coefficient for the agreement of urine dilution-
corrected phthalate metabolite quartiles based on either specific gravity or creatinine in 
the CCEH cohort, comparison of measured and imputed creatinine concentrations  
Metabolite Measured creatinine Imputed creatinine 
MEP 0.57 0.68 
MnBP 0.53 0.59 
MiBP 0.52 0.59 
MCPP 0.52 0.56 
MBzP 0.68 0.64 
∑DEHP 0.61 0.61 
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Bayesian Priors for Multiple Metabolites 
Because estimates of association between outcomes and an individual phthalate 
metabolite may be confounded by other correlated metabolites, we estimated associations in 
multiple metabolite hierarchical models within our Bayesian framework. The beta coefficient of 
each standardized phthalate metabolite was given an independent normal prior distribution with 
a mean of zero and variance of 1/τ2 (MacLehose et al. 2007). We selected values of τ that 
reflect our prior belief that 95% of the effects of a SD difference in natural log phthalate 
metabolite concentration are within an odds ratio (OR) of 0.14 to 7.1 for overweight/obese 
status (τ = 1), or, for continuous outcomes, approximately ± one SD of the outcome mean in the 
study population (τ = 0.0625 for percent fat mass, τ = 1 for BMI, weight, and height z-scores).  
 
Covariate Adjustment 
 We assessed covariates using directed acyclic graphs and adjusted for variables 
determined to be in the minimally-sufficient adjustment set. For Specific Aim 1, these variables 
included maternal race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic or other), 
maternal age at delivery, maternal education (> college degree / ≤ college degree), maternal 
work status during pregnancy (homemaker or student/ employed), maternal pre-pregnancy BMI, 
maternal height, adequacy of gestational weight gain, maternal smoking during pregnancy 
(yes/no), breastfeeding (ever/never), calendar date of urine collection, natural log creatinine, 
child’s sex (female/male), and months of age at follow-up. We also included physical activity at 
follow-up (active/inactive) to improve precision as it was a strong predictor of the outcome. For 
continuous variables, we included higher order polynomials if they exhibited non-linear 
associations with percent fat mass.  
 For Specific Aim 2, we adjusted for cohort, maternal race/ethnicity (non-Hispanic white, 
non-Hispanic black, Hispanic, other), maternal age at delivery, maternal education (<high 
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school, high school or GED, some college, ≥ college degree), maternal work status during 
pregnancy (homemaker or student/employed), maternal pre-pregnancy BMI, maternal height, 
gestational weight gain, maternal smoking during pregnancy (yes/no), breastfeeding 
(ever/never), natural log creatinine, calendar date of urine collection, parity 
(primiparous/multiparous), child’s sex (female/male), and months of age at follow-up. In z-score 
models, we also adjusted for an interaction between child’s sex and age at follow-up because 
outcome distributions by age differed between girls and boys. We included a quadratic term for 
maternal pre-pregnancy BMI and cubic terms for maternal age and gestational weight gain 
based on non-linear associations with child body size outcomes. 
 
Outcome Models 
For both Specific Aims, we estimated associations in our Bayesian framework using 
mixed effects models with random intercepts to account for multiple observations per child. For 
continuous outcomes (percent fat mass and z-scores), we estimated beta coefficients and 95% 
credible intervals (CI) per SD increase in natural log phthalate metabolite concentrations in 
linear mixed effects models. For overweight/obese status, we estimated odds ratios (ORs) and 
95% CIs per SD increase in natural log phthalate metabolite concentrations in logistic mixed 
effects models. We ran Bayesian models in WinBUGS version 1.4.3 (MRC Biostatistics Unit, 
Cambridge, UK) with a 10,000 iteration burn-in followed by 50,000 additional iterations. We 
assessed model convergence using visual diagnostics (Gelman et al. 2013). 
 
Effect Measure Modification 
Due to potential differences in the effects of phthalate metabolites with anti-androgenic 
activity among girls versus boys, we examined heterogeneity of associations between maternal 
urinary phthalate concentrations and body size by child’s sex in both Specific Aims. As sample 
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size was limited in Specific Aim 1, we did not evaluate modification by any other variables. In 
Specific Aim 2, we additionally assessed cohort and race/ethnicity as potential modifiers and 
further examined heterogeneity of associations by both cohort and child’s sex or race/ethnicity.  
We assessed effect measure modification in our multiple metabolite models by including 
interaction terms between the modifier and each metabolite, and between the modifier and 
natural log creatinine. For Aim 2, models assessing modification by both cohort and either sex 
or race/ethnicity included all two- and three-way interaction terms between metabolites, cohort, 
and the covariate. When assessing modification by race/ethnicity in Aim 2, we excluded children 
of other race as well as Hispanic children in HOME due to small numbers. We considered there 
to be meaningful effect modification if the 80% CI for the interaction term did not cross the null 
value. 
 
Non-linear Dose Response  
As described in Section C. Exposure Assessment, we categorized exposure into tertiles 
(Specific Aim 1) or quartiles (Specific Aim 2) based on creatinine-corrected phthalate metabolite 
concentrations to assess non-linear dose response relationships. For these models, we 
replaced the linear terms in our models described above with indicator variables for the second 
and third tertiles (Specific Aim 1) or second through fourth quartiles (Specific Aim 2) of each 
metabolite and we did not include natural log creatinine in these models. 
In Specific Aim 2, we also examined dose-response relationships using restricted 
quadratic splines with knots at the 20th, 40th, 60th, and 80th percentile of each metabolite or sum. 
We computed spline variables using the SAS macro RQSMACRO (Howe et al. 2011) and 
included them in multiple metabolite outcome models using the approach described above.  We 
did not use splines in Specific Aim 1 because we could not combine this method with our 
approach for imputing concentrations <LOD within the MCMC algorithm.  
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 Sensitivity Analyses G.
Single Metabolite Models 
The vast majority of studies examining phthalate exposures in relation to health 
outcomes estimate associations in separate models for each metabolite. The motivation for this 
approach is to avoid multicollinearity since phthalate metabolites are correlated. However, this 
correlation might also lead to confounding of associations with each metabolite by the other 
metabolites. Therefore, we compared our associations estimated in multiple metabolite models 
to those in single metabolite models. We specified the same prior distributions for phthalate 
metabolite beta coefficients as the main analyses but included only one metabolite at a time, 
e.g. β ~ Normal(0,1). 
 
Potentially Nonignorable Missing Outcomes 
Lack of subject retention is a common problem in longitudinal studies and occurred in all 
three of the study cohorts. Loss to follow-up may result in selection bias since clinic non-
attendance may be missing not at random (MNAR). While most studies ignore participant drop 
out and conduct analyses only among subjects who returned for clinic visits, we explored this 
potential bias. 
For both Aims, our primary analyses of children with at least one follow-up visit assumed 
that responses were missing at random (MAR) conditional on observed outcomes and 
covariates. However, there were some minor differences in the distribution of observed 
variables between the birth cohorts and the children who were followed-up. Furthermore, the 
probability of a missing body size measure may depend upon its true (unobserved) value. 
Therefore, we assessed the sensitivity of our findings to potential selection bias using a 
selection model approach (Little 1995). 
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For Specific Aim 1, we used a selection model to assess the association between 
phthalate exposures and percent fat mass among all 380 children with measured prenatal 
phthalate metabolite concentrations under a nonignorable (MNAR) missing data mechanism. 
We created a binary missing outcome indicator variable for whether or not percent fat mass was 
observed at each follow-up visit (0 if observed, 1 if missing). We jointly fit our model for percent 
fat mass (described above) with a logistic mixed effects model with random intercepts for the 
binary missing outcome indicator variable. The missing data indicator model was dependent on 
the (potentially unobserved) percent fat mass value as well as baseline covariates either 
observed or expected to be associated with loss to follow-up (maternal age, race, work status, 
pre-pregnancy BMI, and adequacy of gestational weight gain).  
We used a very similar approach for Specific Aim 2, though there were differences in 1) 
the construction of the binary missing outcome indicator variable, and 2) the predictors included 
in the missing outcome indicator model. In the pooled study, some outcomes were unobserved 
not because the children were lost to follow-up but because we restricted the study to include 
outcomes among children observed at ages 4 to 7 years. Thus, we assigned values for the 
binary missing indicator based on whether or not the child completed a follow-up visit in the 
scheduled cohort-specific visit window, regardless of whether that outcome was included in our 
analysis. The logistic mixed effects model for the missing outcome indicator included a large set 
of predictors including the outcome (potentially unobserved), maternal age, race/ethnicity, 
education, and pre-pregnancy BMI; child’s birth weight and sex; and calendar date of urine 
collection. In addition, we included interaction terms to allow the beta coefficient for each 
predictor to vary by cohort. Finally, we included receipt of public assistance during pregnancy, 
maternal satisfaction with living conditions, neighborhood poverty rate, and Spanish language 
linguistic isolation in the missing outcome indicator model for members of the CCEH cohort (see 
section E. Covariates for additional details). We ran a model for each of the four primary 
outcomes in the pooled cohort (overweight/obese status and BMI, weight, and height z-scores). 
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For both Aims, we ran ten chains for inference from the MCMC procedure and compared 
results to models that assumed dropout was missing at random (MAR).  
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CHAPTER IV. RESULTS FOR SPECIFIC AIM 1 
 
 Introduction A.
Childhood obesity rates increased substantially in the past several decades (Ogden and 
Carroll 2010). In the United States, 16.9% of children aged 2-19 years are obese (Ogden et al. 
2014). Compared to normal weight children, obese children are at greater risk of becoming 
obese adults (Freedman et al. 2005a), with associated risks of diabetes, heart disease, cancer, 
and many other ailments. Evidence suggests that factors other than energy balance may 
contribute to the rapid rise in obesity rates (Keith et al. 2006). The concomitant increase in 
production of synthetic chemicals with rising obesity rates and the recognition that prenatal 
factors influence childhood obesity have led to a search for environmental obesogens (Baillie-
Hamilton 2002; Heindel and vom Saal 2009). 
Phthalates, synthetic chemicals with endocrine disrupting properties, are hypothesized 
to be obesogens. Human exposure to phthalates is ubiquitous, arising from contact with a wide 
range of consumer products including polyvinyl chloride plastics, building materials, medical 
devices, pharmaceuticals, toys, food packaging, cosmetics, and fragrances (Schettler 2006). 
Early life phthalate exposures have been associated with health outcomes in childhood 
including physical and neurological development, allergic diseases, and anogenital distance in 
boys (Braun et al. 2013). For some developmental endpoints, phthalate associations have been 
reported to vary by sex (Engel et al. 2009; Swan et al. 2010; Wolff et al. 2008). 
Toxicological evidence suggests that perinatal exposures to phthalates may promote an 
obesogenic phenotype in offspring through several mechanisms (Grun 2010). Although a 
number of studies, primarily cross-sectional, have reported associations between urinary 
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phthalate metabolite concentrations and body size in children (recently reviewed in (Goodman 
et al. 2014)), findings are inconsistent regarding which phthalates are associated with outcomes 
or whether associations are positive or inverse. Furthermore, a causal link between phthalate 
exposures and subsequent body size cannot be established in cross-sectional studies that 
measure concurrent exposures and outcomes (Engel and Wolff 2013). 
Although one small study reported on associations between di-(2-ethylhexyl) phthalate 
(DEHP) metabolite concentrations measured in cord blood and BMI in the first year of life (de 
Cock et al. 2014), no previous study has examined gestational exposure, the hypothesized 
critical window for an effect of phthalates on obesity. To address this gap, we assessed the 
associations between third trimester urinary phthalate metabolite concentrations and fat mass at 
ages 4 to 9 years in a prospective birth cohort. 
 
 Methods B.
Study population 
The Mount Sinai Children’s Environmental Health Study enrolled 479 primiparous 
women with singleton pregnancies from the Mount Sinai Diagnostic and Treatment Center and 
two adjacent private practices in New York City between 1998 and 2002. Women delivered at 
the Mount Sinai Medical Center and seventy-five women were subsequently excluded for 
reasons described elsewhere (Engel et al. 2007). The final cohort consists of 404 infants for 
whom birth data were available.  
Children were invited to return for three follow-up visits scheduled at approximately ages 
4-5.5 (mean=4.9), 6 (mean=6.2), and 7-9 (mean=7.8) years, hereafter referred to as visits 1, 2, 
and 3. Women provided informed consent prior to participation and children aged ≥7 years 
provided assent. The study received approval from the Mount Sinai School of Medicine 
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Institutional Review Board. The involvement of the Centers for Disease Control and Prevention 
(CDC) laboratory was determined not to constitute engagement in human subjects research. 
 
Phthalate exposures  
Mothers provided a spot urine sample between 25 and 40 weeks’ gestation (mean=31.5 
weeks). Samples were analyzed at the CDC laboratory for the following phthalate metabolites: 
monoethyl phthalate (MEP), mono-n-butyl phthalate (MnBP), monoisobutyl phthalate (MiBP), 
mono(3-carboxypropyl) phthalate (MCPP), monobenzyl phthalate (MBzP), mono(2-ethylhexyl) 
phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-
oxohexyl) phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP). Quality 
control methods have been reported previously (Kato et al. 2005). Correction factors were 
applied to MBzP (0.72) and MEP (0.66) concentrations and limits of detection (LOD) to adjust 
for inaccuracies in analytical standards (Centers for Disease Control and Prevention 2012).  
Of the 188 children with body composition measurements between ages 4 and 9 years, 
maternal prenatal phthalate metabolite concentrations were available for 182 children. Following 
previous work (Wolff et al. 2008), two observations obtained from a very dilute urine (<10 mg/dL 
creatinine) were excluded from all analyses due to the potential for inaccurate biomarker 
measurements. Thus, the current analysis includes 180 children (364 total visits). Distributions 
of prenatal phthalate metabolite concentrations were similar among children with and without a 
follow-up visit (Engel et al. 2010).     
 
Outcome assessment 
At each follow-up visit, we measured children in bare or stocking feet wearing a pediatric 
gown or light clothing. We assessed weight and body composition via bioelectrical impedance 
analysis using a pediatric Tanita scale (model TBF-300; Tanita Corporation of America, 
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Arlington Heights, Illinois). We obtained duplicate measures of height using a stadiometer, and 
collected a third measure if the difference between the first two measures exceeded 2.0 
centimeters.  
Using the fat mass estimates reported by the Tanita scale, we calculated percent fat 
mass as (fat mass / weight) x 100. Because the Tanita equations for fat mass have not been 
validated for children aged <7 years, we tested two alternative equations validated for 
estimating fat mass from bioelectrical impedance measures in children (Clasey et al. 2011a; 
Horlick et al. 2002). The Horlick et al. equation did not perform well in this sample (data not 
shown). Percent fat mass values estimated with the Clasey et al. equation were highly 
correlated with the Tanita values (Pearson R2 = 0.97) but there were some implausible 
estimates (e.g., fat free mass > total mass). Thus, we used the Tanita proprietary equations. For 
supplementary analyses, we also calculated BMI as weight (kg) / height (m)2 and determined 
age- and sex-standardized BMI z-scores using the CDC SAS macro (Centers for Disease 
Control and Prevention 2004). 
   
Covariates 
We collected covariate data from mothers during a two hour structured interview at 
enrollment. We ascertained pregnancy and delivery characteristics from a computerized 
perinatal database at Mount Sinai Hospital. We calculated adequacy of gestational weight gain 
as the ratio of observed gestational weight gain (last pregnancy weight minus self-reported pre-
pregnancy weight) to expected gestational weight gain based on the 2009 Institute of Medicine 
recommendations x 100, and categorized gains as less than recommended (<86%), 
recommended (86-120%), or more than recommended (>120%) (Bodnar et al. 2010; Bodnar et 
al. 2011). We classified physical activity at each follow-up visit as active if the parent/caretaker 
reported the child was “active most of the time” or inactive if the child was “active some of the 
time” or “hardly at all”. 
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Statistical analysis 
We used a Bayesian modeling framework to assess associations between prenatal 
phthalate metabolite concentrations and fat mass. We selected this approach in order to 
estimate associations while simultaneously accounting for several potential biases by (1) 
imputing metabolite concentrations below the LOD, (2) stabilizing estimates from multiple 
metabolite models, (3) imputing missing at random covariate data, and (4) accounting for 
potentially informative loss to follow-up. 
First, we accounted for phthalate metabolite concentrations below the LOD by imputing 
values from a truncated normal distribution, an approach applied in previous studies 
(Carmichael et al. 2010; Uh et al. 2008). For each metabolite, the parameters of the truncated 
normal distribution were defined by the mean and standard deviation (SD) of the observed 
distribution, a lower bound of 0, and an upper bound set equal to the LOD. The natural logs of 
these parameters were used to impute natural log metabolite concentration values at each 
iteration of the Markov chain Monte Carlo (MCMC) algorithm using the WinBUGS package 
djl.trunc.norm. Because DEHP metabolites (MECPP, MEHHP, MEHP, MEOHP) represent 
exposure from the same sources and are highly correlated (Wolff et al. 2008), they were 
examined as a molar sum (ΣDEHP) that was computed using component metabolite values at 
each MCMC iteration. The natural log of each phthalate metabolite or sum was standardized to 
its mean and SD in order to facilitate comparison of relative phthalate effect sizes in relation to 
their distribution in the study population.  
Because estimates of association between fat mass and an individual phthalate 
metabolite may be confounded by other correlated metabolites, we estimated associations in 
multiple metabolite hierarchical models within our Bayesian framework. The beta coefficient of 
each standardized phthalate metabolite was given an independent normal prior distribution with 
a mean of zero and variance of 1/τ2 (MacLehose et al. 2007). We selected a value of τ that 
reflects our prior belief that 95% of the effects of a SD difference in natural log phthalate 
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metabolite concentration are within approximately ± one SD of the mean percent fat mass in the 
study population (τ = 1/16). As a sensitivity analysis, we estimated associations using single 
metabolite models that specified the same prior distributions for phthalate beta coefficients but 
included only one metabolite at a time.   
We adjusted for potential confounding variables identified using directed acyclic graphs. 
Demographic and socioeconomic characteristics included maternal race/ethnicity, age, 
education, and work status during pregnancy. We adjusted for maternal body size 
characteristics (pre-pregnancy BMI, height, and adequacy of gestational weight gain), maternal 
smoking during pregnancy (yes/no), and breastfeeding (ever/never) to account for early life 
factors that are associated with childhood overweight status (Weng et al. 2012). We adjusted for 
calendar date of urine collection to account for temporal trends in phthalate exposure and 
prevalence of childhood obesity. Additionally, we adjusted for natural log creatinine (to account 
for urine dilution), child’s sex, and months of age at follow-up. We also included physical activity 
at follow-up (active/inactive) to improve precision as it was a strong predictor of the outcome. 
Child’s sex was evaluated as an effect measure modifier by including an interaction term 
between sex and each metabolite. Continuous covariates (maternal age, pre-pregnancy BMI, 
maternal height, adequacy of gestational weight gain, calendar date of urine collection, natural 
log creatinine, and age at follow-up) were standardized as (x - µx)/(2σx) to improve MCMC 
convergence and facilitate comparisons of effect sizes with dichotomous covariates (Gelman et 
al. 2013). We included higher order polynomials if continuous variables exhibited non-linear 
associations with percent fat mass. Covariates were given independent null-centered priors with 
τ = 1/64, reflecting our prior belief that 95% of the effects of binary covariates (or a two SD 
change in continuous covariates) are within ± two SDs of the mean percent fat mass in the 
study population.  
Again taking advantage of the Bayesian framework for multiple imputation, we imputed 
missing at random values for adequacy of gestational weight gain (n = 22), breastfeeding (n =1), 
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and physical activity at follow-up (n = 3 children with 8 visits) within the MCMC procedure. 
Because missing adequacy of gestational weight gain was due to missing last pregnancy 
weights, we modeled last pregnancy weight as a normally distributed random variable 
conditional on maternal education, race/ethnicity, child’s sex, smoking during pregnancy, work 
status during pregnancy, maternal age at delivery, birth weight, maternal height, gestational 
age, maternal first pregnancy weight, and maternal pre-pregnancy BMI. At each iteration of the 
MCMC algorithm, adequacy of gestational weight gain was calculated using the imputed last 
pregnancy weight. We modeled breastfeeding using a logistic model conditional on maternal 
education, race/ethnicity, child’s sex, smoking during pregnancy, work status during pregnancy, 
maternal age at delivery, adequacy of gestational weight gain, maternal pre-pregnancy BMI, 
and birth weight. We modeled physical activity at each follow-up visit using a logistic mixed 
effects model with random intercepts, conditional on race/ethnicity, maternal pre-pregnancy 
BMI, smoking during pregnancy, age at follow-up (months), birth weight, and child’s sex. Beta 
coefficients in the imputation models were given independent, null-centered priors with τ = 1, 
reflecting our prior belief that 95% of the effects of binary covariates (or a two SD change in 
continuous covariates) are within ± two SDs of the mean last pregnancy weight or within an 
odds ratio of 0.14 to 7.1 for breastfeeding and physical activity. 
We assessed associations of third trimester maternal urinary phthalate metabolite 
concentrations with percent fat mass using linear mixed effects regression models to account 
for multiple observations per child. We estimated posterior mean beta coefficients and 95% 
credible intervals (CI) per SD increase in natural log phthalate metabolite concentrations. The 
interpretation of a CI is more intuitive than that of a confidence interval from a conventional 
analysis; specifically, given the data and the model, there is a 95% chance that the true value is 
within this interval. In models examining modification by child’s sex, we included interaction 
terms between sex and each metabolite, as well as between sex and natural log creatinine, and 
considered there to be meaningful modification if the 80% CI did not cross the null value. To 
51 
 
assess potential non-linear dose-response relationships, we also fit models with indicator 
variables for the second and third tertile categories of each metabolite. To account for urine 
dilution in these analyses, we categorized exposure using creatinine-corrected concentrations 
(micrograms per gram creatinine for metabolites or micromoles per gram creatinine for 
∑DEHP).  
To assess a second measure of childhood adiposity and facilitate comparisons to 
studies without body composition data, we also estimated associations between phthalate 
metabolite concentrations and BMI z-scores using the approach described above.  
We ran each of the final Bayesian models for 50,000 iterations after an initial 10,000 
iteration burn-in and assessed model convergence using standard diagnostic measures 
described elsewhere (Gelman et al. 2013). We conducted descriptive analyses in SAS version 
9.3 (SAS Institute, Cary, NC) and Bayesian modeling in WinBUGS version 1.4.3 (MRC 
Biostatistics Unit, Cambridge, UK).   
 
Sensitivity analysis for loss to follow-up 
Our primary analyses of children with at least one follow-up visit (N=180) assumed that 
responses were missing at random conditional on observed outcomes and covariates. Because 
there were some differences in the distribution of observed variables between the birth cohort 
and the follow-up sample and because the probability of a missing fat mass measure may 
depend upon its true (unobserved) value, we assessed the sensitivity of our findings to potential 
selection bias. We used a selection model approach (Little and Rubin 2002) to model the 
association between phthalate exposures and percent fat mass among all 380 children with 
measured prenatal phthalate metabolite concentrations, under a potentially nonignorable 
(missing not at random) missing data mechanism. For this analysis, we jointly fit our model for 
percent fat mass with a logistic model for a binary indicator of whether the outcome value was 
missing at each follow-up visit. The missing data indicator model was dependent on the 
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(possibly unobserved) percent fat mass value as well as covariates either observed or expected 
to be associated with loss to follow-up (maternal age at delivery, race/ethnicity, work status 
during pregnancy, pre-pregnancy BMI, adequacy of gestational weight gain, child’s sex). 
Because results from selection models are sensitive to the assumed missing data mechanism 
(Little 1995), we explored models with additional covariates in the missing data indicator model 
(maternal smoking during pregnancy, breastfeeding, maternal education, birth weight, months of 
age at follow-up) and varied parameterization of continuous variables. Beta coefficients were 
given null-centered, independent priors with τ = 2 to reflect our prior belief that 95% of the 
effects of a binary covariate (or a two SD change in continuous covariates) are within an odds 
ratio of 0.25 to 4. We ran ten chains for inference from the MCMC procedure and compared 
results to models that assumed dropout was missing at random. 
 
 Results C.
Although baseline characteristics of children included in the study sample were similar to 
those in the birth cohort, there were minor differences (Table 3). For example, children of 
mothers with younger maternal age, underweight pre-pregnancy BMI, and less than 
recommended gestational weight gain were more likely to be lost to follow-up. All phthalate 
metabolites were measured in >90% of third trimester maternal urine samples (Table 4).  
Percent fat mass increased with age and differed by child’s sex, with a larger SD among 
girls than among boys at all ages (Table 5). As expected, BMI z-score distributions were less 
variable as they are age- and sex-standardized (Table 6). Correlations between percent fat 
mass and BMI z-scores increased with age; Spearman R2s were 0.75, 0.82, and 0.91 and the 
1st, 2nd, and 3rd visits, respectively. 
Estimates of association between standardized natural log phthalate metabolite 
concentrations and percent fat mass are reported in Table 7. All 95% CIs crossed the null and 
no associations were modified by child’s sex, though estimates were imprecise. In models 
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assessing metabolite tertiles, there was an inverse dose-response relationship for the 
association of ∑DEHP with percent fat mass (Figure 2). Compared to the lowest ∑DEHP tertile, 
fat mass decreased by 1.77 percent (95% CI = -4.48, 0.97) in the middle tertile and by 3.06 
percent (95% CI = -5.99, -0.09) in the highest tertile. We found no evidence of associations 
between tertile categories of other metabolites and percent fat mass (Table 8). 
Results of sensitivity analyses are reported in Table 9. Associations estimated in multiple 
and single metabolite models were similar, though the multiple metabolite model beta 
coefficients tended to be slightly farther from the null and CIs were less precise. Results of the 
sensitivity analysis for loss to follow-up indicated that missing fat mass data may indeed be 
nonignorable; children with more fat mass were less likely to be loss to follow-up. For each 1 
percent increase in fat mass, the odds ratio for loss to follow-up was 0.75 (95% CI: 0.67, 0.82). 
However, associations between phthalate metabolites and percent fat mass were similar to the 
primary analysis. Varying parameters in the missing data model did not alter results. 
Patterns of association between phthalate metabolite concentrations and BMI z-scores 
were generally consistent with our analyses of percent fat mass, though estimates were 
attenuated toward the null (Table 10). 
 
 Discussion D.
  
To our knowledge, this is the first prospective study of gestational phthalate exposures 
and adiposity in childhood. We observed an association of third trimester maternal urinary 
concentrations of DEHP metabolites with lower percent fat mass among children aged 4 to 9 
years. We did not observe notable modification of associations by child’s sex though there is 
limited ability to detect heterogeneity in this small sample. Findings were robust to adjustment 
for a comprehensive set of confounders and to a sensitivity analysis assessing bias from loss to 
follow-up.  
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Phthalate exposures during gestation are hypothesized to affect later life adiposity by 
modifying peroxisome proliferator activated receptors (PPARs), associated with adipogenesis, 
lipid and carbohydrate metabolism, and androgen levels, or by disrupting thyroid hormone 
function (Desvergne et al. 2009; Kim and Park 2014). Our findings suggest an anti-adipogenic 
effect of DEHP exposure, which is consistent with toxicological studies reporting that relatively 
high dose DEHP exposure (2% by body weight) induces PPAR alpha-mediated reductions in 
body weight and fat mass in both rats (Itsuki-Yoneda et al. 2007) and mice (Xie et al. 2002). 
However, toxicological studies examining early life exposure to DEHP or its hydrolytic 
metabolite, MEHP, have reported species- and dose-specific effects on subsequent body fat of 
offspring. Two studies of perinatal MEHP or DEHP exposure in mice reported increased body 
weight and fat deposition in offspring, though one study observed effects only at the lowest dose 
administered (0.05 but not 0.25 or 0.5 mg MEHP/kg/day) (Hao et al. 2012) and the other 
reported effects at both low and high doses (0.05 and 5 mg DEHP/kg/day) (Schmidt et al. 2012). 
Two studies of pregnant rats exposed to doses ranging from 1 to 400 mg DEHP/kg/day reported 
no difference in offspring total body weight (Campioli et al. 2014; Kobayashi et al. 2006). 
Interestingly, Feige et al. reported that although high dose DEHP exposure (500 mg/kg body 
mass/day) protected against diet-induced obesity via PPAR alpha activation in wild-type mice, 
mice with humanized PPAR alpha gained more weight and adipose tissue than untreated 
controls (Feige et al. 2010). While the causes of species differences remain unclear, effects of 
DEHP on other, less understood pathways (e.g., liver metabolism, thyroid function, or androgen 
activity) may play a role.  
A recent study examined DEHP metabolite concentrations in cord plasma in relation to 
repeated BMI measurements in the first year of life among 89 infants (de Cock et al. 2014). 
They report higher BMI among one-year-olds for one metabolite, MEOHP. Although these 
findings are consistent with the inverse association between ∑DEHP and fat mass observed in 
our analysis, the de Cock study was based on a small sample at each time point (n<10). 
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Further, the use of phthalate metabolite concentrations in blood or blood products as exposure 
biomarkers is questionable (Calafat et al. 2013). While the authors only measured secondary or 
oxidative metabolites, that may reflect true biological exposures, it is possible that cord plasma 
DEHP metabolites arise from hospital-based exposures to DEHP at the time of delivery 
(Vandentorren et al. 2011; Yan et al. 2009). 
 A number of cross-sectional analyses have examined phthalate exposures and obesity, 
BMI, waist circumference, or related measures in humans (recently reviewed in (Goodman et al. 
2014). Many of these studies reported associations between phthalate metabolites and 
adiposity-related outcomes, with results often differing between groups defined by age, sex, 
race/ethnicity, or other characteristics. Such cross-sectional analyses are problematic as it is 
unclear whether phthalate exposures are causally related to obesity or phthalate body burden 
differs in obese individuals due to differences in exposure to phthalate sources, such as diet 
(Serrano et al. 2014), personal care products (Buckley et al. 2012; Duty et al. 2005; Just et al. 
2010; Watkins et al. 2014), or medications (Hernandez-Diaz et al. 2013). In addition, these 
analyses did not assess exposures during gestation, a hypothesized critical window for an effect 
of phthalates on pathways related to development of obesity.  
Phthalates have relatively short half-lives (<24 hours) (Koch et al. 2005) and exposures 
are likely episodic in nature, so that a single third trimester urine sample may not be 
representative of exposure during all of gestation. However, fetal growth and adipocyte 
replication is rapid during the third trimester, indicating that it is a relevant exposure period for 
fat development (Dietz 1994). Additionally, concentrations of phthalate metabolites in a single 
urine sample may be moderately predictive of dibutyl, di-iso-butyl, diethyl, and benzylbutyl 
phthalate exposures during pregnancy, with greater variability for DEHP (Adibi et al. 2008; 
Braun et al. 2012; Ferguson et al. 2014a).  
Although we adjusted for maternal pre-pregnancy BMI and adequacy of gestational 
weight gain, there may be residual confounding through shared maternal and child diet if the 
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dietary sources of a woman’s phthalate intake during pregnancy are similar to her child’s at 
ages 4 to 9 years. The contribution of diet to total exposure varies by phthalate. Foods typically 
contain low levels of diethyl phthalate (Serrano et al. 2014) whereas food packaging may 
account for over half of total DEHP exposure (Rudel et al. 2011). To explain the inverse 
association we observed between ∑DEHP and percent fat mass, foods that are part of a healthy 
family diet would also have to contain more DEHP. However, because DEHP has consistently 
been identified in high fat foods such as dairy, poultry, and cooking oils (Serrano et al. 2014), 
any confounding by dietary sources of DEHP is more likely in the opposite direction of the 
association we observed. 
While body composition equations built into the Tanita scale are not validated in children 
under age 7 years, percent fat mass values estimated using an equation validated for this age 
group was strongly correlated with the values estimated by the proprietary equation. 
Furthermore, associations between phthalate metabolite concentrations and percent fat mass 
were consistent across study visits (data not shown) and patterns of association were similar to 
those for BMI z-score associations. Our sample size was not adequate to examine potential 
critical windows of susceptibility. Future studies may consider exploring relationships between 
phthalate exposures and obesity with respect to differing growth trajectories, timing of adiposity 
rebound, or pubertal onset.  
This analysis has several important strengths.  First, we examined exposure to 
phthalates during the hypothesized critical window for developmental programming of obesity. 
Second, we incorporated repeated measures of fat mass in children. Third, we adjusted for 
many important confounders including maternal anthropometric characteristics and multiple 
measures of socioeconomic status. Fourth, we utilized a Bayesian framework to incorporate 
prior information and account for potential confounding by correlated metabolite concentrations. 
Finally, we investigated and accounted for missing data in exposures (values <LOD), 
covariates, and outcomes. 
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 Conclusions E.
In this prospective study, we observed an inverse relation between maternal third 
trimester concentrations of ∑DEHP metabolites and percent fat mass in children aged 4 to 9 
years. While a substantial cross-sectional literature has assessed phthalate metabolite 
concentrations and obesity-related outcomes, larger prospective studies examining prenatal 
exposures are needed to replicate these findings. 
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 Tables and Figures F.
 
Table 3. Characteristics of participants at birth and follow-up, Mount Sinai Children’s 
Environmental Health Study 1998 – 2002 
Characteristic 
Birth cohort Study sample 
n (%) n (%) 
Total (N) 404 180 
Race/ethnicity   
White 86 (21.3) 34 (18.9) 
Black 112 (27.7) 51 (28.3) 
Hispanic or other 206 (51) 95 (52.8) 
Maternal age at delivery (years)   
< 20 142 (35.2) 56 (31.1) 
20–24 132 (32.7) 60 (33.3) 
25–29 44 (10.9) 26 (14.4) 
≥ 30 86 (21.3) 38 (21.1) 
Maternal education (≥ college degree) 100 (24.8) 40 (22.2) 
Maternal work status (employed) 235 (58.2) 107 (59.4) 
Maternal smoking during pregnancy 67 (16.6) 31 (17.2) 
Maternal pre-pregnancy BMI (kg/m2)   
< 18.5 82 (20.3) 10 (5.6) 
18.5-24.9 215 (53.2) 111 (61.7) 
25-29.9 72 (17.8) 42 (23.3) 
≥ 30 35 (8.7) 17 (9.4) 
Maternal height (m) (mean and SD) 1.63 (0.07) 1.62 (0.08) 
Adequacy of gestational weight gain   
Less than recommended 44 (12.3) 14 (8.9) 
Recommended  75 (21) 40 (25.3) 
More than recommended 238 (66.7) 104 (65.8) 
Missing 47 22 
Year of maternal urine collection   
1998 84 (21.9) 34 (18.9) 
1999 127 (33.2) 55 (30.6) 
2000 134 (35) 72 (40) 
2001 35 (9.1) 18 (10) 
2002 3 (0.8) 1 (0.6) 
Urine not collected 21 0 
Child's sex (male) 222 (55) 98 (54.4) 
Breastfed   
Ever 206 (63) 113 (63.1) 
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Characteristic 
Birth cohort Study sample 
n (%) n (%) 
Never 121 (37) 66 (36.9) 
Missing 77 1 
Physical activity at follow-upa   
Inactive  100 (56.5) 
Active most of the time  77 (43.5) 
Missing  3 
Body mass index (BMI); standard deviation (SD) 
a Proportion classified as inactive at any follow-up visit 
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Table 4. Distributions of phthalate metabolite concentrations in third trimester maternal urine samples (N=180), Mount 
Sinai Children’s Environmental Health Study 1998 – 2002 
Metabolite (µg/L) LOD Percent detected Geometric meana Minimum 25th percentile 75th percentile Maximum 
MEP 0.26 99.4 223 <LOD 87.1 525 29528 
MnBP 0.4 100 32.9 0.800 14.3 79.5 4043 
MiBP 0.26 97.8 5.83 <LOD 2.90 15.1 76.6 
MCPP 0.16 97.8 2.87 <LOD 1.50 6.30 129 
MBzP 0.08 99.4 14.1 <LOD 5.70 32.8 481 
∑DEHPb n/a n/a 0.284 <LOD 0.125 0.530 19.9 
MECPP 0.25 99.4 36.0 <LOD 15.1 72.7 2055 
MEHHP 0.32 99.4 21.0 <LOD 8.80 41.3 2051 
MEHP 0.9 91.7 6.15 <LOD 3.00 14.2 478 
MEOHP 0.45 99.4 18.7 <LOD 8.20 38.3 1335 
Limits of detection (LOD) 
a To compute the geometric mean, phthalate metabolite concentrations <LOD were replaced by LOD/√2. 
b ∑DEHP is expressed as micromoles/L. 
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Table 5. Percent fat mass distributions in the Mount Sinai Children’s Environmental Health Study 1998 – 2002 
Visit 
Mean age (years) ± 
SD 
Overall 
 
Girls 
 
Boys 
n Mean ± SD 
 
n Mean ± SD 
 
n Mean ± SD 
All visits 6.5 ± 1.3 363 18.4 ± 8.4 
 
173 17.5 ± 9.8 
 
190 19.3 ± 6.8 
Visit 1 4.9 ± 0.4 97 15.3 ± 7.5 
 
47 12.6 ± 8.8 
 
50 17.8 ± 4.8 
Visit 2 6.1 ± 0.2 117 17.5 ± 7.2 
 
57 16.4 ± 8.6 
 
60 18.5 ± 5.4 
Visit 3 7.8 ± 0.8 149 21.2 ± 9.0 
 
69 21.6 ± 9.8 
 
80 20.9 ± 8.3 
Standard deviation (SD) 
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Table 6. Age- and sex- standardized body mass index z-score distributions in the Mount Sinai Children’s Environmental 
Health Study 1998 – 2002 
Visit 
Mean age 
(years) ± SD 
 Overall 
 
Girls 
 
Boys 
n Mean ± SD 
 
n Mean ± SD 
 
n Mean ± SD 
All visits 6.5 ± 1.3  364 0.56 ± 1.15 
 
174 0.50 ± 1.10 
 
190 0.62 ± 1.20 
Visit 1 4.9 ± 0.4  99 0.51 ± 1.18 
 
49 0.51 ± 1.07 
 
50 0.52 ± 1.29 
Visit 2 6.1 ± 0.2  117 0.50 ± 1.04 
 
57 0.41 ± 1.04 
 
60 0.59 ± 1.05 
Visit 3 7.8 ± 0.8  148 0.63 ± 1.21 
 
68 0.57 ± 1.17 
 
80 0.69 ± 1.25 
Standard deviation (SD) 
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Table 7. Adjusted associations between third trimester maternal urinary phthalate metabolite concentrations and percent 
fat mass among children aged 4 to 9 years in the Mount Sinai Children’s Environmental Health Study 1998 – 2002 
Metabolite Overall Girls Boys 
MEP 0.12 (-1.34, 1.58) -0.35 (-2.43, 1.75) 0.75 (-1.31, 2.80) 
MnBP -0.86 (-3.07, 1.36) -0.34 (-3.71, 3.05) -0.86 (-3.46, 1.74) 
MiBP 0.34 (-1.54, 2.20) 1.04 (-1.36, 3.44) -0.88 (-3.44, 1.68) 
MCPP 0.63 (-1.55, 2.82) 1.21 (-1.44, 3.87) -0.08 (-3.22, 3.03) 
MBzP 0.67 (-1.31, 2.65) 0.62 (-1.77, 3.02) 0.98 (-2.17, 4.14) 
∑DEHP -0.89 (-2.24, 0.47) -0.80 (-2.81, 1.23) -0.64 (-2.46, 1.16) 
Beta coefficients (95% credible intervals) per standard deviation increase in natural log phthalate metabolite concentrations were 
estimated in a multiple metabolite linear mixed effects regression model. Sex-specific estimates were estimated in models including 
an interaction term for child sex.  
Estimates are adjusted for urine dilution and collection date; maternal race/ethnicity, age, education, work status, and smoking during 
pregnancy; maternal height and pre-pregnancy body mass index; adequacy of gestational weight gain; breastfeeding; months of age 
and physical activity at follow-up; and, for overall models, child sex. 
  
 6
4
 
 
Figure 2. Adjusted associations between tertiles of third trimester maternal urinary phthalate metabolite concentrations 
and percent fat mass among children aged 4 to 9 years in the Mount Sinai Children’s Environmental Health Study 1998 – 
2002 
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Table 8. Adjusted associations between third trimester maternal urinary phthalate metabolite concentrations and percent 
fat mass among children aged 4 to 9 years in the Mount Sinai Children’s Environmental Health Study 1998 – 2002 
Metabolite Exposure metric Exposure unita Overall Girls Boys 
MEP Lowest tertile <186  ref ref ref 
 Middle tertile 186–546  -0.75 (-3.45, 1.95) -1.66 (-4.95, 1.69) -0.20 (-3.81, 3.43) 
 Highest tertile >546  0.69 (-2.15, 3.53) 1.46 (-2.82, 5.73) 2.46 (-1.49, 6.36) 
 Continuous SD 0.12 (-1.34, 1.58) -0.35 (-2.43, 1.75) 0.75 (-1.31, 2.80) 
MnBP Lowest tertile <32.0  ref ref ref 
 Middle tertile 32.0–64.6  -0.69 (-3.66, 2.27) 1.00 (-2.64, 4.60) -1.80 (-5.68, 2.10) 
 Highest tertile >64.6  -1.27 (-4.69, 2.16) -2.79 (-7.17, 1.62) -1.71 (-6.19, 2.82) 
 Continuous SD -0.86 (-3.07, 1.36) -0.34 (-3.71, 3.05) -0.86 (-3.46, 1.74) 
MiBP Lowest tertile <6.0  ref ref ref 
 Middle tertile 6.0–12.2  0.46 (-2.30, 3.20) 0.55 (-2.94, 4.02) 0.71 (-2.93, 4.32) 
 Highest tertile >12.2  0.57 (-2.63, 3.79) 0.16 (-4.18, 4.51) -0.07 (-4.44, 4.32) 
 Continuous SD 0.34 (-1.54, 2.20) 1.04 (-1.36, 3.44) -0.88 (-3.44, 1.68) 
MCPP Lowest tertile <2.8  ref ref ref 
 Middle tertile 2.8-6.2  -0.61 (-3.48, 2.24) -0.50 (-3.87, 2.90) -0.72 (-4.60, 3.18) 
 Highest tertile >6.2  1.79 (-1.61, 5.17) -0.22 (-4.62, 4.17) 1.64 (-2.98, 6.32) 
 Continuous SD 0.63 (-1.55, 2.82) 1.21 (-1.44, 3.87) -0.08 (-3.22, 3.03) 
MBzP Lowest tertile <12.7  ref ref ref 
 Middle tertile 12.7–30.5  -0.93 (-3.65, 1.77) -2.19 (-5.70, 1.34) -0.72 (-4.35, 2.92) 
 Highest tertile >30.5  0.84 (-2.29, 4.01) 1.48 (-2.99, 5.93) -0.79 (-5.28, 3.74) 
 Continuous SD 0.67 (-1.31, 2.65) 0.62 (-1.77, 3.02) 0.98 (-2.17, 4.14) 
∑DEHP Lowest tertile <0.23 ref ref ref 
 Middle tertile 0.23–0.60 -1.77 (-4.48, 0.97) -1.53 (-4.96, 1.88) -1.79 (-5.34, 1.75) 
 Highest tertile >0.60 -3.06 (-5.99, -0.09) -0.27 (-4.51, 4.00) -2.99 (-7.10, 1.15) 
 Continuous SD -0.89 (-2.24, 0.47) -0.80 (-2.81, 1.23) -0.64 (-2.46, 1.16) 
Referent category (ref), standard deviation (SD) 
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a Tertile cut points are expressed as micrograms per gram creatinine (or micromoles per gram creatinine for ∑DEHP) 
Beta coefficients (95% credible intervals) were estimated in multiple metabolite linear mixed effects regression models adjusted for 
urine collection date; maternal race/ethnicity, age, education, work status, and smoking during pregnancy; maternal height and pre-
pregnancy body mass index; adequacy of gestational weight gain; breastfeeding; months of age and physical activity at follow-up; 
and, for overall models, child sex. Models of continuous metabolite concentrations were additionally adjusted for natural log 
creatinine. Sex-specific estimates were estimated in models including an interaction term between child sex and variables for each 
metabolite or ∑DEHP. 
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Table 9. Sensitivity analyses for associations between third trimester maternal urinary phthalate metabolite concentrations 
and percent fat mass among children aged 4 to 9 years in the Mount Sinai Children’s Environmental Health Study 1998 – 
2002 
Metabolite Primary analysisa Single metabolite modelsb Loss to follow-upc 
MEP 0.12 (-1.34, 1.58) 0.08 (-1.14, 1.30) -0.33 (-1.82, 1.15) 
MnBP -0.86 (-3.07, 1.36) -0.07 (-1.41, 1.27) -0.96 (-3.24, 1.31) 
MiBP 0.34 (-1.54, 2.20) 0.23 (-1.12, 1.52) 1.24 (-0.70, 3.19) 
MCPP 0.63 (-1.55, 2.82) 0.30 (-1.05, 1.66) 0.26 (-1.99, 2.48) 
MBzP 0.67 (-1.31, 2.65) 0.40 (-0.93, 1.74) 0.49 (-1.48, 2.49) 
∑DEHP -0.89 (-2.24, 0.47) -0.57 (-1.79, 0.57) -0.47 (-1.90, 0.96) 
Beta coefficients (95% credible intervals) per SD increase in natural log phthalate metabolite concentrations, adjusted for urine 
dilution and collection date; maternal race/ethnicity, age, education, work status, and smoking during pregnancy; maternal height 
and pre-pregnancy body mass index; adequacy of gestational weight gain; breastfeeding; months of age and physical activity at 
follow-up; and child sex. 
a Associations among children with at least one follow-up visit (N=180) estimated in a multiple metabolite linear mixed effects 
regression model.  
b Associations among children with at least one follow-up visit (N = 180) estimated in a separate linear mixed effects regression model 
for each metabolite. 
c Associations among all children in the birth cohort with measured phthalate metabolite concentrations (N = 380) estimated in a 
multiple metabolite linear mixed effects regression model using a selection model for potentially nonignorable missing outcome 
data. 
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Table 10. Adjusted associations between third trimester maternal urinary phthalate metabolite concentrations and age- 
and sex- standardized body mass index z-scores among children aged 4 to 9 years in the Mount Sinai Children’s 
Environmental Health Study 1998 – 2002 
Metabolite Exposure metric Exposure unita Overall Girls Boys 
MEP Lowest tertile <186  ref ref ref 
 Middle tertile 186–546  0.16 (-0.23, 0.55) -0.02 (-0.48, 0.44) 0.34 (-0.18, 0.87) 
 Highest tertile >546  0.17 (-0.24, 0.58) 0.13 (-0.35, 0.61) 0.23 (-0.33, 0.79) 
 Continuous SD 0.05 (-0.16, 0.27) 0.02 (-0.28, 0.33) 0.15 (-0.15, 0.45) 
MnBP Lowest tertile <32.0  ref ref ref 
 Middle tertile 32.0–64.6  -0.17 (-0.59, 0.25) 0.07 (-0.43, 0.57) -0.41 (-0.96, 0.15) 
 Highest tertile >64.6  -0.19 (-0.67, 0.30) -0.16 (-0.69, 0.38) -0.25 (-0.90, 0.39) 
 Continuous SD -0.13 (-0.45, 0.19) -0.10 (-0.57, 0.37) -0.15 (-0.53, 0.23) 
MiBP Lowest tertile <6.0  ref ref ref 
 Middle tertile 6.0–12.2  0.10 (-0.30, 0.50) 0.16 (-0.33, 0.65) 0.05 (-0.47, 0.57) 
 Highest tertile >12.2  0.03 (-0.42, 0.49) 0.06 (-0.44, 0.57) -0.05 (-0.68, 0.58) 
 Continuous SD -0.02 (-0.29, 0.25) 0.04 (-0.30, 0.38) -0.13 (-0.51, 0.24) 
MCPP Lowest tertile <2.8  ref ref ref 
 Middle tertile 2.8-6.2  0.11 (-0.31, 0.52) 0.11 (-0.37, 0.59) 0.19 (-0.37, 0.74) 
 Highest tertile >6.2  0.32 (-0.16, 0.79) 0.35 (-0.18, 0.87) 0.40 (-0.26, 1.05) 
 Continuous SD 0.14 (-0.17, 0.46) 0.16 (-0.22, 0.54) 0.16 (-0.29, 0.61) 
MBzP Lowest tertile <12.7  ref ref ref 
 Middle tertile 12.7–30.5  -0.18 (-0.56, 0.22) -0.23 (-0.72, 0.26) -0.23 (-0.75, 0.29) 
 Highest tertile >30.5  -0.20 (-0.65, 0.25) -0.06 (-0.56, 0.44) -0.38 (-1.02, 0.26) 
 Continuous SD -0.02 (-0.32, 0.27) 0.03 (-0.33, 0.38) -0.11 (-0.56, 0.34) 
∑DEHP Lowest tertile <0.23 ref ref ref 
 Middle tertile 0.23–0.60 -0.10 (-0.49, 0.29) -0.17 (-0.65, 0.30) 0.01 (-0.50, 0.52) 
 Highest tertile >0.60 -0.13 (-0.55, 0.29) -0.13 (-0.60, 0.35) -0.08 (-0.66, 0.51) 
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 Continuous SD -0.05 (-0.25, 0.15) -0.05 (-0.34, 0.24) -0.01 (-0.28, 0.26) 
Referent category (ref), standard deviation (SD) 
a Tertile cut points are expressed as micrograms per gram creatinine (or micromoles per gram creatinine for ∑DEHP) 
Beta coefficients (95% credible intervals) were estimated in multiple metabolite linear mixed effects regression models adjusted for 
urine collection date; maternal race/ethnicity, age, education, work status, and smoking during pregnancy; maternal height and pre-
pregnancy body mass index; adequacy of gestational weight gain; breastfeeding; months of age and physical activity at follow-up; 
and, for overall models, child sex. Models of continuous metabolite concentrations were additionally adjusted for natural log 
creatinine. Sex-specific estimates were estimated in models including an interaction term between child sex and variables for each 
metabolite or ∑DEHP. 
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CHAPTER V. RESULTS FOR SPECIFIC AIM 2 
 Introduction  A.
One out of three children aged 2 to 19 years in the United States is overweight or obese 
(Ogden et al. 2014). Obese children have poorer physical and psychosocial health compared to 
their normal-weight peers (Daniels et al. 2005) and exhibit early physiologic changes associated 
with chronic health conditions such as cardiovascular disease (Friedemann et al. 2012). While 
energy intake is a key determinant of weight change, the “environmental obesogen hypothesis” 
posits that prenatal environmental chemical exposures may have contributed to the rise in 
obesity in the last several decades (Grun and Blumberg 2006).  
Phthalates are industrial chemicals used as plasticizers and solvents in consumer goods 
and personal care products (Schettler 2006). Biomonitoring studies have reported widespread 
exposure to phthalates in the United States (Centers for Disease Control and Prevention 2014) 
and prenatal exposures to certain phthalates have been associated with reproductive and 
developmental outcomes in children (Braun et al. 2013). Furthermore, early life phthalate 
exposures may alter metabolic and homeostatic mechanisms related to the development of 
obesity (Grun and Blumberg 2006). For example, toxicological studies have demonstrated that 
certain phthalates affect thyroid or steroid hormone levels and interfere with peroxisome 
proliferator-activated receptors (PPARs), which regulate lipid metabolism and adipogenesis 
(Grun and Blumberg 2009; Hatch et al. 2010).  
Two prospective investigations of prenatal (Buckley et al. submitted) or intrapartum (de 
Cock et al. 2014) phthalate exposures reported negative associations of di-(2-ethylhexyl) 
phthalate (DEHP) metabolites with fat mass or body mass index (BMI) in children. However, 
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these studies were small with limited ability to evaluate the relation between phthalate 
exposures and adiposity or assess potential differences in associations within population 
subgroups. We examined associations of prenatal urinary phthalate metabolite concentrations 
and BMI assessed in children between ages 4 and 7 years in three cohort studies in the United 
States. 
 
 Methods B.
Children’s Environmental Health Center cohorts 
The Mount Sinai School of Medicine Center for Children’s Environmental Health (MSSM) 
enrolled 479 primiparous women with singleton pregnancies from the Mount Sinai prenatal clinic 
and two adjacent private practices in New York City between 1998 and 2002. Women delivered 
at the Mount Sinai Medical Center. Seventy-five women were subsequently excluded for 
reasons described elsewhere (Engel et al. 2007). The final cohort consists of 404 mother-infant 
pairs for whom birth data were available.  
The Columbia Center for Children’s Environmental Health (CCEH) enrolled 727 
pregnant women between 1998 and 2006. The cohort was restricted to non-smoking women 
18-35 years old who self-identified as either African American or Dominican and who had 
resided in Northern Manhattan or the South Bronx in New York City for >1 year prior to 
pregnancy. Additional details of the study population have been previously reported (Perera et 
al. 2003; Whyatt et al. 2003). 
The Health Outcomes and Measures of the Environment (HOME) Study, a prospective 
birth cohort located in Cincinnati, Ohio, enrolled 468 women between 2003 and 2006. Because 
the HOME Study contains a nested, randomized trial of in-home lead and injury hazard controls 
women had to be living in housing built before 1978. Additional eligibility criteria and study 
population characteristics have been described (Braun et al. 2009). A total of 389 women 
delivered live-born, singleton infants without birth defects.  
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Questionnaires were administered to each mother at study enrollment to ascertain 
maternal characteristics including age at delivery, race/ethnicity, education, work status during 
pregnancy, parity, height, and pre-pregnancy BMI. We calculated gestational weight gain as last 
pregnancy weight minus self-reported pre-pregnancy weight. Women provided a spot urine 
sample at mean ± standard deviation (SD) gestational ages of 31.6 ± 5.1 (MSSM), 34.4 ± 3.0 
(CCEH), and 27.1 ± 2.2 (HOME) weeks. Child’s sex was ascertained from birth records and 
breastfeeding was assessed by questionnaire at follow-up.  
For MSSM, we determined maternal smoking during pregnancy based on self-report. 
For HOME, we classified women as active smokers during pregnancy if the average of three 
cotinine concentrations (measured at 16 weeks, 26 week, and birth) exceeded 3 ng/mL 
(Benowitz et al. 2009). CCEH excluded women with evidence of active smoking (Whyatt et al. 
2003). 
 
Human subjects 
Women provided informed consent prior to participation and children aged ≥ 7 years 
provided assent. The MSSM, CCEH, and HOME studies received approval from the Institutional 
Review Boards of the Mount Sinai School of Medicine, Columbia University, and the University 
of Cincinnati College of Medicine, respectively. The involvement of the Centers for Disease 
Control and Prevention (CDC) laboratory was determined not to constitute engagement in 
human subjects research. 
 
Phthalate exposures 
All spot urine samples were analyzed by CDC for monoethyl phthalate (MEP), mono-n-
butyl phthalate (MnBP), monoisobutyl phthalate (MiBP), mono(3-carboxypropyl) phthalate 
(MCPP), monobenzyl phthalate (MBzP), mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-
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hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-
ethyl-5-carboxypentyl) phthalate (MECPP). Sample collection and storage practices, analytic 
methods, and quality control procedures have been described (Kato et al. 2005; Silva et al. 
2007). We replaced values below the LOD by the LOD divided by the square root of two for all 
analyses (Hornung and Reed 1990; Perkins et al. 2007). Following previous work (Wolff et al. 
2008), we examined DEHP metabolites (MECPP, MEHHP, MEHP, MEOHP) as a micromolar 
sum (ΣDEHP, micromoles per liter). To facilitate comparison of phthalate effect sizes, we 
standardized the natural log concentration of each phthalate metabolite to its mean and SD in 
the pooled sample.  
 
Outcome assessment 
Weight and height were measured at follow-up visits scheduled for approximately ages 
4-5.5, 6, and 7-9 years (MSSM), 5 and 7 years (CCEH), and 4, 5, and 7-9 years (HOME). We 
measured children in bare or stocking feet wearing light clothing (i.e., pediatric gown, 
underwear, or shorts and a t-shirt). We assessed weight using a digital scale (HOME and CCEH 
5 year visit) or a pediatric Tanita scale (MSSM and CCEH 7 year visit) (models TBF-300 and 
BC-418, Tanita Corporation of America, Arlington Heights, Illinois) and determined height using 
wall-mounted stadiometers. We calculated BMI [weight (kg) / height (m)2] as a measure of 
excess weight for height that is a moderately sensitive and highly specific indicator of adiposity 
(Freedman and Sherry 2009). We computed age- and sex-standardized z-scores and 
percentiles for BMI using a CDC macro (Centers for Disease Control and Prevention 2004). We 
then classified children as overweight or obese at each follow-up visit if their age- and sex-
standardized BMI percentile exceeded 85. As supplementary outcomes, we also calculated 
age- and sex-standardized weight and height z-scores using the CDC macro (Centers for 
Disease Control and Prevention 2004). 
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Statistical analysis 
The current analysis includes infants of singleton pregnancies born at ≥32 weeks 
gestation and ≥1500 grams with measured maternal urinary phthalate concentrations. After 
excluding samples with a very dilute urine concentration (<10 mg/dL creatinine, n = 9),(Wolff et 
al. 2008) 1143 children met our baseline inclusion criteria. To examine BMI prior to puberty, we 
further restricted the sample to children with weight and height data collected at one or more 
follow-up visits occurring between 4 and 7 years of age (707 children with 1416 follow-up visits).  
We assessed associations of prenatal phthalate exposures with overweight/obesity and 
BMI z-scores using a Bayesian modeling framework to (1) account for missing at random 
covariate data, (2) stabilize estimates of correlated metabolites, and (3) conduct sensitivity 
analyses for potentially nonignorable loss to follow-up.  
We identified potential confounders using directed acyclic graphs and adjusted for 
cohort, maternal race/ethnicity, maternal age at delivery, maternal education, maternal work 
status during pregnancy, maternal pre-pregnancy BMI, maternal height, gestational weight gain, 
maternal smoking during pregnancy, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up. To account for urine dilution in models assessing 
continuous phthalate concentrations, natural log creatinine was included as a covariate (Barr et 
al. 2005). In z-score models, we also adjusted for an interaction between child’s sex and age at 
follow-up because outcome distributions by age differed between girls and boys. We included a 
quadratic term for maternal pre-pregnancy BMI and cubic terms for maternal age and 
gestational weight gain based on non-linear associations with outcomes.  
MSSM and HOME measured creatinine to account for urinary dilution. CCEH measured 
specific gravity in all urine samples (n = 339), with creatinine additionally measured in a subset 
(n = 137). To obtain a common measure of urine dilution, we multiply imputed missing natural 
log creatinine concentrations in CCEH using a linear regression model at each iteration of the 
MCMC algorithm in our Bayesian models. We modeled natural log creatinine as a normally 
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distributed random variable conditional on specific gravity; gestational age and calendar date at 
urine collection; maternal education, race/ethnicity, parity, BMI, and height; child’s sex; and 
gestational weight gain.  
We also multiply imputed missing at random values of breastfeeding (n = 6), maternal 
pre-pregnancy BMI (n = 58), and gestational weight gain (n = 107) within our Bayesian 
framework. We modeled breastfeeding using a logistic model conditional on cohort, maternal 
education, race/ethnicity, parity, and maternal smoking during pregnancy. We modeled maternal 
pre-pregnancy weight, maternal last pregnancy weight, and maternal height as normally 
distributed random variables conditional on cohort, maternal education, race/ethnicity, parity, 
maternal smoking during pregnancy, maternal work status during pregnancy, child’s sex, and 
maternal age at delivery. At each iteration of the MCMC algorithm, maternal pre-pregnancy BMI 
and gestational weight gain were calculated based on these imputed values.  
To account for potential confounding among correlated phthalate metabolites, we 
estimated associations in multiple metabolite Bayesian hierarchical models (MacLehose et al. 
2007). Following standard practice, the beta coefficient for each standardized phthalate 
metabolite was given an independent normally-distributed prior distribution with a mean of zero 
and variance of 1/τ2. We set τ = 1, which represents a prior belief that 95% of the effects of a SD 
difference in natural log phthalate metabolite concentration are within an odds ratio (OR) of 0.14 
to 7.1 for overweight/obese status or approximately ± one SD of the mean BMI, weight, and 
height z-score distribution in the study sample.  
 We estimated posterior mean ORs and beta coefficients, and associated 95% credible 
intervals (CI), per SD increase in natural log phthalate metabolite concentrations in logistic and 
linear mixed effects models with random intercepts to account for multiple observations per 
child. We examined effect measure modification by cohort, child’s sex, and race/ethnicity by 
including interaction terms between the modifier and each metabolite. In models assessing 
modification by both cohort and either sex or race/ethnicity, we included all two- and three-way 
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interaction terms between metabolites, cohort, and the covariate. When assessing modification 
by race/ethnicity, we excluded children of other race as well as Hispanic children in HOME due 
to small numbers. We considered there to be meaningful effect modification if the 80% CI for the 
interaction term did not cross the null value. Finally, we explored dose-response relationships in 
models that replaced continuous variables for standardized metabolite concentrations with 
restricted quadratic splines (Howe et al. 2011). 
As a sensitivity analysis, we compared associations estimated in multiple metabolite 
models to those estimated in models including only one metabolite at a time, a common 
approach that may result in confounding by correlated metabolites. Single metabolite models 
specified the same prior distributions for phthalate beta coefficients as the main analyses, i.e. β 
~ N(0,1).  
Additionally, we conducted a sensitivity analysis for loss to follow-up due to concern that 
the probability of follow-up visit attendance may depend on a child’s outcome value at the time. 
For this analysis, we compared results from our primary models, which assume outcome data 
are missing at random, to a selection model approach (Little and Rubin 2002) that assumes a 
potentially nonignorable (missing not at random) missing data mechanism. We constructed a 
binary missing outcome indicator variable for attendance at each follow-up visit based on the 
cohort-specific visit schedules (0 if observed, 1 if missing). Within our MCMC algorithm, we 
jointly fit the outcome model with cohort-specific models for the missing outcome indicator to 
allow predictors of missingness to vary by cohort. We specified the missing outcome indicator 
models as logistic mixed effects regression models with random intercepts, dependent on the 
outcome (potentially unobserved) as well as maternal age, race/ethnicity, maternal education, 
maternal pre-pregnancy BMI, birth weight, child’s sex, and calendar date of urine collection. The 
CCEH missing outcome indicator model additionally included four variables that were 
unmeasured in the other cohorts but previously reported to predict subject retention in CCEH 
(receipt of public assistance during pregnancy, maternal satisfaction with living conditions, 
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neighborhood poverty rate, Spanish language linguistic isolation) (Rundle et al. 2012). Finally, 
because selection models are sensitive to unverifiable assumptions underlying the specification 
of the missing data model (Little 1995), we varied the parameterization of the missing outcome 
indicator models by using different functional forms for continuous variables, fitting a single 
missing indicator model for all three cohorts, and including interaction terms between age at 
follow-up and child’s sex and race/ethnicity. 
We conducted descriptive analyses in SAS version 9.3 (SAS Institute, Cary, NC). We 
ran Bayesian models in WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) with a 
10,000 iteration burn-in followed by 50,000 additional iterations. We ran ten chains for inference 
from the MCMC procedure for our sensitivity analyses for nonignorable missing data. We 
assessed model convergence using standard diagnostic measures (Gelman et al. 2013). 
 
 Results C.
Distributions of participant characteristics by cohort illustrate differences in the inclusion 
criteria and source populations of each study (Table 11). For example, HOME enrolled primarily 
white, non-Hispanic mothers who were older and had more years of education than women in 
the New York City cohorts. Within each cohort, characteristics of the study sample were similar 
to those of the eligible population at birth (Table 12).  
Except for MEHP, a hydrolytic metabolite of DEHP, urinary phthalate metabolite 
concentrations were measured in ≥95% of urine samples (Table 13). Although geometric mean 
urinary phthalate metabolite concentrations were lower in HOME than among MSSM and CCEH 
participants, exposure distributions exhibited substantial overlap (Table 13). Children in HOME 
were also leaner than children in the other two cohorts. Notably, HOME participants were 
classified as overweight or obese at 19% of follow-up visits compared to 32% in MSSM and 
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41% in CCEH (Table 14). Similarly, mean age- and sex- standardized BMI z-scores were 
highest among CCEH children and lowest in HOME (Table 15).  
Adjusted associations of prenatal urinary phthalate concentrations with 
overweight/obese status and age- and sex-standardized BMI z-scores are reported in Table 16 
(overall and by child’s sex) and Table 17 (by race/ethnicity). MCPP was associated with 
increased odds of overweight/obese status, with a stronger magnitude of association among 
Hispanic children. MCPP was not associated with age- and sex- standardized BMI z-scores. We 
observed modification of the association between MEP and BMI z-scores by child’s sex, with a 
negative association among girls but not boys (Table 16).  
In supplementary analyses of age- and sex-standardized weight and height z-scores, 
MEP was negatively associated with weight and height z-scores among girls (Table 18). We 
observed a negative association of MBzP with weight and height z-scores among non-Hispanic 
black children only (Table 19). We did not observe any associations between MnBP, MiBP, or 
∑DEHP and overweight/obese status or BMI, weight, or height z-scores. 
Spline models assessing the shape of relationships between prenatal urinary phthalate 
metabolite concentrations and outcomes were consistent with null associations or a linear dose-
response trend for all metabolites and outcomes (data not shown).  
Cohort-specific associations are reported in Tables 20-23. Associations with 
overweight/obese status did not differ by cohort. Associations of two metabolites, MnBP and 
MEP, with BMI z-scores were modified by cohort such that beta coefficients were on the 
opposite side of the null in MSSM compared to CCEH and HOME. However, MSSM was the 
smallest cohort and CIs were imprecise.  
Associations were similar whether estimated in single or multiple metabolite models 
(Table 24). Our sensitivity analysis for loss to follow-up indicated that children with higher BMI z-
scores were more likely to be observed. However, estimates of association between prenatal 
phthalate concentrations and overweight/obese status and BMI z-scores were similar whether 
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or not we accounted for potentially nonignorable missing outcomes (Table 24). Findings were 
similar in models with alternative specifications of the missing outcome indicator model (data not 
shown). 
 
 Discussion D.
In this pooled study of three birth cohorts, each SD increase in prenatal urinary MCPP 
concentrations was associated with greater than twice the odds of overweight or obesity among 
4 to 7 year old children. We also observed a negative association of prenatal MEP 
concentrations with BMI z-scores among girls.  
Two prospective studies have assessed early life phthalate exposures and childhood 
adiposity, one small study utilizing intrapartum cord blood measures of DEHP metabolites (de 
Cock et al. 2014) and a previous analysis of the MSSM cohort in which third trimester urinary 
concentrations of both high and low molecular weight phthalate metabolites were assessed 
(Buckley et al. submitted). In the first study, low cord blood MEOHP concentrations were 
associated with greater BMI among infant boys (de Cock et al. 2014). However, intrapartum 
phthalate concentrations may be influenced by medically-related exposures occurring during 
delivery that cannot be generalized to the antecedent prenatal period. In the previous MSSM 
study(Buckley et al. submitted), children in the highest tertile of ∑DEHP concentrations had 
lower percent fat mass than children in the first tertile. Other metabolites were not associated 
with percent fat mass in children. In the current study, we did not observe associations of 
∑DEHP metabolites with outcomes, though there were weak negative associations in some 
subgroups. It is possible that associations of ∑DEHP with body fatness are not detectable using 
BMI measurements that do not distinguish between fat and lean mass.  
We observed an association of MCPP with increased odds of overweight/obese status 
but not with differences in BMI z-scores. In children, use of BMI cut points to identify those with 
excess body fat is moderately sensitive and highly specific (Freedman and Sherry 2009). 
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Consequently, the association of MCPP with overweight/obese status but not BMI z-scores may 
reflect that BMI is a less sensitive marker of fat mass. While toxicological literature investigating 
DnOP is sparse, it does not appear to affect estrogen (Chen et al. 2014) or androgen (Saillenfait 
et al. 2011) activity but may impact the thyroid and liver (Poon et al. 1997). Consistent with our 
findings, a study of first trimester urinary phthalate metabolite concentrations and cord blood 
levels of two adipocyte-produced hormones reported associations of MCPP, but not other 
phthalate metabolites, with leptin and adiponectin levels (Ashley-Martin et al. 2014). Male 
infants in the second, third, and fourth quartiles of MCPP exposure had increased odds of high 
(≥90th percentile) leptin and females in the highest quartile of MCPP exposure had higher odds 
of high (≥90th percentile) adiponectin.  
MCPP is a metabolite of di-n-octyl phthalate (DnOP), which, like DEHP, is a high 
molecular weight phthalate used in plastics and food packaging (National Science Foundation 
2008). Both MCPP and DEHP have been associated with consumption of meat, diary, and other 
fatty foods (Serrano et al. 2014). We lacked information on diet and cannot rule out confounding 
by dietary sources of a woman’s phthalate exposures that may also be related to obesity in her 
child. The strongest predictor of childhood overweight is maternal overweight (Salsberry and 
Reagan 2005), and we adjusted for maternal pre-pregnancy BMI and gestational weight gain to 
control for potential confounding through shared maternal and child diet. Furthermore, the 
inverse association of ∑DEHP concentrations with overweight/obese status provides indirect 
evidence that associations are not strongly confounded by diet since ∑DEHP and MCPP 
exposures are associated with intake of similar foods (Serrano et al. 2014). 
We evaluated heterogeneity of associations by child’s sex because certain phthalates 
exhibit anti-androgenic activity (National Science Foundation 2008). The metabolite for which 
we observed sexual dimorphism, MEP, does not produce anti-androgen effects in animal 
studies (National Science Foundation 2008). It has been asserted that associations of MEP with 
outcomes related to androgen insufficiency in human studies may be due to its correlation with 
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other phthalates (National Science Foundation 2008). Our associations were co-adjusted but 
could have been confounded by phthalates not measured in this study or other endocrine 
disrupting chemicals contained in personal care products. Alternatively, MEP may be related to 
sex differences in other pathways related to development, such as effects on thyroid hormones. 
Thyroid dysfunction is more common among women, potentially due to estrogen-mediated 
differences in oxidative stress (Fortunato et al. 2014). 
We restricted our analysis to early childhood because phthalate exposures may affect 
puberty (Ferguson et al. 2014b; Wolff et al. 2014), a developmental stage that is also strongly 
tied to BMI. Similar to our finding that MEP concentrations were associated with decreased BMI 
z-scores among girls, Harley et al. reported an inverse association of prenatal urinary BPA 
concentrations with BMI and body fat among girls only, and this association was stronger 
among girls who had not yet reached puberty (Harley et al. 2013). Evaluating associations 
among older children is warranted to determine whether associations persist with age and to 
evaluate the timing of potential obesogenic effects with respect to puberty. 
Associations by race/ethnicity must be interpreted with caution. Because over 80% of 
the non-Hispanic white children in the study sample were HOME Study participants, differences 
in associations among white compared to black or Hispanic children may reflect differences in 
unmeasured characteristics of the HOME population. In particular, HOME Study mothers were 
older and more educated and their children were leaner compared to the other two cohorts, 
leading to potential differences in the magnitude of residual confounding in the HOME study as 
well as susceptibility to obesogenic effects. Hispanic participants in MSSM were primarily of 
Puerto Rican origin whereas CCEH Hispanics were Dominican. Although estimates of 
association among Hispanic children in MSSM and CCEH were similar for overweight/obese 
status, there were differences in some associations with z-score outcomes. Cohort-specific 
estimates among non-Hispanic black children, who were included in all three studies, were 
more comparable. For example, the negative association of MBzP and height z-scores among 
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non-Hispanic black children was observed at a similar magnitude in each of the three cohorts (β 
= -0.38, -0.32, -0.40 in MSSM, CCEH, and HOME, respectively).  
We measured phthalate metabolite concentrations in a single spot urine sample, which 
may not represent exposures throughout pregnancy since phthalates are quickly eliminated 
from the body (<24 hours) (Koch et al. 2005) and exposure to phthalate sources is episodic. 
However, many sources of phthalate exposure are frequent and may result in steady-state 
levels (Calafat and McKee 2006; Hauser et al. 2004). The probability of correctly classifying 
“high exposure” over a 6-12 week period using a single urine sample was reported in two 
studies to range between 0.50 and 0.74, depending on the metabolite (Adibi et al. 2008; Hauser 
et al. 2004).  
Despite limitations noted above, this prospective study has several important strengths. 
We assessed exposures during the fetal period, which is thought to be a susceptible 
developmental window for the origins of obesity (Dietz 1994). Assessing associations in three 
independent cohorts with notable variation in population characteristics supports the robustness 
of our findings. Pooling the cohorts provided a large sample size to assess heterogeneity of 
associations by hypothesized modifying factors. We employed a flexible Bayesian modeling 
approach that accommodated methods to multiply impute missing covariate data and control for 
confounding among correlated metabolites. Finally, we conducted sensitivity analyses to 
explore potential bias from loss to follow-up.  
 
  Conclusions E.
We observed a positive association of prenatal urinary MCPP concentrations with 
overweight/obese status in children aged 4 to 7 years. Our findings do not suggest that prenatal 
exposures to other phthalates are obesogenic. We observed a negative association of MEP with 
BMI z-scores among girls, indicating that MEP may interfere with physical development though 
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we cannot rule out confounding (e.g., other environmental obesogens) as an alternative 
explanation. 
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 Tables and Figures F.
Table 11. Characteristics of the study sample at baseline by cohort and pooled 
Characteristic MSSM CCEH HOME Pooled 
Total (N) 151 339 217 707 
Maternal age at delivery (years)     
< 20  42 (28) 47 (14) 13 (6) 102 (14) 
20–24  53 (35) 121 (36) 37 (17) 211 (30) 
25–29  21 (14) 100 (30) 62 (29) 183 (26) 
≥ 30 35 (23) 71 (21) 105 (48) 211 (30) 
Race/ethnicity     
Non-Hispanic white 31 (21) 0 (0) 135 (62) 166 (23) 
Non-Hispanic black  41 (27) 120 (35) 69 (32) 230 (33) 
Hispanic 76 (50) 219 (65) 4 (2) 299 (42) 
Other 3 (2) 0 (0) 9 (4) 12 (2) 
Maternal education     
<High school 34 (23) 124 (37) 20 (9) 178 (25) 
High school or GED 34 (23) 126 (37) 27 (12) 187 (26) 
Some college 45 (30) 74 (22) 64 (29) 183 (26) 
≥ College degree 38 (25) 15 (4) 106 (49) 159 (22) 
Maternal work status during pregnancy 
(employed) 
92 (61) 199 (59) 181 (83) 472 (67) 
Parity (multiparous) 0 (0) 188 (55) 117 (54) 305 (43) 
Maternal smoking during pregnancy (yes) 26 (17) 0 (0) 22 (10) 48 (7) 
Maternal height (m) (mean ± SD) 64.0 (2.9) 63.7 (2.8) 65.0 (2.8) 64.2 (2.9) 
Pre-pregnancy body mass index (kg/m2)     
< 18.5 9 (6) 16 (5) 7 (4) 32 (5) 
18.5-24.9 90 (60) 170 (51) 72 (43) 332 (51) 
25-29.9 37 (25) 75 (23) 48 (29) 160 (25) 
≥ 30 15 (10) 70 (21) 40 (24) 125 (19) 
Missing 0 8 50 58 
Gestational weight gain (lb)     
< 25 21 (16) 77 (25) 75 (45) 173 (29) 
25-34.9 38 (29) 79 (26) 38 (23) 155 (26) 
35-44.9 26 (20) 73 (24) 35 (21) 134 (22) 
≥ 45 45 (35) 74 (24) 19 (11) 138 (23) 
Missing 21 36 50 107 
Year of urine collection     
1998-2000 133 (88) 94 (28) 0 (0) 227 (32) 
2001-2003 18 (12) 125 (37) 26 (12) 169 (24) 
2004-2006 0 (0) 120 (35) 191 (88) 311 (44) 
Child's sex (male) 80 (53) 161 (47) 94 (43) 335 (47) 
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Characteristic MSSM CCEH HOME Pooled 
Breastfed (ever) 94 (63) 256 (76) 176 (81) 526 (75) 
Missing 1 4 1 6 
Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures 
of the Environment Study (HOME), Mount Sinai School of Medicine Center for Children’s 
Environmental Health (MSSM), standard deviation (SD)
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Table 12. Characteristics of the birth cohorts at baseline by cohort and pooled 
Characteristic MSSM CCEH HOME Pooled 
Total (N) 376 407 360 1143 
Maternal age at delivery (years)     
< 20  133 (35) 57 (14) 24 (7) 214 (19) 
20–24  125 (33) 149 (37) 62 (17) 336 (29) 
25–29  41 (11) 119 (29) 102 (28) 262 (23) 
≥ 30 77 (20) 82 (20) 172 (48) 331 (29) 
Race/ethnicity     
Non-Hispanic white 76 (20) 0 (0) 226 (63) 302 (26) 
Non-Hispanic black  107 (28) 130 (32) 109 (30) 346 (30) 
Hispanic 188 (50) 277 (68) 8 (2) 473 (41) 
Other 5 (1) 0 (0) 15 (4) 20 (2) 
Missing 0 0 2 2 
Maternal education     
<High school 113 (30) 151 (37) 36 (10) 300 (26) 
High school or GED 79 (21) 150 (37) 47 (13) 276 (24) 
Some college 96 (26) 85 (21) 94 (26) 275 (24) 
≥ College degree 88 (23) 20 (5) 181 (51) 289 (25) 
Missing 0 1 2 3 
Maternal work status during pregnancy 
(employed) 
219 (58) 230 (57) 291 (81) 740 (65) 
Missing 0 1 2 3 
Parity (multiparous) 0 (0) 226 (56) 201 (56) 427 (37) 
Missing 0 2 1 3 
Maternal smoking during pregnancy (yes) 65 (17) 0 (0) 41 (11) 106 (9) 
Maternal height (m) (mean ± SD) 
64.0 
(2.9) 
63.7 
(2.8) 
64.9 
(2.6) 
64.2 
(2.8) 
Pre-pregnancy body mass index (kg/m2)     
< 18.5 25 (7) 22 (6) 8 (3) 55 (5) 
18.5-24.9 249 (66) 206 (52) 121 (48) 576 (56) 
25-29.9 69 (18) 88 (22) 69 (27) 226 (22) 
≥ 30 33 (9) 80 (20) 55 (22) 168 (16) 
Missing 0 11 107 118 
Gestational weight gain (lb)     
< 25 46 (14) 89 (25) 105 (42) 240 (25) 
25-34.9 85 (26) 94 (26) 65 (26) 244 (26) 
35-44.9 81 (24) 87 (24) 56 (22) 224 (24) 
≥ 45 121 (36) 91 (25) 27 (11) 239 (25) 
Missing 43 46 107 196 
Year of urine collection     
1998-2000 339 (90) 105 (26) 0 (0) 444 (39) 
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Characteristic MSSM CCEH HOME Pooled 
2001-2003 37 (10) 155 (38) 60 (17) 252 (22) 
2004-2006 0 (0) 147 (36) 300 (83) 447 (39) 
Child's sex (male) 207 (55) 197 (48) 172 (48) 576 (50) 
Breastfed (ever) 191 (62) 293 (76) 281 (81) 765 (73) 
Missing 68 22 11 101 
Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures 
of the Environment Study (HOME), Mount Sinai School of Medicine Center for Children’s 
Environmental Health (MSSM), standard deviation (SD) 
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Table 13. Distributions of phthalate metabolite concentrations in maternal urine samples 
during pregnancy, by cohort and pooled 
Metabolite (µg/L)/ 
cohort 
N LOD 
Percent 
detected 
Geometric 
meana 
Minimum 
25th 
percentile 
75th 
percentile 
Maximum 
MEP         
MSSM 151 0.3 99 198.9 <LOD 81.0 495 7819 
CCEH 339 0.5 100 162.0 7.79 69.4 334 6046 
HOME 217 0.5 100 119.3 3.30 36.0 335 26004 
Pooled 707  100 154.1 <LOD 63.4 353 26004 
MnBP         
MSSM 151 0.4 100 32.0 0.800 14.3 75.2 4043 
CCEH 339 0.6 100 38.0 1.20 20.3 81.3 1110 
HOME 217 0.6 100 21.1 0.800 8.50 49.1 2240 
Pooled 707  100 30.6 0.800 14.2 66.5 4043 
MiBP         
MSSM 151 0.3 97 5.96 <LOD 2.90 15.3 76.6 
CCEH 339 0.3 100 9.22 <LOD 5.10 19.0 374 
HOME 217 0.3 95 3.90 <LOD 1.50 11.4 84.1 
Pooled 707  98 6.45 <LOD 3.20 15.9 374 
MCPP         
MSSM 151 0.2 97 2.78 <LOD 1.50 5.50 129 
CCEH 339 0.2 97 2.06 <LOD 1.20 4.10 32.7 
HOME 217 0.2 98 1.73 <LOD 0.900 3.60 23.6 
Pooled 707  97 2.08 <LOD 1.10 4.30 129 
MBzP         
MSSM 151 0.1 99 13.3 <LOD 4.75 29.8 481 
CCEH 339 0.2 100 13.5 <LOD 5.76 31.4 550 
HOME 217 0.2 98 8.25 <LOD 3.74 22.5 653 
Pooled 707  99 11.6 <LOD 4.75 28.7 653 
∑DEHPb         
MSSM 151 n/a n/a 0.278 <LOD 0.129 0.507 19.9 
CCEH 339 n/a n/a 0.298 <LOD 0.141 0.608 18.6 
HOME 217 n/a n/a 0.248 <LOD 0.0959 0.537 6.56 
Pooled 707 n/a n/a 0.277 <LOD 0.128 0.562 19.9 
MECPP         
MSSM 151 0.3 99 35.2 <LOD 15.0 70.1 2055 
CCEH 339 0.6 100 39.5 3.00 19.5 77.9 1840 
HOME 217 0.6 100 30.7 1.70 12.6 63.6 641 
Pooled 707  100 35.7 <LOD 16.1 74.4 2055 
MEHHP         
MSSM 151 0.3 99 20.6 <LOD 8.70 39.4 2051 
CCEH 339 0.7 100 22.5 1.10 10.6 48.4 1750 
HOME 217 0.7 100 20.4 <LOD 8.00 47.0 784 
Pooled 707  100 21.4 <LOD 9.20 45.1 2051 
MEHP         
MSSM 151 0.9 90 5.81 <LOD 3.00 11.8 478 
CCEH 339 1.2 83 5.04 <LOD 2.20 12.8 613 
HOME 217 1.2 77 4.23 <LOD 1.50 10.8 233 
Pooled 707  83 4.92 <LOD 2.00 11.9 613 
MEOHP         
MSSM 151 0.5 99 18.3 <LOD 8.30 37.8 1335 
CCEH 339 0.7 100 18.7 <LOD 8.90 37.6 1320 
HOME 217 0.7 99 16.8 <LOD 6.40 36.9 448 
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Metabolite (µg/L)/ 
cohort 
N LOD 
Percent 
detected 
Geometric 
meana 
Minimum 
25th 
percentile 
75th 
percentile 
Maximum 
Pooled 707   99 18.0 <LOD 8.00 37.5 1335 
Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures 
of the Environment Study (HOME), limit of detection (LOD), Mount Sinai School of Medicine 
Center for Children’s Environmental Health (MSSM) 
a To compute the geometric mean, phthalate metabolite concentrations <LOD were replaced by 
LOD/√2. 
b Micromoles per liter. 
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Table 14. Percent of children classified as overweight/obese by age at follow-up 
Group/category 
Age (years) 
4 (n = 420) 5 (n = 361) 6 (n = 258) 7 (n = 377) 
Overall 28 26 38 36 
Cohort     
MSSM 35 30 28 36 
CCEH 36 35 47 44 
HOME 17 19 0 21 
Child’s sex     
Girls 28 27 39 35 
Boys 27 25 37 37 
Race/ethnicity     
Non-Hispanic white 17 16 13 15 
Non-Hispanic black 22 30 37 32 
Hispanic 43 34 44 48 
Other 13 11 33 20 
Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures 
of the Environment Study (HOME), Mount Sinai School of Medicine Center for Children’s 
Environmental Health (MSSM) 
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Table 15. Age- and sex- standardized body mass index, weight, and height z-score 
distributions (mean ± standard deviation) at follow-up by selected characteristics  
Group/ category n Body mass index Weight Height 
Overall 1416 0.47 ± 1.20 0.59 ± 1.16 0.54 ± 1.12 
Cohort     
MSSM 308 0.55 ± 1.13 0.57 ± 1.14 0.40 ± 1.09 
CCEH 632 0.64 ± 1.32 0.92 ± 1.11 0.86 ± 1.04 
HOME 476 0.19 ± 1.00 0.18 ± 1.11 0.22 ± 1.16 
Age (years)     
4 420 0.32 ± 1.26 0.55 ± 1.16 0.70 ± 1.20 
5 361 0.36 ± 1.19 0.48 ± 1.16 0.57 ± 1.16 
6 258 0.69 ± 1.18 0.78 ± 1.14 0.55 ± 0.98 
7 377 0.59 ± 1.11 0.63 ± 1.16 0.35 ± 1.07 
Child’s sex     
Girls 756 0.44 ± 1.20 0.54 ± 1.17 0.53 ± 1.15 
Boys 660 0.50 ± 1.20 0.65 ± 1.14 0.57 ± 1.10 
Race/ethnicity     
Non-Hispanic white 358 0.17 ± 0.93 0.18 ± 1.02 0.23 ± 1.12 
Non-Hispanic black 463 0.46 ± 1.21 0.60 ± 1.20 0.58 ± 1.19 
Hispanic 570 0.69 ± 1.29 0.88 ± 1.12 0.73 ± 1.02 
Other 25 -0.09 ± 1.23 -0.11 ± 1.16 0.02 ± 1.14 
Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures 
of the Environment Study (HOME), Mount Sinai School of Medicine Center for Children’s 
Environmental Health (MSSM), standard deviation (SD) 
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Table 16. Adjusted associations between prenatal urinary phthalate metabolite 
concentrations and overweight/obese status and body mass index (BMI) z-scores 
among children aged 4 to 7 years, overall and by child’s sex 
Metabolite / groupa Overweight/obeseb BMI z-scorec 
MEP   
Overall 0.68 (0.42, 1.08) -0.05 (-0.15, 0.05) 
Girls  0.60 (0.32, 1.12) -0.14 (-0.28, 0.00) 
Boys  0.85 (0.44, 1.65) 0.07 (-0.07, 0.21) 
MnBP   
Overall 1.00 (0.51, 1.98) 0.03 (-0.12, 0.18) 
Girls  1.29 (0.55, 3.01) 0.16 (-0.06, 0.39) 
Boys  0.76 (0.30, 1.92) -0.08 (-0.28, 0.13) 
MiBP   
Overall 0.84 (0.44, 1.63) 0.01 (-0.14, 0.15) 
Girls  0.92 (0.41, 2.01) -0.07 (-0.26, 0.13) 
Boys  0.67 (0.27, 1.64) 0.02 (-0.18, 0.22) 
MCPP   
Overall 2.12 (1.16, 3.96) -0.02 (-0.15, 0.11) 
Girls  2.81 (1.35, 6.00) 0.06 (-0.11, 0.23) 
Boys  1.54 (0.66, 3.66) -0.09 (-0.28, 0.09) 
MBzP   
Overall 0.63 (0.34, 1.15) -0.07 (-0.20, 0.06) 
Girls  0.66 (0.31, 1.37) -0.09 (-0.27, 0.09) 
Boys  0.69 (0.29, 1.60) -0.04 (-0.22, 0.15) 
∑DEHP    
Overall 0.87 (0.53, 1.42) -0.04 (-0.15, 0.06) 
Girls  0.68 (0.36, 1.29) -0.12 (-0.27, 0.02) 
Boys  1.19 (0.59, 2.36) 0.04 (-0.11, 0.19) 
Associations per standard deviation increase in natural log phthalate metabolite concentrations 
estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal 
age at delivery, maternal education, maternal work status during pregnancy, maternal pre-
pregnancy BMI, maternal height, gestational weight gain, maternal smoking during pregnancy, 
natural log creatinine, calendar date of urine collection, parity, child’s sex, breastfeeding, and 
months of age at follow-up. 
a Number of children/number of follow-up visits for each group: 707/1416 (overall), 372/756 
(girls), and 335/660 (boys). 
b Posterior mean of odds ratios (95% credible intervals). 
c Posterior mean of beta coefficients (95% credible intervals). 
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Table 17. Adjusted associations between prenatal urinary phthalate metabolite 
concentrations and overweight/obese status and body mass index (BMI) z-scores 
among children aged 4 to 7 years by race/ethnicity  
Metabolite / groupa Overweight/obeseb BMI z-scorec 
MEP   
Non-Hispanic white 0.74 (0.27, 1.99) 0.01 (-0.19, 0.21) 
Non-Hispanic black 0.69 (0.34, 1.37) -0.05 (-0.21, 0.12) 
Hispanic 0.62 (0.28, 1.32) -0.08 (-0.25, 0.09) 
MnBP   
Non-Hispanic white 1.12 (0.32, 3.90) 0.04 (-0.23, 0.32) 
Non-Hispanic black 1.05 (0.43, 2.57) 0.00 (-0.27, 0.26) 
Hispanic 0.85 (0.30, 2.47) 0.04 (-0.21, 0.29) 
MiBP   
Non-Hispanic white 1.00 (0.32, 3.14) -0.02 (-0.26, 0.22) 
Non-Hispanic black 0.55 (0.22, 1.39) -0.04 (-0.32, 0.25) 
Hispanic 0.72 (0.27, 1.94) 0.01 (-0.22, 0.25) 
MCPP   
Non-Hispanic white 1.17 (0.35, 3.87) -0.13 (-0.39, 0.13) 
Non-Hispanic black 1.79 (0.76, 4.22) 0.00 (-0.25, 0.24) 
Hispanic 3.68 (1.55, 9.07) 0.08 (-0.11, 0.27) 
MBzP   
Non-Hispanic white 0.74 (0.22, 2.50) -0.16 (-0.42, 0.10) 
Non-Hispanic black 0.58 (0.25, 1.37) -0.08 (-0.32, 0.16) 
Hispanic 0.63 (0.26, 1.51) -0.01 (-0.21, 0.18) 
∑DEHP    
Non-Hispanic white 1.44 (0.58, 3.60) 0.10 (-0.09, 0.29) 
Non-Hispanic black 0.98 (0.46, 2.10) -0.04 (-0.25, 0.16) 
Hispanic 0.59 (0.27, 1.27) -0.14 (-0.31, 0.03) 
Associations per standard deviation increase in natural log phthalate metabolite concentrations 
estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal 
age at delivery, maternal education, maternal work status during pregnancy, maternal pre-
pregnancy BMI, maternal height, gestational weight gain, maternal smoking during pregnancy, 
natural log creatinine, calendar date of urine collection, parity, child’s sex, breastfeeding, and 
months of age at follow-up. 
a Number of children/number of follow-up visits for each group: 166/358 (non-Hispanic white), 
230/463 (non-Hispanic black), and 299/570 (Hispanic). 
b Posterior mean of odds ratios (95% credible intervals). 
c Posterior mean of beta coefficients (95% credible intervals). 
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Table 18. Adjusted associations between prenatal urinary phthalate metabolite 
concentrations and weight and height z-scores among children aged 4 to 7 years, 
overall and by child’s sex 
Metabolite / groupa Weight z-scoreb Height z-scoreb 
MEP   
Overall -0.08 (-0.18, 0.01) -0.07 (-0.15, 0.02) 
Girls  -0.18 (-0.31, -0.05) -0.14 (-0.26, -0.01) 
Boys  0.04 (-0.09, 0.17) 0.02 (-0.10, 0.14) 
MnBP   
Overall 0.03 (-0.11, 0.18) 0.02 (-0.11, 0.15) 
Girls  0.14 (-0.07, 0.34) 0.03 (-0.16, 0.23) 
Boys  -0.05 (-0.24, 0.14) 0.00 (-0.18, 0.18) 
MiBP   
Overall 0.03 (-0.11, 0.16) 0.05 (-0.08, 0.18) 
Girls  0.01 (-0.17, 0.19) 0.09 (-0.08, 0.26) 
Boys  0.00 (-0.19, 0.18) 0.01 (-0.16, 0.18) 
MCPP   
Overall 0.00 (-0.12, 0.12) -0.02 (-0.13, 0.10) 
Girls  0.08 (-0.08, 0.24) 0.03 (-0.13, 0.18) 
Boys  -0.09 (-0.27, 0.08) -0.07 (-0.24, 0.09) 
MBzP   
Overall -0.09 (-0.22, 0.03) -0.10 (-0.21, 0.02) 
Girls  -0.11 (-0.27, 0.06) -0.07 (-0.23, 0.08) 
Boys  -0.05 (-0.22, 0.12) -0.10 (-0.26, 0.06) 
∑DEHP    
Overall -0.05 (-0.15, 0.05) -0.03 (-0.12, 0.06) 
Girls  -0.07 (-0.20, 0.06) 0.02 (-0.10, 0.15) 
Boys  -0.03 (-0.17, 0.11) -0.09 (-0.22, 0.04) 
Associations per standard deviation increase in natural log phthalate metabolite concentrations 
estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal 
age at delivery, maternal education, maternal work status during pregnancy, maternal pre-
pregnancy body mass index, maternal height, gestational weight gain, maternal smoking during 
pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up. 
a Number of children/number of follow-up visits for each group: 707/1416 (overall), 372/756 
(girls), and 335/660 (boys). 
b Posterior mean of beta coefficients (95% credible intervals).  
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Table 19. Adjusted associations between prenatal urinary phthalate metabolite 
concentrations and weight and height z-scores among children aged 4 to 7 years by 
race/ethnicity 
Metabolite / groupa Weight z-scoreb Height z-scoreb 
MEP   
Non-Hispanic white -0.08 (-0.26, 0.11) -0.14 (-0.32, 0.03) 
Non-Hispanic black -0.05 (-0.20, 0.11) 0.02 (-0.12, 0.17) 
Hispanic -0.13 (-0.29, 0.03) -0.11 (-0.26, 0.03) 
MnBP   
Non-Hispanic white 0.01 (-0.25, 0.27) -0.03 (-0.27, 0.21) 
Non-Hispanic black 0.03 (-0.22, 0.28) 0.06 (-0.17, 0.29) 
Hispanic 0.06 (-0.16, 0.30) 0.04 (-0.17, 0.26) 
MiBP   
Non-Hispanic white 0.08 (-0.15, 0.30) 0.15 (-0.06, 0.36) 
Non-Hispanic black 0.05 (-0.21, 0.32) 0.14 (-0.10, 0.39) 
Hispanic -0.05 (-0.27, 0.16) -0.08 (-0.28, 0.12) 
MCPP   
Non-Hispanic white -0.11 (-0.36, 0.13) -0.06 (-0.29, 0.16) 
Non-Hispanic black 0.10 (-0.13, 0.32) 0.14 (-0.07, 0.36) 
Hispanic 0.05 (-0.12, 0.22) -0.05 (-0.21, 0.12) 
MBzP   
Non-Hispanic white -0.10 (-0.35, 0.14) -0.03 (-0.26, 0.20) 
Non-Hispanic black -0.24 (-0.46, -0.02) -0.35 (-0.56, -0.14) 
Hispanic 0.01 (-0.17, 0.19) 0.04 (-0.13, 0.20) 
∑DEHP    
Non-Hispanic white 0.06 (-0.11, 0.24) 0.02 (-0.14, 0.18) 
Non-Hispanic black -0.12 (-0.31, 0.06) -0.18 (-0.35, 0.00) 
Hispanic -0.09 (-0.24, 0.07) 0.01 (-0.13, 0.16) 
Associations per standard deviation increase in natural log phthalate metabolite concentrations 
estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal 
age at delivery, maternal education, maternal work status during pregnancy, maternal pre-
pregnancy body mass index, maternal height, gestational weight gain, maternal smoking during 
pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up. 
a Number of children/number of follow-up visits for each group: 166/358 (non-Hispanic white), 
230/463 (non-Hispanic black), and 299/570 (Hispanic). 
b Posterior mean of beta coefficients (95% credible intervals).  
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Table 20. Adjusted associations between prenatal urinary phthalate metabolite concentrations and overweight/obese 
status by cohort, child’s sex, and race/ethnicity 
Metabolite 
/cohort 
Overall Girls Boys 
Non-Hispanic 
white 
Non-Hispanic 
black 
Hispanic 
MEP       
MSSM 0.89 (0.40, 1.98) 0.79 (0.32, 1.94) 1.39 (0.46, 4.15) 0.97 (0.21, 4.36) 0.82 (0.32, 2.12) 0.86 (0.25, 2.88) 
CCEH 0.59 (0.27, 1.26) 0.58 (0.21, 1.56) 0.61 (0.21, 1.73)  0.73 (0.22, 2.36) 0.50 (0.18, 1.30) 
HOME 0.56 (0.25, 1.24) 0.51 (0.19, 1.31) 0.66 (0.20, 2.10) 0.64 (0.20, 2.05) 0.50 (0.16, 1.50)  
MnBP       
MSSM 0.69 (0.27, 1.80) 0.96 (0.32, 2.85) 0.46 (0.13, 1.60) 0.63 (0.12, 3.17) 0.67 (0.22, 2.05) 0.52 (0.12, 2.25) 
CCEH 1.18 (0.42, 3.35) 1.61 (0.46, 5.64) 0.92 (0.22, 3.77)  1.23 (0.30, 5.05) 1.16 (0.30, 4.39) 
HOME 1.49 (0.48, 4.60) 1.60 (0.45, 5.78) 1.55 (0.28, 8.11) 1.27 (0.24, 6.42) 1.59 (0.38, 6.61)  
MiBP       
MSSM 0.87 (0.34, 2.22) 0.99 (0.36, 2.78) 0.68 (0.18, 2.49) 0.77 (0.16, 3.72) 0.55 (0.18, 1.72) 0.85 (0.22, 3.34) 
CCEH 0.66 (0.24, 1.79) 0.79 (0.24, 2.56) 0.37 (0.08, 1.57)  0.54 (0.13, 2.14) 0.60 (0.17, 2.08) 
HOME 1.03 (0.36, 3.04) 1.00 (0.29, 3.57) 0.94 (0.21, 4.35) 1.16 (0.29, 4.94) 0.54 (0.11, 2.55)  
MCPP       
MSSM 2.15 (0.88, 5.31) 2.94 (1.09, 8.04) 1.82 (0.53, 6.23) 1.47 (0.32, 6.68) 1.89 (0.64, 5.55) 3.84 (1.00, 14.76) 
CCEH 2.64 (1.14, 6.41) 3.50 (1.30, 9.96) 1.93 (0.56, 6.90)  1.79 (0.53, 6.27) 3.74 (1.28, 11.58) 
HOME 1.34 (0.41, 4.45) 1.95 (0.50, 7.70) 0.79 (0.16, 4.05) 0.95 (0.19, 4.77) 1.86 (0.41, 8.63)  
MBzP       
MSSM 0.79 (0.31, 1.99) 0.80 (0.29, 2.20) 0.85 (0.22, 3.15) 0.75 (0.15, 3.81) 0.69 (0.23, 2.05) 0.96 (0.23, 3.92) 
CCEH 0.46 (0.20, 1.03) 0.59 (0.21, 1.62) 0.42 (0.13, 1.31)  0.39 (0.11, 1.30) 0.49 (0.17, 1.37) 
HOME 0.78 (0.25, 2.42) 0.66 (0.19, 2.31) 1.13 (0.22, 5.67) 0.80 (0.17, 3.63) 1.02 (0.22, 4.62)  
∑DEHP       
MSSM 0.71 (0.33, 1.51) 0.59 (0.24, 1.46) 0.81 (0.30, 2.17) 1.32 (0.34, 5.10) 0.76 (0.28, 2.07) 0.44 (0.14, 1.36) 
CCEH 0.90 (0.42, 1.92) 0.67 (0.26, 1.67) 1.47 (0.46, 4.67)  1.11 (0.37, 3.29) 0.71 (0.26, 1.92) 
HOME 1.13 (0.44, 2.85) 0.76 (0.25, 2.28) 2.06 (0.55, 7.53) 1.53 (0.48, 4.91) 0.96 (0.24, 3.83)  
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Posterior mean of odds ratios (95% credible intervals) per standard deviation increase in natural log phthalate metabolite 
concentrations estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
maternal education, maternal work status during pregnancy, maternal pre-pregnancy body mass index, maternal height, gestational 
weight gain, maternal smoking during pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up.  
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Table 21. Adjusted associations between prenatal urinary phthalate metabolite concentrations and body mass index z-
scores by cohort, child’s sex, and race/ethnicity  
Metabolite 
/cohort 
Overall Girls Boys 
Non-Hispanic 
white 
Non-Hispanic 
black 
Hispanic 
MEP       
MSSM 0.14 (-0.09, 0.37) 0.03 (-0.28, 0.34) 0.29 (-0.03, 0.61) 0.06 (-0.44, 0.56) 0.08 (-0.26, 0.43) 0.15 (-0.19, 0.49) 
CCEH -0.10 (-0.27, 0.07) -0.14 (-0.37, 0.09) -0.02 (-0.25, 0.21)  0.03 (-0.26, 0.31) -0.16 (-0.36, 0.05) 
HOME -0.06 (-0.22, 0.09) -0.20 (-0.41, 0.00) 0.11 (-0.12, 0.34) 0.01 (-0.21, 0.23) -0.11 (-0.36, 0.14)  
MnBP       
MSSM -0.23 (-0.54, 0.09) -0.04 (-0.52, 0.45) -0.27 (-0.64, 0.10) -0.16 (-0.73, 0.41) -0.27 (-0.74, 0.21) -0.29 (-0.77, 0.19) 
CCEH 0.04 (-0.21, 0.28) 0.27 (-0.07, 0.61) -0.17 (-0.51, 0.17)  -0.17 (-0.61, 0.27) 0.15 (-0.15, 0.44) 
HOME 0.18 (-0.07, 0.44) 0.18 (-0.16, 0.52) 0.19 (-0.16, 0.55) 0.08 (-0.24, 0.40) 0.21 (-0.22, 0.64)  
MiBP       
MSSM -0.02 (-0.30, 0.27) 0.04 (-0.33, 0.40) -0.14 (-0.54, 0.25) -0.39 (-0.95, 0.17) -0.16 (-0.69, 0.38) 0.03 (-0.37, 0.42) 
CCEH 0.05 (-0.19, 0.29) -0.08 (-0.40, 0.23) 0.07 (-0.27, 0.41)  0.21 (-0.22, 0.63) -0.01 (-0.29, 0.28) 
HOME -0.02 (-0.24, 0.21) -0.11 (-0.41, 0.20) 0.03 (-0.27, 0.34) 0.05 (-0.22, 0.32) -0.19 (-0.67, 0.28)  
MCPP       
MSSM 0.17 (-0.12, 0.46) 0.19 (-0.17, 0.55) 0.15 (-0.25, 0.55) -0.05 (-0.54, 0.44) 0.19 (-0.30, 0.67) 0.40 (-0.03, 0.83) 
CCEH -0.05 (-0.23, 0.13) 0.06 (-0.17, 0.29) -0.17 (-0.45, 0.12)  -0.09 (-0.42, 0.23) -0.03 (-0.25, 0.18) 
HOME -0.05 (-0.31, 0.21) -0.03 (-0.41, 0.34) -0.07 (-0.41, 0.28) -0.10 (-0.42, 0.22) 0.21 (-0.27, 0.70)  
MBzP       
MSSM -0.03 (-0.34, 0.27) -0.02 (-0.39, 0.35) -0.12 (-0.59, 0.35) -0.03 (-0.63, 0.57) 0.07 (-0.42, 0.56) -0.01 (-0.45, 0.42) 
CCEH -0.09 (-0.27, 0.09) -0.08 (-0.33, 0.17) -0.03 (-0.28, 0.23)  -0.12 (-0.44, 0.2) -0.07 (-0.30, 0.15) 
HOME -0.13 (-0.38, 0.11) -0.12 (-0.44, 0.19) -0.15 (-0.51, 0.21) -0.18 (-0.47, 0.12) -0.03 (-0.50, 0.43)  
∑DEHP       
MSSM -0.13 (-0.32, 0.07) -0.16 (-0.46, 0.14) -0.06 (-0.32, 0.20) 0.28 (-0.12, 0.68) -0.20 (-0.60, 0.20) -0.28 (-0.56, 0.00) 
CCEH -0.05 (-0.21, 0.12) -0.19 (-0.40, 0.03) 0.12 (-0.15, 0.38)  -0.06 (-0.34, 0.21) -0.05 (-0.26, 0.17) 
HOME 0.05 (-0.14, 0.24) 0.03 (-0.23, 0.28) 0.10 (-0.18, 0.37) 0.07 (-0.15, 0.30) -0.02 (-0.44, 0.40)  
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Posterior mean of beta coefficients (95% credible intervals) per standard deviation increase in natural log phthalate metabolite 
concentrations estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
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Table 22. Adjusted associations between prenatal urinary phthalate metabolite concentrations and weight z-scores by 
cohort, child’s sex, and race/ethnicity 
Metabolite 
/cohort 
Overall Girls Boys 
Non-Hispanic 
white 
Non-Hispanic 
black 
Hispanic 
MEP       
MSSM 0.15 (-0.06, 0.36) 0.05 (-0.24, 0.33) 0.33 (0.04, 0.63) 0.22 (-0.11, 0.55) -0.02 (-0.48, 0.44) 0.12 (-0.19, 0.43) 
CCEH -0.16 (-0.32, -0.01) -0.20 (-0.41, 0.02) -0.09 (-0.30, 0.12) -0.02 (-0.29, 0.24)  -0.21 (-0.4, -0.02) 
HOME -0.09 (-0.24, 0.05) -0.25 (-0.45, -0.06) 0.11 (-0.10, 0.32) -0.15 (-0.38, 0.08) -0.08 (-0.28, 0.12)  
MnBP       
MSSM -0.30 (-0.59, 0.00) -0.13 (-0.58, 0.34) -0.35 (-0.69, -0.01) -0.37 (-0.82, 0.07) -0.27 (-0.80, 0.25) -0.26 (-0.71, 0.18) 
CCEH 0.10 (-0.12, 0.33) 0.31 (0.00, 0.62) -0.09 (-0.41, 0.22) -0.02 (-0.43, 0.39)  0.17 (-0.11, 0.44) 
HOME 0.20 (-0.04, 0.43) 0.10 (-0.21, 0.41) 0.32 (-0.01, 0.66) 0.27 (-0.14, 0.67) 0.07 (-0.23, 0.36)  
MiBP       
MSSM 0.03 (-0.24, 0.29) 0.11 (-0.23, 0.45) -0.13 (-0.49, 0.23) -0.10 (-0.62, 0.41) -0.23 (-0.74, 0.30) 0.03 (-0.34, 0.39) 
CCEH -0.04 (-0.26, 0.18) -0.10 (-0.39, 0.20) -0.06 (-0.37, 0.25) 0.18 (-0.22, 0.57)  -0.11 (-0.37, 0.15) 
HOME 0.08 (-0.12, 0.29) 0.03 (-0.25, 0.32) 0.08 (-0.20, 0.36) 0.05 (-0.39, 0.49) 0.13 (-0.12, 0.38)  
MCPP       
MSSM 0.20 (-0.08, 0.46) 0.23 (-0.11, 0.57) 0.22 (-0.15, 0.59) 0.32 (-0.14, 0.77) 0.04 (-0.42, 0.50) 0.34 (-0.05, 0.74) 
CCEH -0.04 (-0.20, 0.13) 0.04 (-0.17, 0.25) -0.12 (-0.38, 0.14) -0.02 (-0.31, 0.28)  -0.03 (-0.23, 0.17) 
HOME 0.00 (-0.24, 0.24) 0.09 (-0.26, 0.44) -0.12 (-0.44, 0.19) 0.37 (-0.08, 0.82) -0.11 (-0.40, 0.19)  
MBzP       
MSSM -0.11 (-0.39, 0.17) -0.03 (-0.37, 0.31) -0.30 (-0.74, 0.14) -0.13 (-0.60, 0.34) -0.02 (-0.58, 0.53) -0.07 (-0.48, 0.33) 
CCEH -0.09 (-0.25, 0.08) -0.10 (-0.33, 0.13) 0.00 (-0.24, 0.23) -0.25 (-0.55, 0.05)  -0.02 (-0.22, 0.18) 
HOME -0.18 (-0.40, 0.05) -0.13 (-0.42, 0.16) -0.24 (-0.57, 0.10) -0.25 (-0.68, 0.19) -0.11 (-0.38, 0.16)  
∑DEHP       
MSSM -0.09 (-0.27, 0.09) -0.07 (-0.35, 0.20) -0.04 (-0.28, 0.20) -0.29 (-0.67, 0.08) 0.19 (-0.17, 0.56) -0.17 (-0.42, 0.09) 
CCEH -0.04 (-0.19, 0.12) -0.11 (-0.31, 0.09) 0.06 (-0.19, 0.30) -0.11 (-0.36, 0.14)  -0.03 (-0.23, 0.17) 
HOME -0.01 (-0.18, 0.17) 0.00 (-0.23, 0.24) -0.02 (-0.27, 0.23) -0.18 (-0.58, 0.21) 0.06 (-0.15, 0.26)  
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Columbia Center for Children’s Environmental Health (CCEH), Health Outcomes and Measures of the Environment Study (HOME), 
Mount Sinai School of Medicine Center for Children’s Environmental Health (MSSM) 
Posterior mean of beta coefficients (95% credible intervals) per standard deviation increase in natural log phthalate metabolite 
concentrations estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
maternal education, maternal work status during pregnancy, maternal pre-pregnancy body mass index, maternal height, gestational 
weight gain, maternal smoking during pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up. 
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Table 23. Adjusted associations between prenatal urinary phthalate metabolite concentrations and height z-scores by 
cohort, child’s sex, and race/ethnicity 
Metabolite 
/cohort 
Overall Girls Boys 
Non-Hispanic 
white 
Non-Hispanic 
black 
Hispanic 
MEP       
MSSM 0.12 (-0.08, 0.31) 0.09 (-0.18, 0.37) 0.25 (-0.03, 0.53) -0.09 (-0.52, 0.35) 0.30 (-0.01, 0.62) 0.05 (-0.24, 0.35) 
CCEH -0.14 (-0.28, 0.01) -0.16 (-0.36, 0.04) -0.09 (-0.29, 0.11)  -0.02 (-0.27, 0.23) -0.16 (-0.34, 0.01) 
HOME -0.06 (-0.20, 0.07) -0.20 (-0.38, -0.02) 0.10 (-0.10, 0.29) -0.14 (-0.33, 0.05) -0.06 (-0.28, 0.15)  
MnBP       
MSSM -0.22 (-0.50, 0.05) -0.18 (-0.61, 0.26) -0.24 (-0.57, 0.08) -0.24 (-0.74, 0.26) -0.29 (-0.72, 0.14) -0.11 (-0.53, 0.31) 
CCEH 0.12 (-0.09, 0.33) 0.19 (-0.11, 0.49) 0.01 (-0.29, 0.30)  0.16 (-0.22, 0.54) 0.09 (-0.16, 0.34) 
HOME 0.11 (-0.11, 0.34) -0.04 (-0.33, 0.26) 0.30 (-0.01, 0.62) 0.02 (-0.26, 0.29) 0.20 (-0.18, 0.58)  
MiBP       
MSSM 0.08 (-0.17, 0.33) 0.15 (-0.18, 0.48) -0.04 (-0.38, 0.31) 0.09 (-0.40, 0.59) 0.03 (-0.47, 0.53) 0.04 (-0.30, 0.39) 
CCEH -0.10 (-0.31, 0.11) -0.05 (-0.33, 0.23) -0.12 (-0.42, 0.18)  0.12 (-0.25, 0.49) -0.15 (-0.40, 0.09) 
HOME 0.16 (-0.03, 0.36) 0.16 (-0.11, 0.43) 0.13 (-0.14, 0.40) 0.16 (-0.07, 0.39) 0.24 (-0.18, 0.65)  
MCPP       
MSSM 0.11 (-0.14, 0.37) 0.16 (-0.16, 0.48) 0.18 (-0.17, 0.53) 0.13 (-0.30, 0.57) 0.32 (-0.12, 0.76) 0.07 (-0.30, 0.45) 
CCEH -0.04 (-0.19, 0.12) -0.04 (-0.24, 0.16) -0.02 (-0.27, 0.23)  0.07 (-0.22, 0.34) -0.05 (-0.24, 0.13) 
HOME 0.03 (-0.20, 0.26) 0.16 (-0.17, 0.48) -0.14 (-0.45, 0.16) -0.09 (-0.36, 0.19) 0.34 (-0.08, 0.76)  
MBzP       
MSSM -0.21 (-0.48, 0.06) -0.05 (-0.38, 0.28) -0.48 (-0.89, -0.06) -0.13 (-0.66, 0.39) -0.38 (-0.83, 0.08) -0.13 (-0.51, 0.25) 
CCEH -0.05 (-0.20, 0.11) -0.06 (-0.28, 0.16) -0.01 (-0.23, 0.21)  -0.32 (-0.60, -0.04) 0.06 (-0.13, 0.26) 
HOME -0.17 (-0.38, 0.04) -0.09 (-0.36, 0.19) -0.27 (-0.58, 0.04) -0.01 (-0.26, 0.24) -0.40 (-0.81, 0.00)  
∑DEHP       
MSSM -0.01 (-0.18, 0.16) 0.05 (-0.22, 0.31) 0.02 (-0.20, 0.24) 0.00 (-0.34, 0.35) -0.29 (-0.65, 0.07) 0.05 (-0.20, 0.29) 
CCEH -0.03 (-0.17, 0.12) 0.02 (-0.17, 0.20) -0.07 (-0.30, 0.16)  -0.14 (-0.38, 0.09) 0.00 (-0.19, 0.18) 
HOME -0.04 (-0.21, 0.12) 0.00 (-0.23, 0.22) -0.10 (-0.34, 0.14) 0.04 (-0.15, 0.24) -0.25 (-0.62, 0.13)  
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Posterior mean of beta coefficients (95% credible intervals) per standard deviation increase in natural log phthalate metabolite 
concentrations estimated in multiple metabolite models, adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
maternal education, maternal work status during pregnancy, maternal pre-pregnancy body mass index, maternal height, gestational 
weight gain, maternal smoking during pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up. 
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Table 24. Sensitivity analyses for confounding among metabolites and loss to follow-up 
Metabolite/outcome 
Multiple metabolite 
modelsa 
(N = 707) 
Single metabolite 
modelsb 
(N = 707) 
Multiple metabolite 
models accounting 
for loss to follow-upc 
(N = 1143) 
MEP    
Overweight/obesed 0.68 (0.42, 1.08) 0.66 (0.42, 1.03) 0.69 (0.43, 1.12) 
BMI z-scoree -0.05 (-0.15, 0.05) -0.06 (-0.15, 0.03) -0.04 (-0.14, 0.06) 
Weight z-scoree -0.08 (-0.18, 0.01) -0.10 (-0.19, -0.01) -0.10 (-0.19, -0.01) 
Height z-scoree -0.07 (-0.15, 0.02) -0.08 (-0.16, 0.00) -0.08 (-0.16, 0.01) 
MnBP    
Overweight/obesed 1.00 (0.51, 1.98) 0.91 (0.56, 1.50) 0.96 (0.49, 1.91) 
BMI z-scoree 0.03 (-0.12, 0.18) -0.03 (-0.14, 0.08) -0.01 (-0.16, 0.14) 
Weight z-scoree 0.03 (-0.11, 0.18) -0.04 (-0.14, 0.06) 0.04 (-0.10, 0.18) 
Height z-scoree 0.02 (-0.11, 0.15) -0.04 (-0.14, 0.05) 0.03 (-0.11, 0.16) 
MiBP    
Overweight/obesed 0.84 (0.44, 1.63) 0.78 (0.46, 1.31) 0.87 (0.45, 1.67) 
BMI z-scoree 0.01 (-0.14, 0.15) -0.04 (-0.15, 0.08) 0.04 (-0.11, 0.18) 
Weight z-scoree 0.03 (-0.11, 0.16) -0.04 (-0.15, 0.07) 0.06 (-0.08, 0.19) 
Height z-scoree 0.05 (-0.08, 0.18) -0.02 (-0.12, 0.08) 0.07 (-0.06, 0.20) 
MCPP    
Overweight/obesed 2.12 (1.16, 3.96) 1.42 (0.88, 2.30) 2.22 (1.21, 4.12) 
BMI z-scoree -0.02 (-0.15, 0.11) -0.05 (-0.16, 0.05) 0.03 (-0.11, 0.16) 
Weight z-scoree 0.00 (-0.12, 0.12) -0.05 (-0.15, 0.05) -0.01 (-0.13, 0.12) 
Height z-scoree -0.02 (-0.13, 0.10) -0.06 (-0.15, 0.04) -0.03 (-0.14, 0.09) 
MBzP    
Overweight/obesed 0.63 (0.34, 1.15) 0.71 (0.44, 1.15) 0.62 (0.34, 1.13) 
BMI z-scoree -0.07 (-0.20, 0.06) -0.08 (-0.19, 0.02) -0.06 (-0.19, 0.08) 
Weight z-scoree -0.09 (-0.22, 0.03) -0.10 (-0.20, 0.00) -0.12 (-0.24, 0.00) 
Height z-scoree -0.10 (-0.21, 0.02) -0.10 (-0.20, -0.01) -0.11 (-0.22, 0.00) 
    
 
1
0
5
 
Metabolite/outcome 
Multiple metabolite 
modelsa 
(N = 707) 
Single metabolite 
modelsb 
(N = 707) 
Multiple metabolite 
models accounting 
for loss to follow-upc 
(N = 1143) 
∑DEHP    
Overweight/obesed 0.87 (0.53, 1.42) 0.89 (0.57, 1.38) 0.86 (0.53, 1.41) 
BMI z-scoree -0.04 (-0.15, 0.06) -0.07 (-0.16, 0.03) -0.04 (-0.15, 0.06) 
Weight z-scoree -0.05 (-0.15, 0.05) -0.08 (-0.17, 0.01) -0.03 (-0.13, 0.06) 
Height z-scoree -0.03 (-0.12, 0.06) -0.06 (-0.14, 0.02) -0.02 (-0.11, 0.07) 
BMI Body mass index 
Associations per standard deviation increase in natural log phthalate metabolite concentrations, adjusted for cohort, maternal 
race/ethnicity, maternal age at delivery, maternal education, maternal work status during pregnancy, maternal pre-pregnancy BMI, 
maternal height, gestational weight gain, maternal smoking during pregnancy, natural log creatinine, calendar date of urine 
collection, parity, child’s sex, breastfeeding, and months of age at follow-up. 
a Associations among children with at least one follow-up visit estimated in a multiple metabolite linear mixed effects regression 
model.  
b Associations among children with at least one follow-up visit estimated in a separate linear mixed effects regression model for each 
metabolite. 
c Associations among all children with measured prenatal phthalate metabolite concentrations estimated in a multiple metabolite linear 
mixed effects regression model using a selection model for nonignorable missing outcome data. 
d Posterior mean of odds ratios (95% credible intervals).  
e Posterior mean of beta coefficients (95% credible intervals). 
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CHAPTER VI. CONCLUSIONS 
 Summary of Findings A.
A growing body of literature suggests that prenatal environmental chemical exposures 
may be a factor in the rise in childhood obesity rates in the last several decades. In this 
dissertation, we examined whether prenatal phthalate exposures are associated with body size 
in early childhood.   
In the first Specific Aim, we examined whether third trimester maternal urinary 
concentrations of phthalate metabolites were associated with percent fat mass, measured using 
bio-electrical impedance analysis, among children aged 4 to 9 years. We found that children in 
the highest tertile of creatinine-corrected ∑DEHP metabolite concentrations had lower percent 
fat mass than children in the lowest tertile of ∑DEHP metabolite concentrations (β = -3.06, 95% 
CI: -5.99, -0.09). There was no evidence of associations between other phthalate metabolites 
and percent body fat.  Furthermore, we did not observe heterogeneity of associations by child 
sex, though our sample size was limited.   
In the second Specific Aim, we assessed prenatal phthalate exposures in relation to 
several anthropometry-based outcomes among children aged 4 to 7 years in a pooled sample 
comprised of children in three birth cohorts.  We found evidence that higher prenatal exposure 
to MCPP, a high molecular weight phthalate found in food packaging and plastics, was 
associated with higher odds of overweight or obese status at follow-up (OR per SD = 2.12, 95% 
CI = 1.16, 3.96). We also observed an inverse association of maternal urinary MEP 
concentrations with BMI, weight, and height z-scores among girls, but not boys. MBzP was 
negatively associated with weight and height z-scores among non-Hispanic black children only. 
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We did not observe associations between MnBP, MiBP, or ∑DEHP and measures of childhood 
body size.   
Taken together, these results do not provide strong evidence for the hypothesis that 
prenatal phthalate exposures are obesogenic. While we observed a positive association 
between MCPP and overweight/obese status in Aim 2, there was only weak evidence of an 
association of MCPP with percent fat mass in Aim 1. MCPP was not associated with percent fat 
mass in models assessing continuous MCPP concentrations (β per SD = 0.63, 95% CI: -1.55, 
2.82). Comparing the highest to lowest tertile of MCPP exposure yielded positive associations 
with percent fat mass (β = 1.79, 95% CI: -1.61, 5.17) and BMI z-scores (β = 0.32, 95% CI = -
0.16, 0.79), though the CIs were wide and crossed the null.  
Our finding of increased odds of overweight/obesity in Aim 2 may be evidence that 
MCPP is a weak obesogen. Consistent with our findings, a study of first trimester urinary 
phthalate metabolite concentrations and cord blood levels of two adipocyte-produced hormones 
reported associations of MCPP, but not other phthalate metabolites, with leptin and adiponectin 
levels (Ashley-Martin et al. 2014). Male infants in the second, third, and fourth quartiles of 
MCPP exposure had increased odds of high (≥90th percentile) leptin and females in the highest 
quartile of MCPP exposure had higher odds of high (≥90th percentile) adiponectin.  
It is possible that we could not fully control for confounding by shared maternal and child 
diet as MCPP exposure is most commonly through packaging of high fat foods.  However, the 
inverse association of ∑DEHP concentrations with overweight/obese status provides indirect 
evidence that associations are not strongly confounded by diet since ∑DEHP and MCPP 
exposures are associated with intake of similar foods (Serrano et al. 2014). 
We observed stronger associations of MCPP with overweight/obese status among girls 
than boys.  It is not immediately clear whether this is true biological variability in this association 
as MCPP has not been shown to affect estrogen (Chen et al. 2014) or androgen (Saillenfait et 
al. 2011) activity in animal studies. However, this phthalate is not well-studied in the 
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toxicological literature. There is some evidence that MCPP may impact the thyroid and liver, 
which are additional potential pathways for an effect of this phthalate on obesity (Poon et al. 
1997). 
MCPP was also more strongly associated with overweight and obesity among Hispanic 
children than among non-Hispanic children. While interpreting heterogeneity of associations by 
race/ethnicity in Aim 2 is somewhat complicated by other differences between the three cohorts, 
differences in associations by race/ethnicity have been observed in previous studies of 
phthalates in relation to body size. For example, a cross-sectional study of urinary phthalate 
metabolites measured in a sample of NHANES children and adolescents reported an 
association of low molecular weight phthalates with higher odds of overweight and obesity 
among non-Hispanic black children, but not non-Hispanic white or Hispanic children (Trasande 
et al. 2013). The underlying mechanism for such a difference in unclear. A causal association 
could be due to differences in genetic susceptibility or in the childhood food environment. For 
example, if MCPP affects satiety, ethnic differences related to food availability or nutrient 
content may explain differences in associations by ethnicity. Hispanic children had a higher 
prevalence of overweight/obesity and greater BMI z-scores than non-Hispanic white and black 
children. Thus, other factors related to increased obesity in this population (e.g., poor diet, 
physical activity) may potentiate accumulation of fat cells and lipid content of adipocytes, 
resulting in greater fat mass in Hispanic children.  Alternatively, it is possible that the association 
of MCPP with obesity in Aim 2 is more highly confounded by diet or other unmeasured factors 
within the Hispanic population.  
We found evidence that ∑DEHP was associated with lower percent fat mass in Specific 
Aim 1, but it was not associated with body size in Specific Aim 2. It is possible that associations 
of ∑DEHP with body fatness are not detectable using anthropometric measurements that do not 
distinguish between fat and lean mass. An inverse association between DEHP and obesity has 
been hypothesized since DEHP is a PPAR alpha agonist and DEHP exposures cause PPAR 
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alpha-mediated lipid mobilization, fatty acid oxidation, and adipose tissue atrophy in animal 
studies (Grun and Blumberg 2009). In contrast, DEHP metabolites are also known to affect 
PPAR gamma, which would be expected to result in more adipoctyes and increased fat mass 
(Grun and Blumberg 2009). Interpretation of animal studies is complicated as they have 
reported differences in direction of associations by animal and dose, which may reflect the fact 
that DEHP influences many biological processes that are related to both increased and 
decreased fat accumulation.  
Notably, associations of MCPP with body size were positive and associations of ∑DEHP 
with body size were negative for all outcomes in both Aims. Because the sources of exposure to 
these high molecular weight phthalate metabolites are similar, i.e., food packaging and plastics, 
one might expect that any residual confounding would be in the same direction for both 
phthalates. Since food sources of these phthalates include dairy, protein, and other high fat 
foods, it is more plausible that confounding would be positive. Thus, if there is a true negative 
association of DEHP with body size, it is likely that positive confounding by diet attenuated 
estimates up and toward the null. 
In Specific Aim 2, MEP and MBzP were associated with reduced body size among girls 
and non-Hispanic black children, respectively. These findings suggest that MEP and MBzP may 
have effects on body size, though not through an obesogenic mechanism. These metabolites 
may interfere with thyroid or growth hormone regulation to disrupt typical physical development. 
Though cross-sectional studies do not provide causal evidence, studies assessing associations 
between urinary phthalate metabolites and thyroid hormones have generally reported inverse 
associations (Boas et al. 2010; Huang et al. 2007; Meeker et al. 2007; Meeker and Ferguson 
2011), consistent with a potential negative effect of MEP and MBzP on body size mediated by 
their inhibitory effects on thyroid function. While MEP is not thought to be anti-androgenic, we 
found sexually dimorphic effects in Aim 2 such that MEP was associated with reduced body size 
only among girls. This finding could be consistent with thyroid effects as thyroid dysfunction is 
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more common among women, potentially due to estrogen-mediated differences in oxidative 
stress (Fortunato et al. 2014).   
Dibutyl phthalates have been reported in animal studies to be anti-androgenic and affect 
PPARs and thyroid function. However, associations of the DBP metabolites MnBP and MiBP 
with body size were null in both Aims. The primary routes of exposure for MnBP and MiBP are 
dermal application of personal care products (e.g., nail polish, cosmetics) whereas MEP 
exposure is primarily through inhalation of fragrances, and MCPP and DEHP exposures occur 
through ingestion of contaminated food.  Thus, the lack of associations for DBP metabolites, 
which have been hypothesized to be obesogenic based on toxicological evidence, may be due 
to lower bioavailability of metabolite exposures via dermal absorption as compared to inhalation 
or ingestion.  
In addition to our primary study findings regarding the relationship between phthalate 
exposures and body size, both Aims explored two important potential biases: 1) confounding by 
correlated metabolites, and 2) bias from potentially nonignorable missing outcome data. While 
most of our associations were null, we did not observe substantial differences in effect 
estimates when comparing single and multiple metabolite models or models that assumed 
outcomes were MAR or MNAR. While these issues should be explored in further studies, 
particularly where stronger associations are observed, our findings provide some evidence that 
correlated metabolites and missing outcome data may not result in substantial bias of 
associations of prenatal phthalate exposures and childhood health effects. Nevertheless, our 
finding that loss to follow-up may indeed depend on the child’s unobserved body size is an 
important consideration for future studies. Our estimates were not biased, likely because 
phthalate exposures were not associated with loss to follow-up (i.e, there was no backdoor path 
from exposure to outcome through loss to follow-up). Studies of exposures that are more 
strongly related to subject retention may be more susceptible to selection bias through a 
nonignorable missing outcome mechanism.  
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 Strengths and Limitations B.
Strengths 
The current study is innovative in that it is the first prospective study of prenatal 
phthalate exposures and childhood body size.  Previous cross-sectional analyses cannot 
disentangle the temporal ordering of exposure and outcome and are particularly susceptible to 
confounding by sources of phthalate exposure that are also related to body size. Furthermore, 
this study examines associations with exposures during the prenatal period, a hypothesized 
critical window for an effect of phthalates on growth and obesity (Dietz 1994). 
In addition, the multiethnic composition of the study population is a study strength. In 
particular, the MSSM and CCEH cohorts include a high proportion of participants belonging to 
racial and ethnic groups at increased risk of childhood obesity. In the 2007 NHANES survey, 
overweight and obesity prevalence was higher among both non-Hispanic black (35.9%, 20.0%) 
and Hispanic (38.2%, 20.9%) children aged 2-19 years compared to non-Hispanic white 
children (29.3%, 15.3%) (Ogden et al. 2010). Thus, our findings generalize to children at highest 
risk of obesity.  
The analysis of BIA measures of body composition in Aim 1 is also a strength of our first 
Aim. Because phthalates are hypothesized to affect adipocyte number and differentiation, 
percent body fat is a particularly relevant and sensitive endpoint for evaluating whether 
phthalates are environmental obesogens.   
Aim 2 assessed associations in three independent cohorts with notable variation in 
population characteristics, supporting the robustness of our findings. This pooled analysis 
utilized data from the only existing US cohorts with measured prenatal phthalate exposures and 
longitudinal follow-up of growth in both girls and boys. Although each of the three cohorts 
collected data on the exposures and outcomes of interest, power to detect an association within 
any individual study is limited. Pooling the cohorts thus provided sufficient sample size to more 
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precisely estimate associations of prenatal phthalate exposures on body size, while controlling 
for a rich set of potential confounding variables and assessing heterogeneity of associations by 
factors such as child’s sex and race/ethnicity.  
We employed a flexible Bayesian modeling approach that accommodated methods to 
multiply impute missing at random covariate data and control for confounding among correlated 
metabolites. Previous studies typically conduct complete case analyses and assess phthalate 
metabolites one at a time.  Accounting for these potential biases increases the robustness of 
our findings. Furthermore, we were able to compare results of analyses using single and 
multiple metabolite models and found that co-adjustment did not substantially alter our findings. 
Lack of subject retention is a common problem in longitudinal cohort studies. Loss to 
follow-up may result in selection bias if clinic non-attendance is missing not at random. While 
previous studies have ignored participant drop out and conducted analyses only among 
subjects who returned for clinic visits, this study explored this potential bias using selection 
models for data missing not at random.  
 
Limitations 
As noted previously, lack of information on dietary sources of high molecular weight 
phthalate exposures may have resulted in confounding of associations for MCPP and ∑DEHP. 
Maternal consumption of meat, diary, and other fatty foods may result in higher exposures to 
high molecular weight phthalates (Serrano et al. 2014). If the mother’s diet is similar to her 
child’s, then a high fat diet would also be expected to increase her child’s risk of overweight or 
obesity. Although we adjusted for maternal pre-pregnancy BMI and gestational weight gain to 
control for this pathway, there may be residual confounding, most likely up and away from the 
null. If present, this confounding pathway might explain the association we observed in Aim 2 of 
MCPP with overweight/obese status in children. For ∑DEHP, associations with body size 
outcomes were negative and this bias would have resulted in an attenuation of effect estimates.  
113 
 
Similarly, we lacked information on postnatal phthalate exposures and pre- and post-
natal exposures to other potentially obesogenic chemicals (e.g., persistent organic pollutants, 
perfluoroalkyl compounds, bisphenol A). Although childhood phthalate exposures during 
childhood occur temporally after pregnancy and thus cannot affect prenatal exposures, there 
may be unblocked backdoor paths through unmeasured predictors of both pre- and post-natal 
phthalate levels. In addition, there may be unmeasured confounding by other chemicals if they 
affect childhood obesity and are correlated with phthalate exposures.  
Confounding by diet, environmental obesogens, and other factors may operate 
differently within different population subgroups. Thus, residual confounding of associations may 
contribute to differences in associations by race/ethnicity or cohort. For example, Hispanic 
children had higher BMIs on average than non-Hispanic children. Stronger associations of 
confounders with phthalate exposure and obesity among Hispanics could explain the larger 
magnitude of association we observed between MCPP and overweight/obesity among Hispanic 
children compared to non-Hispanic children. We adjusted for a number of demographic, 
socioeconomic, and anthropometric variables in an effort to minimize this potential bias. 
However, there is little information on differences in phthalate exposure sources between racial 
and ethnic groups, limiting our ability to characterize all important predictors of both phthalate 
exposure and obesity that may vary by race/ethnicity. 
We measured phthalate metabolite concentrations in a single spot urine sample, which 
may not represent exposures throughout pregnancy since phthalates are quickly eliminated 
from the body (<24 hours) (Koch et al. 2005) and exposure to phthalate sources is episodic. 
However, many sources of phthalate exposure are frequent and may result in steady-state 
levels (Calafat and McKee 2006; Hauser et al. 2004). Urinary concentrations of phthalate 
metabolites in a single urine sample may be moderately predictive of DBP, MEP, and BzBP 
exposures during pregnancy, with greater variability for DEHP (Adibi et al. 2008; Braun et al. 
2012; Ferguson et al. 2014a). Further, the probability of correctly classifying “high exposure” 
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over a 6-12 week period using a single urine sample was reported in two studies to range 
between 0.50 and 0.74, depending on the metabolite (Adibi et al. 2008; Hauser et al. 2004). 
Studies with repeat urine samples throughout pregnancy would allow for a more robust 
characterization of phthalate exposures and provide insight into whether the third trimester is 
the relevant time period for an effect.  For example, the association of MCPP with overweight 
and obesity was null in the HOME Study. If the third trimester is a critical window for adverse 
effects on adipogenesis (Dietz 1994), this null association may have been due to the earlier age 
at urine collection in this cohort than in MSSM or CCEH. 
In addition to differences in gestational age at urine collection, the study populations of 
the three cohorts differed by design in terms of race/ethnicity, parity, and maternal smoking 
during pregnancy. These differences and other, unmeasured factors complicate the 
interpretation of findings that differed by cohort in our second Aim. However, analyzing these 
data using the same methods and controlling for the same confounders helps to rule out many 
potential differences that would have existed had these results been published in separate 
studies using different methods and yields a narrower range of plausible explanations for 
differences. 
For Specific Aim 2, adiposity is estimated using weight and BMI. Although these 
anthropometric measures do not directly assess adiposity, BMI is a moderately sensitive and 
highly specific indicator of childhood adiposity and adolescents with a high BMI are at greater 
risk for health risks in adulthood (Freedman and Sherry 2009).  Anthropometry during childhood 
may also be susceptible to measurement error, particularly at young ages when children are 
experiencing periods of rapid growth and plateaus (e.g., adiposity rebound). Measurement error 
was minimized in each cohort by using trained staff, standardized protocols, and repeat 
measurements. However, we did not measure body size outcomes with great enough frequency 
to assess growth trajectories. Thus, children may have been measured just before or after a 
growth spurt, leading to noise in our outcome measurements.   
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Finally, the current study examined body size outcomes in children during a relatively 
narrow age range. We restricted our analysis to early childhood because phthalate exposures 
have been associated with delayed puberty in boys and girls (Ferguson et al. 2014b; Wolff et al. 
2014), and pubertal development is also strongly tied to BMI. Similar to our finding that MEP 
concentrations were associated with decreased BMI z-scores among girls, Harley et al. reported 
an inverse association of prenatal urinary BPA concentrations with BMI and body fat among 
girls only, and this association was stronger among girls who had not yet reached puberty 
(Harley et al. 2013). Therefore, evaluating associations among older children is warranted to 
determine whether observed associations persist with age and to evaluate the timing of 
additional potential obesogenic effects with respect to puberty or other sensitive periods in 
development. 
 
 Public Health Significance C.
If causal, the observed association of prenatal MCPP exposure with overweight and 
obesity during early childhood may have substantial public health impact since nearly 40% of 
US children are overweight or obese (Ogden et al. 2010). We observed over a doubling of the 
odds of overweight/obese status for each SD increase in natural log MCPP concentrations (with 
approximately a 6 SD range in MCPP exposure). If further research supports an association of 
MCPP with childhood obesity, government regulation of its parent phthalate ester, DnOP, may 
help to reduce the burden of childhood obesity and does not require individual behavior change 
(i.e., diet and exercise) that is difficult to implement at a population level. Since the costs 
associated with childhood obesity are great, even a small shift in the BMI distribution could have 
an important impact on public health. 
While our primary hypotheses posited that early life phthalate exposures are related to 
increased fat accumulation in children, we observed negative associations of prenatal 
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exposures to DEHP, DEP, and BBzP with body size. These negative associations suggest that 
certain phthalates may affect physical development through non-obesogenic mechanisms, 
possibly related to thyroid or growth hormone regulation. Phthalates have been reported to 
adversely affect neurodevelopment, which is also critically related to thyroid functioning. Thus, 
these studies contribute to a growing body of evidence suggesting that phthalate exposures 
during gestation may indeed interfere with normal development of the fetus.  
Currently, regulations governing phthalates are discrepant across and within nations due 
to a lack of high quality data quantifying risks. Given the proliferation of cross-sectional studies 
investigating hypothesized obesogens, which are particularly prone to confounding bias, the 
studies conducted as part of this dissertation provide much needed prospective evidence 
evaluating potential risks of prenatal phthalate exposures with respect to childhood body size. 
While this dissertation does not indicate a strong, definitive causal association, we did observe 
relations of prenatal exposures to certain phthalates with increased or decreased body size in 
children. Given that gestation is a sensitive period in development, the precautionary principal 
suggests that it is prudent for pregnant women to limit their phthalate exposures when possible. 
However, current regulatory requirements in the US do not stipulate that phthalate-containing 
products be labeled as such, limiting a woman’s ability to reduce her exposures.  
 
 Directions for Future Research  D.
There is little toxicological evidence examining whether early life exposure to DnOP or 
its metabolite, MCPP, alter biologic processes related to development of obesity. Animal studies 
evaluating the effects of DnOP on hypothesized pathways such as PPARs alpha and gamma, 
thyroid and growth hormones, or androgen levels would aid in assessing the plausibility of our 
observation of increased overweight and obesity among prenatally-exposed children.  
Given that the MSSM, CCEH, and HOME studies constitute the only existing US cohorts 
available for evaluating associations of prenatal environmental chemicals with childhood body 
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size, future analyses of these cohorts could 1) integrate measures of childhood phthalate 
exposures, 2) examine prenatal and childhood co-exposures to other potential obesogenic 
chemicals, and 3) continue to follow children through adolescence. Examining associations of 
phthalates measured during childhood would be beneficial to determine whether pregnancy is 
the relevant time period for phthalate effects and assess whether ongoing phthalate exposures 
alter or potentiate associations. Development of methods to assess joint effects of phthalate 
exposures would aid in the characterization of how phthalates may interact with each other (and 
with other environmental chemicals) to produce changes in growth and physical development. 
Finally, examining associations at older ages may provide insight as to whether the effects of 
prenatal phthalate exposures manifest at different developmental stages, especially given that 
phthalate exposures have been associated with delayed puberty.  
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